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Enantiopure canonical and non-canonical amino acids (NCAA) have found numerous 
applications over the years as chiral building blocks employed in the pharmaceutical, 
agrochemical and fine chemical industries and as fundamental tools for enzyme evolution 
and development of biotherapeutics via genetic code expansion. Unfortunately, the classic 
chemosynthetic strategies for the production of these compounds relies on the use of toxic 
reagents and usually lead to the formation of a racemic mixture. In recent years numerous 
environmentally friendly biocatalytic strategies have been developed to achieve the 
stereoselective synthesis of NCAAs in high yields and enantiomeric excesses. The 
employment of enzymes in synthesis brings many advantages as the use of biodegradable 
catalysts, mild reaction conditions and intrinsic high selectivity, however biocatalysis is also 
characterised by various limitations, such as low protein stability, unfavourable reaction 
equilibrium and enzyme’s narrow substrate scope. Strategies as enzyme engineering and 
immobilization have been developed and employed to try to overcome the biocatalysts 
limitations. 
In this work the coupling of an engineered N-acetyl amino acid racemase (NAAAR) with two 
deacetylases: E. coli ArgE and S. viridochromogenes Tü494 Dea, will be explored to develop a 
biocatalytic dynamic kinetic resolution for the production of the natural herbicide 





The market demand for enantiopure non-canonical amino acids (NCAA) has been increasing 
in recent years, given the importance of these compounds as chiral building blocks employed 
in the synthesis of many pharmaceuticals and agrochemicals. An example is the use of L-
phosphinothricin (L-PT), a bioactive amino acid with potent herbicidal properties produced 
as a secondary metabolite by the Gram positive bacterium Streptomyces viridochromogenes. 
Recently, the use of NCAAs has been expanded to include applications in protein engineering, 
thanks to the advances achieved in the field of genetic code expansion. Over the last decade 
various biocatalytic strategies have been developed for the enantioselective production of 
these compounds, using a variety of enzymes, such as aminotransferases and ammonia 
lyases. A well-established biocatalytic protocol allows for the efficient preparation of NCAAs 
from their N-acylated derivatives via a dynamic kinetic resolution (DKR). This is achieved by 
coupling an engineered Amycolatopsis N-acyl amino acid racemase (NAAAR) with a 
compatible stereoselective deacetylase (amide hydrolase). 
Two recombinant hydrolytic enzymes: E. coli ArgE and S. viridochromogenes Tü494 Dea have 
been investigated in this work. Purified ArgE is a zinc-dependant, L-selective N-acetyl-L-
ornithine deacetylase and a thorough kinetic study revealed that it displays a wide substrate 
scope but poor activity for acidic and aromatic substrates. Various tests were carried out to 
optimise biotransformation conditions, which were employed in the coupling of ArgE with 
the engineered NAAAR double mutant (NAAAR DM: G291D F323Y) for the DKR of N-acetyl 
NCAAs derivatives. Directed evolution was employed to increase deacetylase activity 
towards acidic N-acetylated amino acids; unfortunately, thus far no improved variant has 
been isolated. Prism-shaped protein crystals were obtained, but with poor resolution, which 
prevents the determination of the E. coli ArgE X-ray structure. Despite this, homology 
modelling and site-directed mutagenesis were successfully employed to probe the enzyme 
active and substrate binding sites. 
The deacetylase S. viridochromogenes Dea is a novel member of the hormone-sensitive lipase 
(HSL) family. It was proposed that this enzyme catalyses the hydrolysis of N-Ac-L-bialaphos, 
the precursor of the tripeptide bialaphos (PTT), a natural herbicide that contains the L-PT 
building block. Similar to other members of the HSL family SvDea catalyses the deacetylation 
reaction by employing a catalytic triad of highly conserved serine, histidine and glutamate 
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residues in the active site, but the basis of its substrate specificity is unknown. To study its 
synthetic utility recombinant SvDea was isolated from E. coli and activity screening using 
various assays (including a novel 1H NMR assay) revealed a narrow substrate scope, limited 
to small acetylated esters and N-acetyl-L-PTT. Initial crystal trials failed to deliver positive 
hits, so structure and sequence analysis generated a homology model to obtain further 
insights into the substrate binding and direct future engineering efforts. 
In the last section of this thesis the synthetic scope of a novel NAAAR quadruple mutant 
(NAAAR QM: Q26I M50I G291D F323Y) was explored. This engineered racemase was found 
to display enhanced activity for bulky N-acetylated amino acids and could be coupled with 
either L- and D-selective acylases to prepare enantiopure target L- or D- amino acids. 
Following small scale screening, eight DKRs were set up at 1 g scale to highlight the 
biocatalytic potential of this versatile enzyme for the preparation of valuable, optically pure 
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teaching me that through determination everything is possible in life and for giving me the 




“How would you like to live in Looking-Glass House, Kitty? I wonder if they'd give you milk 
in there? Perhaps Looking-Glass milk isn't good to drink?” 
Lewis Carroll, Through the Looking-Glass 
 
“The aim of science is not to open the door to infinite wisdom, but to set a limit to infinite 
error [...] Nowadays, anyone who wishes to combat lies and ignorance and to write the 
truth must overcome at least five difficulties. He must have the courage to write the truth 
when truth is everywhere opposed; the keenness to recognize it, although it is everywhere 
concealed; the skill to manipulate it as a weapon; the judgment to select those in whose 
hands it will be effective; and the running to spread the truth among such persons.” 
Bertolt Brecht, Life of Galileo 
 
“È di nuovo fra noi, in un bicchiere di late. È inserito in una lunga catena, molto complessa, 
tuttavia tale che quasi tutti i suoi anelli sono accetti nel corpo umano. Viene ingoiato: e 
poiché ogni struttura vivente alberga una selvaggia diffidenza verso ogni apporto di altro 
materiale di origine vivente, la catena viene meticolosamente frantumata, ed i frantumi, 
uno per uno, accettati o respinti. Uno, quello che ci sta a cuore, varca la soglia intestinale 
ed entra nel torrente sanguigno: migra, bussa alla porta di una cellula nervosa, entra e 
soppianta un altro carbonio che ne faceva parte. Questa cellula appartiene ad un cervello, e 
questo è il mio cervello, di me che scrivo, e la cellula in questione, ed in essa l'atomo in 
questione, è addetta al mio scrivere, in un gigantesco minuscolo gioco che nessuno ha 
ancora descritto. È quella che in questo istante, fuori da un labirintico intreccio di sì e di no, 
fa sì che la mia mano corra in un certo cammino sulla carta, la segni di queste volute che 
sono segni; un doppio scatto, in su ed in giù, fra due livelli d'energia guida questa mia mano 
ad imprimere sulla carta questo punto: questo.” 
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NCAAs and derivatives used in this experimental work. To identify the various compounds a 
classification system based on a letter plus number code was employed. The letter identifies 
the specific amino acids, based on the side chain; while the number indicates if the 
compound is free, or it has been derivatised, as reported in Figure G1.  
 
Figure G1 Classification system used in this experimental work to identify the various NCAAs 
derivatives employed. All NCAAs reported in their L-configuration. 
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Only two exception are the para-chloro and bromo phenylalanine derivatives, which are 
classified as reported in Figure G2. 
 
Figure G2 Classification system used in this experimental work to identify the para-chloro and para-
bromo phenylalanine derivatives. 
For the racemic compounds any change in the sample enantiopurity, following enzymatic 
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1.1 Non-Canonical Amino Acids (NCAAs) 
1.1.1 Applications  
Given their inherent chirality and structural variety, enantiopure canonical and non-canonical 
amino acids (NCAAs) have always played a fundamental role as synthons for the production 
of fine chemicals and additives.1 Since NCAAs are not genetically encoded, they cannot be 
naturally incorporated into proteins during translation. For this reason, NCAAs are often 
referred as non-proteinogenic or unnatural.2 However, the term non-canonical is more 
generic, because it comprises both natural product and synthetic AAs. Indeed, the vast 
majority of known NCAAs are produced by animals, plants and microorganisms as secondary 
metabolites and employed as intermediates in various biosynthetic pathways (e.g. citrulline 
and ornithine are formed during the urea cycle), 3 or as agents for pests’ control.4,5 
 
Figure 1.1 Example of NCAAs employed in the preparation of pharmaceuticals and agrochemicals.6,7 
Figure adapted from Zhou et al.8 
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NCAAs may possess a peculiar group on their side chain, a D-stereoconfiguration, or the chiral 
centre moved further along the carbon chain. Thanks to their structural variety, NCAAs have 
found numerous applications in various fields.9 As biologically active enantiopure compounds 
they have been employed as chiral building blocks for the synthesis of pharmaceuticals and 
agrochemicals (Figure 1.1).6 As of 2010,10 12% of the top 200 drugs on the market contained 
a non-proteinogenic amino acid.  
 
Figure 1.2 Genetic code expansion strategy for the incorporation of a NCAA into a protein sequence. 
An orthogonal aminoacyl-tRNA synthetase (aaRS) catalyse the coupling of the NCAA with the 
orthogonal tRNA molecule consuming ATP. The loaded tRNA is then bound to the ribosome during 
translation to incorporate the NCAA in the protein sequence at the desired position. Adapted from 
Zhao, Burke and Green.11 
The global substitution of a canonical amino acid with a non-canonical analogue is an 
important tool used to tune the chemical and physical properties of proteins and enzymes. 
For instance, the substitution of methionine with selenomethionine12 allows heavy atom 
incorporation and the resolution of a protein X-ray structure; a necessary strategy whenever 
molecular replacement is not a viable option. Recently NCAAs have also been employed as 
tools for protein engineering, thanks to the development of various genetic code expansion 
strategies, which allow to selectively introduce a NCAA at the desired position in a protein 
sequence (Figure 1.2).2,11,12  
 
Scheme 1.1 Synthesis of Anti-Her2-Auristatin. The Anti-Her2 antibody was modified to incorporate 
the non-canonical amino acid p-acetyl phenylalanine (pAcF). The acetate group of the NCAA reacts 




These techniques can be employed to design enzymes with enhanced activity,14 as recently 
reported by Green,15 non-natural cofactors (e.g. artificial metalloenzymes) or novel 
mechanisms.16–18 Genetic code expansions are also employed in the development of 
biotherapeutics with NCAAs, such as antibody-drug conjugates (ADC), therapeutic peptides 
and protein-based vaccines, with increased stability, potency and selectivity (Scheme 1.1).13 
1.1.2 Classic strategies for NCAAs production  
The increase of the applications of NCAAs in recent years led to a rise in the market demand 
of these compounds. The majority of canonical L-amino acids are prepared at large scale via 
fermentation processes using genetically modified bacterial strains including Escherichia coli 
and Corynebacterium glutamicum.19 This technique cannot be applied for the production of 
enantiopure NCAAs, since their biosynthetic pathways are often complex and not well 
studied, which makes metabolic engineering quite challenging.3 However, a few exceptions 
have been described in the literature, such as for β-phenylalanine production. 20  
Following the publication of the first amino acid synthesis, reported by Strecker in 1850,21 a 
wide range of strategies have been developed for the preparation of these compounds. 
According to the work of Nàjera and Sansano22 the stereoselective synthesis of α-amino acids 
can be achieved on a small scale, with good to excellent results, using four main strategies 
(Figure 1.3). However, most of the enantioselective catalysts employed in these reactions are 
either metal complexes with chiral ligands or optically pure organocatalysts and their 
application at industrial scale is limited by the high-cost of production, the toxicity of the 
transition metals and the complex synthesis of the ligands.  
 
Figure 1.3 The four main strategies used for the chemocatalytic synthesis of amino acids.22 
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Currently the majority of non-proteinogenic amino acids are chemically synthesised and sold 
as racemic mixtures. 
1.2 L-phosphinothricin (PT) 
1.2.1 A peculiar natural product 
L-phosphinothricin (PT) is a secondary metabolite produced by various species of 
actinomycetes and a NCAA structural analogue of glutamic acid (Figure 1.4). Being the only 
phosphinic acid-derived natural product isolated, PT belongs to the family of the bioactive C-
P compounds. Phosphinic acids have a structure similar to the phosphate anhydrides, 
however the O-P-O bond is substituted by a stronger C-P-C bond, which is able to resist harsh 
thermal and chemical treatments.23 The bioactivity of C-P natural products is given by their 
structural similarities with carboxylic acids and anhydrides; these compounds usually acts as 
strong inhibitors competing with the substrate for the enzyme active site.23 
1.2.2 Biosynthesis 
In the L-PT biosynthetic pathway the free amino acid is never directly produced, since L-PT is 
always incorporated in the structure of tri- or tetra-peptides (Figure 1.4). Examples include 
bialaphos (PT-Ala-Ala or PTT) isolated from Streptomyces viridochromogenes, phosalacine 
(PT-Ala-Leu) by Kitasatospora phosalacina and trialaphos from Streptomyces hygroscopicus 
(PT-Ala-Ala-Ala).23 These bioactive peptides use a so-called “Trojan Horse” mode of action, 
since they can be easily assimilated through the cell membrane of the target organism and 
hydrolysed by various endogenous non-selective peptidase, releasing the bioactive L-PT. 
 
Figure 1.4 Structure of the L-PT containing non-ribosomal peptides isolated from S. 
viridochromogenes (bialaphos, PTT), S. hygroscopicus (trialaphos) and K. phosalacina (phosalacine). 
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These natural products belong to the family of non-ribosomal peptides (NRP),24 since their 
synthesis is completely independent from the mRNA and ribosomes, but is under the control 
of NRP-synthetases (NRPS). This large multi-enzymatic system formed by various units, which 
are dedicated to the recognition and activation of amino acid residues and peptide bond 
formation. Isolation of the PTT gene cluster from S. viridochromogenes Tü494,25,26 (Figure 1.5 
and Table 1.1) allowed for the elucidation of the steps involved in the tripeptide biosynthesis 
from phosphoenolpyruvate (PEP, Scheme 1.2). Two molecules of PEP serve as starting 
material for the formation of N-acetyl demethyl-phosphinothricin (NAcDMPT); twelve 
enzymes are directly involved in the synthesis of this L-PT precursor. NAcDMPT is then 
activated via adenylation (adenylation A module) by the first module of the NRPS (PhsA), 
while the other two larger modules (PhsB and PhsC) activate, via thioester formation (PCP), 
and add an alanine residue (condensation C module) the growing peptide (Scheme 1.3).24,27 
The formation of the peptide bonds is followed by the methylation of the phosphinic acid 
and the hydrolysis of the acetate group, yielding bialaphos as final product (Scheme 12). 
 
Figure 1.5 The PTT biosynthetic gene cluster from S. viridochromogenes Tü494 with the ORFs drawn 
in scale, according to Schwartz et. al. 26 
Abbreviation Enzyme 
Ppm phosphoenolpyruvate mutase 
Ppd phosphonopyruvate decarboxylase 
PgmP putative phosphoglycerate mutase 
AdhP putative alcohol dehydrogenase 
AldP putative aldehyde dehydrogenase 
Cppm carboxy-PEP phosphonomutase 
Cpps carboxy-PEP synthase 
Pms phosphinomethylmalic acid synthase 
Pmi phosphinomethyl malate isomerase 
L-AT putative aminotransferase 
PAT phosphinothricin N-acetyltransferase 
PhsA phosphinothricin tripeptide synthetase A 
PhsB phosphinothricin tripeptide synthetase B 
PhsC phosphinothricin tripeptide synthetase C 
Pmet P-methylase 
Dea deacetylase 
Table 1.1 List of the sixteen enzymes, abbreviations and full names, involved in the biosynthesis of 




Scheme 1.2 Proposed S. viridochromogenes Tü494 thirteen steps biosynthetic pathway for the 




Scheme 1.3 Mechanism for the formation of the peptide bond catalysed by the condensation 
domain C of NRPs. Following amine attack at the carbonyle, the process passes through the 
formation ofa tetrahedral intermediate, which collapses forming the desired dipeptide product. 
It was found that L-PT displays antibacterial, fungicidal and herbicidal activity, being a strong 
inhibitor of the enzyme glutamine synthetase (GS).28 Racemic PT is employed as the bioactive 
ingredient of various commercial herbicide formulations (e.g. Basta® and Finale® produced 
by Bayer)29 and used for weed control in both uncultivated and crop fields. It is sold as a 
soluble concentrate (200 g/L) at 8.80 $/L and applied on the crops via spraying the diluted 
formulation over the fields. L-PT can also cause acute toxicity in humans via ingestion; a dose 
of ~300 mg/Kg of Basta® produces severe damage to the nervous and circulatory systems 
and it can be fatal if not treated adequately .28 However, its efficacy as an antibiotic is quite 
poor, since the host tissues can easily provide glutamine to the invading organism, effectively 
nullifying L-PT toxicity. 
 The target GS enzyme plays a fundamental role in the metabolism of plants and other 
organisms, since it is able to fix ammonia, using glutamic acid to synthesize the amino acid 
glutamine.30 The GS enzymes have been divided in two groups; the type I found in 
prokaryotes is a dodecamer composed by twelve identical units, while the type II isolated in 
eukaryotes (animals and plants) is a decamer (Figure 1.6).30,31 Despite the structural 
differences, the two GS groups share a common two-step mechanism (Scheme 1.3) in which 
the glutamic acid bound to the enzyme is first activated by transfer of a phosphate group 
from ATP to the γ-carboxylate of the substrate; an ammonium ion is then deprotonated by 
the D56 residue situated on the adjacent chain of GS. The ammonia generated undergoes a 
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nucleophilic substitution with the activated substrate to form glutamine with the release of 
a phosphate group.  
 
Figure 1.6 Bacterial and Plant GSs resolved crystal structures. A) Crystal structure of Mycobacterium 
tuberculosis GS (1HTQ), 6 identical chains interact to form a hexagonal agglomerate. B) Two 
agglomerates stack together to give the dodecameric quaternary structure of the enzyme. C) Crystal 
structure of Maize GS (2D3C), 5 identical units interact to form a pentagonal agglomerate. D) Two 
agglomerates stack together to give the decameric quaternary structure of GS. 
L-PT can compete with L-glutamate for the GS active site; upon PT binding, the amino acid 
phosphinic group is phosphorylated by the enzyme using ATP, generating a stable 
intermediate which is not able to undergo nucleophilic substitution by ammonia, effectively 
inhibiting the enzyme activity (Figure 1.7). This cause an increase in the concentration of 
ammonium ions inside the cell, leading to its death.30 
 
Scheme 1.4 Two-step mechanism of the enzyme GS. Following the phosphorylation of the substrates 
γ-carboxylate, a nucleophilic ammonia attacks the activated intermediate to produce glutamine via a 
nucleophilic acyl substitution. 
Phosphinothricin is able to bind to both eukaryotic and prokaryotic GS enzymes; however 
various PT resistant bacterial strains have been isolated during the years (Rhodococcus, 
Alcaligenes faecalis, Streptomyces and E. coli). These bacteria have evolved various strategies 
for PT detoxification; when the NCAA enters the organism, it is immediately converted to an 
inactive derivative, usually via oxidative deamination, catalysed by an amino acid oxidase 
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(AAO) or transamination. Another strategy used by these microorganisms is the N-
acetylation of L-PT catalysed by a phosphinothricin acetyl transferase (PAT) enzyme. 32–34 The 
PAT isolated from S. viridochromogenes and S. hygroscopicus are well characterised and have 
been employed to create various PT resistant crops used in agriculture.35 
 
Figure 1.7 Crystal Structure of the Maize GS (2D3C) in complex with three Mn2+ ions (red spheres), 
ADP and phosphinothricin phosphate (PT-Pi). The GS active site is formed by residues located on two 
adjacent chains; D56 (cyan) from chain B is involved in the ammonium ion binding and 
deprotonation, while E297 (blue) from chain A plays a role in substrate recognition. 
Commercials herbicide are classified accordingly to which part of the plant metabolism they 
are going to disrupt, usually via inhibition of a target enzyme. Common mode of actions 
includes photobleaching and the disruption of cell division, carotenoid biosynthesis, 
photosynthesis, or lipid synthesis (acetyl-CoA carboxylase inhibitors).36 Other herbicides with 
a similar mode of action (distruption of amino acid synthesis) to L-PT are the inhibitors of 5-
enolpyruvyl-shikimate-3-phosphate synthase (EPSP synthase), involved in the biosynthesis of 
aromatic amino acids (Phe, Tyr and Trp) and of acetolactatesynthase (ALS synthase), which 
intervenes in the production of branched AAs (Val, Leu, Ile).37 
1.2.3 Asymmetric synthesis of phosphinothricin 
As with many other natural products, the two stereoisomers of PT possess different 
proprieties; while the L-enantiomer is a potent inhibitor, the D-isomer is completely inactive. 
For this reason, the development of an efficient enantioselective route for the production of 
L-PT has been an important focus of research. Given the complexity of the phosphinothricin 
biosynthetic pathway metabolic engineering was not a viable option; however, two synthetic 




Scheme 1.5 Enantioselective hydrogenation of PT prochiral intermediate 6a, catalysed by optically 
active Rh(I) bis-phosphines complexes. The ligand R,R-NORPHOS provided a 90.8% ee in the 
synthesis of S-7a in MeOH/H2O with a 150:1 substrate/catalyst ratio loadings.38 
The first stereoselective route38 consisted of a six-step synthesis (Scheme 1.4) where the 
prochiral 6a intermediate undergoes a hydrogenation catalysed by chiral rhodium-phosphine 
complexes; the reduced product is then hydrolysed to give optically pure PT ammonium. By 
changing the ligand on the chiral complexes, it was possible to selectively produce either the 
S or R enantiomer with up to 91% ee. 
 
Scheme 1.6 Two-step synthesis of L-PT from L-vinyl glycine derivative 8a.39 
A second three-step synthesis of L-PT using L-vinyl glycine derivatives as starting material39 
was reported in 1992 (Scheme 1.5). The desired product was obtained in moderate to good 
yield (57-97%) and high enantiopurity (92-97% ee); unfortunately, the preparation of vinyl 
glycine derivatives from L-methionine, or L-glutamic acid, requires the use of toxic reagents, 
such as lead acetate, and yields small amounts of the desired product. 
 
Scheme 1.7 Three-step synthesis of racemic PT from methyl-di-chloro phosphate and acrolein, via 
Strecker reaction.40 
Both stereoselective strategies rely on the use of toxic reagents or expensive catalysts and 
could not be applied for industrial scale production. Currently PT is synthesised using a classic 
Strecker reaction (Scheme 1.6)40 to introduce the α-amino and α-carboxylate groups onto 
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the carbon chain and the final product is sold as a racemic mixture. For every application of 
L-PT based herbicide, 50% of the product used is wasted. Studies of various cultivations 
revealed that ~90% the of D-PT applied41 is not metabolised by plants, but an accumulation 
of this stereoisomer can potentially be dangerous for the environment. An alternative 
solution to the classic organic synthesis strategy is required to develop an industrial scale 
process for L-PT production. 
1.3 Biocatalysis 
1.3.1 Overview 
Biocatalysis, or the use of enzymes to catalyse chemical reactions, has been employed for 
centuries for food and alcoholic drink production; even if its true potential has been 
discovered more than a century ago, only recently biocatalysis has been applied in the 
development of novel synthetic strategies, especially for the design of chiral compounds 
(Figure 1.8). In the last thirty years the progress achieved in the field of molecular biology 
and gene technology has made it possible to isolate, express and evolve the target enzyme 
to obtain the desired process-tailored biocatalysts. Bornscheuer42,43 recently announced the 
rapid approach of a fourth wave of biocatalysis, which would focus on the expansion of the 
pool of biocatalysed reactions and on the development of efficient enzymatic cascade via 
metabolic engineering to achieve a cost-effective strategy for the synthesis and isolation of 
challenging natural products targets. 
 
Figure 1.8 The four waves of biocatalysis. Bornscheuer proposed this classification to describe the 
progress achieved in the field and the current state of the art. 42,43 
While the preparation of optically pure molecules still represents a challenge for organic 
chemistry, enzymes are characterised by intrinsic high chemo, regio and enantioselectivity. 
Furthermore, the set-up for a typical biocatalytic reaction is quite straightforward and “safe” 
since enzymes work at low temperatures (20-37°C), in water-based buffer solutions, at 
neutral pH (6-8) and atmospheric pressure. 44 The mild reaction conditions, coupled with the 
use of biodegradable proteins as catalysts, classifies biocatalysed processes as 
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environmentally friendly; a factor which contributed to the increase in popularity of this filed, 
given the growing concern for the current state of the environment and the need to eliminate 
the use of hazardous reagents in manufacturing.45 
However, the application of biocatalysis at industrial scale has been slowed by several 
limitations of enzymatic processes, such as the low stability of proteins operating outside, far 
from physiological conditions, the limited range of enzyme-catalysed reactions and the low 
tolerance for organic solvents, which make the synthesis and recovery of hydrophobic 
compounds quite challenging. Furthermore, the high selectivity of biocatalysts is also their 
Achilles heel, since they are usually characterised by a narrow substrate scope.44  
Thanks to the pioneering work of Stemmer,46,47 Reetz48,49 and Arnold50,51 (Nobel prize for 
chemistry, 2018) a wide range of novel techniques have been developed and successfully 
employed to engineer enzymes via directed evolution, or rational design. Directed evolution 
is best described as an in vitro Darwinian selection strategy, where a range of techniques 
could be employed to generate a large number of variants of the target enzyme with 
mutations at random positions in the amino acid sequence; this mutant library is then 
screened to isolate the best variant with the desired properties (i.e. activity, stability, 
selectivity). While the rational design approach relies on computational analysis and protein 
structural information, to identify the target amino acid residues to mutate. 
Both strategies have been successfully employed not only for the improvement of enzyme 
stability and activity, but also to alter the substrate specificity and to gain access to novel 
biocatalysed reactions, including Diels-Alder condensations, Kemp elimination and 
cyclopropanation, with few to no previous examples discovered in nature.52 
1.3.2 Industrial biocatalysis 
Progress in the field of molecular biology combined with the successful application of enzyme 
engineering and immobilization has allowed researchers to overcome some of the classic 
limitations of biocatalysis, as a result biocatalysed processes became more suitable for 
industrial applications. 
Currently, enzymes are employed in the manufacture of food (prebiotics and low-calorie 
sweeteners productions), cosmetics (emollient ester synthesis), textile (dyeing and 
bleaching), pulp and paper (lignin and hemicellulose removal) and fine and bulk chemicals 
(acrylamide and glycolic acid production).53,54 In the last five year (2014-2019) ~200 patents, 
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which cover the use of all main enzyme classes, have been approved (Figure 1.9) and a 
growth in the enzyme market from 7$ to 10$ billion is expected by 2024.55 
 
Figure 1.9 Distribution of patented enzymes. A) Number of approved patents for each major class of 
enzymes between 2014 and 2019. B) Distribution of granted patents, which cover the use of an 
enzymatic processes, over the last five years.55 
However, biocatalysis has mainly been exploited in the last decade in the pharmaceutical 
field, as a potent tool for the production of small stereoisomeric active pharmaceutical 
ingredients (API) via resolution (maximum yield 50%), or stereoselective introduction of a 
stereocenter (100% theoretical yield).56,57 The exquisite regio- and enantio-selectivity of 
enzymes, the ability to tune the catalysts to match the desired properties (activity, stability), 
the recent development in bioinformatics (de novo design and biocatalytic retrosynthesis) 
and the decreasing cost of synthetic genes have contributed to the increasing interest that 
has caused many global pharmaceutical companies to take to this field. 58 
In 2010 Merck and Codexis were awarded the Green Chemistry Prize award for the 
biocatalytic production of sitagliptin (treatment of diabetes mellitus type II) via 
transamination (Scheme 1.7).59 The transaminase (TA) ATA-117 was engineered using 
rational design in combination with saturation mutagenesis to isolate an active mutant 
towards the prochiral precursor: the prositagliptin ketone. The final variant contained 27 
mutations (R-TA-27 mut), which were necessary not only to modify the TA substrate scope 
and activity, but also to improve its stability towards the required reaction conditions: high 
concentration of the amino donor isopropylamine (IPA) and DMSO. The final biocatalytic 
process provides sitagliptin with an increase in the final yield and ee, along with a reduction 
of waste and cost production, compared to the classic chemocatalytic strategy, where an 
asymmetric Rh catalysed hydrogenation was necessary to enantioselectively convert the 




Scheme 1.8 Asymmetric synthesis of sitagliptin from the prochiral ketone precursor via 
transamination. 59 
The biocatalytic synthesis of sitaglipin has become a milestone for the employment of 
enzymes in API manufacture, since 2010 numerous applications of engineered enzyme in 
drug discovery have been reported in literature.56 In 2015 Codexis reported the used of an 
evolved Bayer-Villiger monooxygenase (BVMO) for the synthesis of esomeprazole 
(narcolepsy treatment).60 Esomeprazole belongs to a class of APIs containing a chiral 
sulfoxide group, which is usually obtained from the oxidation of a sulphur precursor. 
Unfortunately, classic chemosynthetic strategy relies on the use of the Kagan-Sharpless 
catalyst, which is plagued by various drawbacks: poor yield, low enantioselectivity and 
excessive oxidation, with the formation of the sulfone side-product. A BVMO enzyme with 
activity for the esomeprazole precursor, pyrmetazole, was isolated and subjected to various 
rounds of directed evolution. The final variant contained 41 mutations and displayed an 
140000-fold increase in productivity and < 0.1% sulfone formation. The engineered BVMO 
was coupled with a ketoreductase (KRED) active towards isopropylalcohol for continuous 
cofactor (NADPH) regeneration to create an efficient cost-effective industrial scale process 
(Scheme 1.8). 
 
Scheme 1.9 Engineered Codexis BVMO, coupled with KRED, for the catalysed oxidation of a sulphur 
to sulfoxide for the enantioselective synthesis of esomeprazole. 60 
Recently a biocatalytic retrosynthesis approach has been employed by Merck to create an 
efficient in vitro biocatalytic cascade, consisting of five engineered (Table 1.2) and four 
supporting enzymes for cofactor recycling, for the production of the anti-viral nucleoside 




Scheme 1.10 Enzymatic cascade for the biocatalytic preparation of the anti-viral HIV drug islatravir 
from prochiral ethynyl glycerol. 61 GOase, Fusarium graminearum oxidase; PanK, E. coli phosphate 
transferase; DERA, Shewanella halifaxensis deoxyribose 5-phosphate aldolase; PPM, E. coli 
phosphopentomutase and PNP, E. coli purine nucleoside phosphorylase. 
Biocatalytic cascades exploit the ability of various enzymes to work in cooperative conditions 
and are considered a promising strategy for the synthesis of small molecules with various 
functional groups since no intermediate isolation and protection/deprotection steps are 
required. Furthermore, enzyme coupling is an effective strategy to overcome 
thermodynamically unfavourable steps pushing the equilibrium towards product formation. 
According to the retrosynthetic analysis, five steps are required to obtain islatlavir starting 
from the cheap prochiral ethynyl glycerol. The Fusarium graminearum oxidase (GOase) and 
the E. coli phosphate transferase (PanK) catalyse respectively the oxidation and 
phosphorylation of an alcohol group of ethynyl glycerol for the desymmetrisation of the 
starting material. This is followed by an aldol consensation catalysed by Shewanella 
halifaxensis deoxyribose 5-phosphate aldolase (DERA) for the formation of the sugar moiety, 
which is subsequently phosphorylated by the E. coli phosphopentomutase (PPM). Finally, the 
E. coli purine nucleoside phosphorylase (PNP) catalyse the condensation between the sugar 
moiety and the synthetic nitrogenous base to yield islatravir. A combination of rational design 
and directed evolution was employed to evolve the selected enzymes and once the improved 
variants had been isolated, a strategy on how to best couple the mutants was developed. A 
total of nine enzymes: the five engineered biocatalysts and four auxiliary enzymes, required 
for efficient cofactor recycling and to push the equilibrium towards product formation, were 
employed for the one-pot biocatalytic production of islatravir with an overall yield of 51% 









GOase stereoselectivity 12 34 
Pank activity 3 10 
DERA acetaldehyde tolerance 2 11 
PPM activity 2 5 
PNP activity 4 7 
Table 1.2 Evolution of the five enzymes directly involved in islatravir synthesis.61 
1.3.3 Biocatalytic synthesis of amino acids 
Biocatalysis established itself as a competitive and effective strategy for the production of 
small molecules with a single stereocenter and polar groups (alcohols and amines). Given the 
ability of enzymes to tolerate a wide range of functional groups, without the need of the 
numerous protection and de-protection steps, typical of a chemosynthetic process. Indeed, 
biocatalysis has become a popular tool, even among chemists, for the production of small 
polar compounds, such as amino acids, which can be achieved with two main strategies: (I) 
asymmetric synthesis, or (II) kinetic resolution. A large variety of enzymes have been isolated 
and applied for the enantioselective synthesis of these important chiral building blocks.62 
1.3.3.1  Asymmetric biocatalytic synthesis of amino acids 
This strategy involves the stereoselective introduction of the primary amine group on a 
prochiral starting material, such as keto and unsaturated acids; this type of synthesis can be 
achieved by different classes of enzymes, each with a unique mechanism. 
Amino Acid Dehydrogenases (AADH) catalyse the reversible reductive amination of α-keto 
acids (KA) to α-amino acids. The reduction is achieved using ammonia as amino donor and 
NAD(P)H as cofactor, which is converted to NAD(P)+ during the process. Being quite 
expensive, a good cofactor recycling strategy needs to be employed to obtain an efficient 
and cost-effective synthesis on a large scale. This class of enzymes usually display a high 
stereoselectivity and a favourable equilibrium towards amine formation, unfortunately 
AADH suffers from narrow substrate scope. Enzyme engineering is often employed to 
improve the dehydrogenase activity towards the desired substrates with a good number of 
successful attempts reported in literature. 
In 2006 Novick63 evolved the NADPH dependant C. glutamicum meso-2,6-D-diaminopimerate 
dehydrogenase (meso-DAPDH); the resulting quintuple mutant DAADH showed a broad 
substrate scope and was successfully employed by Turner7 in the synthesis of D-arylalanines 
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(Scheme 1.10). Recently Yang et al. reported the use of an engineered Pseudomonas putida 
GluDH for the large-scale production of L-PT.64 
 
Scheme 1.11 Application of the engineered DAADH for the production of D-Phe analogues. A glucose 
dehydrogenase (GDH) is coupled in the system for the recycling of NADPH.7 
Transaminases (TA) catalyse the PLP mediated transfer of the amine group from a sacrificial 
amino donor to the substrate. TAs are divided in two main groups: α-TAs, which exclusively 
bind α-keto acids and ω-TAs which do not require the presence of a carboxylic acid at the α 
position of the substrate. These enzymes are characterised by a broad substrate scope and 
high stereoselectivity but an unfavourable thermodynamic equilibrium, which results in poor 
conversion and difficult product recovery, due to the large excess of amino donors used in 
the biotransformation. Various strategies employed to overcome this limitation include 
exploiting product solubility, the use of a smart amino donor easily removed via evaporation 
(isopropylamine),59 or by filtration of the precipitate polymeric by-product (o-
xylylenediamine),65 or the coupling of the TA in an enzymatic cascade for amino donor and 
cofactor recycling.  
 
Scheme 1.12 Tri-enzymatic cascade for the production of unnatural AAs.8 
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In 2019, the coupling of a TA, an AADH and an alcohol dehydrogenase (ADH) in a tri-enzymatic 
cascade was successfully employed for the production of unnatural amino acids using a 1:100 
of amino donor to substrate ratio (Scheme 1.11).8 
Ammonia Lyases (AL) and Amminomutases (AM) catalyse the reversible addition of 
ammonia, or amines, to the C-C double bond of α,β-unsatured acids. The reaction is mediated 
by the MIO cofactor, which is formed in situ in the enzyme active site via cyclization and 
dehydration of highly conserved Ala, Ser and Gly residues; no cofactor recycling strategies 
are required for these enzymes. The Turner group has carried out extensive research on the 
phenylalanine ammonia lyase (PAL) enzymes, given their biocatalytic potential and in 2016 
reported an engineered variant of Rhodotorula graminis PAL for the production of electron-
poor L-Phe derivatives (Scheme 1.12).66 
 
Scheme 1.13 PAL catalysed reaction and structure of MIO cofactor. 66 
The natural role of AM is to catalyse the isomerization of α to β-AAs, the enzyme is able to 
transfer the amino group from the α to the β position of the substrate passing through the 
formation of an α,β-usatured acid as intermediate (Scheme 1.13). If able to control the 
regioselectivity of the reaction, this class of enzyme shows a high potential for the selective 
production of β-AAs. Janssen67 reported an efficient engineered phenylalanine AM for the 
production of aromatic β-amino acids. Since the reaction pass through the formation of an 
enolate intermediate, the regioselectivity of the process was tuned by inserting mutations 
that stabilize the negative charge on the aromatic ring, favouring the attack of the amino 
group at β position. 
 
Scheme 1.14 Isomerization of α to β-L-amino acid catalysed by PAM. 
Aldolases are PLP dependant enzymes, various members of this family (threonine aldolases 
and α-methylserine aldolases) are able to catalyse the condensation of an amino acid with 
an aldehyde to form a β-hydroxy-α-amino acid. This condensation has high potential for 
synthetic applications since aldolases have generally a good aldehyde scope and during the 
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reaction a new C-C is formed introducing two stereogenic centre in the product (Scheme 
1.14).68 However, these enzymes suffer from poor diastereoselectivity, especially in the 
formation of the stereocenter at the β carbon; engineering is often required to improve the 
selectivity of the biocatalytic process. 
 
Scheme 1.15 Biocatalytic aldol condensation between glycine and an aldehyde for the formation of 
two β-hydroxy-α-amino acid diastereoisomers. 
1.3.3.2 Kinetic resolution (KR) of amino acids 
The second strategy exploited for the enzymatic synthesis of amino acids is the kinetic 
resolution of racemic derivatives; which can be carried out with a wide variety of hydrolytic 
enzymes.62 The popularity of this process derives from a favourable reaction equilibrium, 
shifted towards the formation of the product and the high stereoselectivity of hydrolases, 
furthermore this family of enzymes do not require the use of expensive cofactors. KRs suffer 
from poor yields; the maximum conversion of a typical process is 50%, leaving half of the 
starting material (the undesired enantiomer) unreacted (Figure 1.10 A). However, this 
limitation can be overcome by introducing an in-situ racemization step (Figure 1.10 B) to 
deplenish the unwanted enantiomer and achieve a maximum theoretical conversion and 
enantiomeric excess of 100% in a dynamic kinetic resolution (DKR).69,70 To obtain an efficient 
DKR a highly enantioselective hydrolysis and a fast racemization equilibrium are required, 
this last step can be either spontaneous, chemo or enzyme catalysed. 
 
Figure 1.10 Schematic representation of a A) KR and B) DKR process. 
Various chemoenzymatic DKRs have been successfully achieved for the synthesis of alcohols 
and amines, combining hydrolytic enzymes with Ru and Pd complexes;71 however, the only 
example of chemoenzymatic DKR for amino acid preparation was reported by Turner in 
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2000.72 The Novozyme lipase was employed to obtain L-amino acid derivatives (81% yield) 
from racemic oxazolones, which racemase at alkali pH in the presence of a base (NEt3), given 
the low pKa of the C4 proton (Scheme 1.15 A). An example of spontaneous racemization was 
described by Wei et al. by employing a nitrilase stable at basic pH to obtain the DKR of 
phenylglycinonitrile; α-aminonitriles undergoes spontaneous racemization under alkali 
conditions (Scheme 1.15 B).73 Chemocatalysed or spontaneous racemisations are not popular 
strategies, since the majority of enzymes do not tolerate harsh conditions or the presence of 
transition metal complexes in solution. 
 
Scheme 1.16 Examples of chemoenzymatic DKR. A) Chemoenzymatic DKR for the synthesis of AAs 
derivative from oxazolones. B) Spontaneous racemization, followed by enzymatic hydrolysis of α-
aminonitriles.72,73 
A class of enzymes called racemases (E.C. 5.1), which catalyse the inversion of 
stereochemistry of a chiral centre of the substrate, have been employed in the development 
of various biocatalytic DKR.74 An attractive trait of racemases is their high substrate 
chemoselectivity, since they bind exclusively to either free amino acids (AA racemase class) 
or their derivatives; an important factor in a DKR process, where a chemoselective 
racemization step is required to avoid low product optical purity. 
Amino acid racemase (AAR) have found application in the synthesis of cyclic amino acid; in 
this DKR an AAR is coupled with a stereoselective cyclodeaminase (Scheme 1.16).75 While 
hydantoin racemase, α‑amino‑ɛ‑caprolactam (ACL) racemase and N-acetyl amino acid 
racemase (NAAAR) were employed in hydrolytic DKR processes for the production of both 
natural and non-natural amino acids.74,76 
 
Scheme 1.17 DKR of racemic lysine for the production of S-pipecolic acid. 75 
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Hydantoin racemase are coupled with two enantioselective hydrolases in the so-called 
hydantoinase process (Scheme 1.17); in this tri-enzymatic process the two enantiomers of 
monosubstituted racemic 5-hydantoines, are in a dynamic equilibrium, catalysed by the 
racemase enzyme. The D-hydantoinase opens the heterocycle via hydrolysis of one amide 
bond and the N-carbamoyl-D-amino acid intermediate is then converted into the final 
product by by the D-selective carbamoylase. This process is employed for the production of 
D-amino acids given the higher number of D-stereospecific hydantoinases isolated.77–80  
 
Scheme 1.18 The hydantoinase process; a hydantoin racemase catalyse the equilibrium between L 
and D-hydantoines, while two enantioselective hydrolytic enzymes (D-hydantoinase and D-
carbamoylase) convert the starting material to D-AA. 
An ACL racemase was also employed in the synthesis of D-arylalanines via a biocatalytic DKR 
of α-aminoamides, by coupling the racemase with a D-selective amidase (Scheme 1.18); 
unfortunately, ACL racemase substrate scope is usually limited and enzyme engineering is 
required to improve the biocatalyst efficiency, as reported by Asano.81 
 
Scheme 1.19 Biocatalytic DKR of α-amino amides for the production of D-amino acids. 81 
NAAARs are particularly attractive since they possess a broad substrate scope and can be 
efficiently coupled with acylases in a DKR for the production of α-amino acids (Scheme 
1.19).76 Acylases are highly stereoselective metalloenzymes, which catalyse the hydrolysis of 
the acetate group of N-acetyl amino acids. They are reported to be active for a wide range of 
N-acetyl-NCAAs,82,83 furthermore both L and D-stereospecific acylases have been isolated by 
various bacterial strains,84,85 thus this process can be employed for the synthesis of both D 
and L-NCAAs. 
 
Scheme 1.20 DKR for the production of L-amino acids from N-acetylated derivatives via coupling of 
NAAAR with an L-acylase. 
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1.3.4 Future challenges 
The last decade has been characterized by a growth of the biocatalysis field, with numerous 
papers and patents being published every year. It is clear that biocatalysis has established 
itself as a fundamental tool for the production of both high (pharmaceuticals) and low-cost 
(bulk chemicals) products in small and large scale; however various bottlenecks still plague 
the sector. One of the main limitations of biocatalysis is the long time and great workload 
required to evolve enzymes, without any assurance to achieve the desired goal; the 
development of artificial intelligence and new technology for faster high throughput 
screening would probably play an important role to speed up the process of evolution.86 
While enzymes which catalyse functional group interconversion are well characterised, more 
research is required to develop efficient biocatalysts for C-C and C-X functionalization, to 
extend the repertoire of enzyme catalysed reactions.57 Moreover, novel enzyme 
immobilization and flow technologies, along with reactor design will be fundamental to 




1.4 N-Acetyl-Amino Acid Racemase  
1.4.1 Overview 
The discovery of NAAAR dates back at the end of the 20th century, with Tokuyama reporting 
the isolation of a novel racemase from the actinomycetes Streptomyces Y53,87 that is able to 
catalyse the stereoinversion of N-acetyl-amino acids. Over 49000 microorganisms were 
screened, however NAAAR activity was exclusively found in actinomycetes strains, such as 
Amycolaptopsis sp. TS1-60,88 A. azurea89 and A. orientalis subsp lurida.90 NAAARs were also 
isolated from several extremophiles strains: Deinococcus Radiodurans,91 Thermus 
thermophilus,92 Geobacillus kaustophilus93,94 and Geobacillus stearothermophilus.95 
At the time, the production of optically pure amino acids via enzymatic KR, was already a 
well-established process. Various industries expressed great interest in this new racemase 
class, given their potential in the development of an efficient DKR of N-Ac-AAs. Extensive 
studies were conducted on NAAAR and numerous patents, were published in the last 30 
years, as summarised in this work.96 Unfortunately, the isolated enzymes often exhibit low 
activity towards N-acetylated amino acids and substrate inhibition at concentration > 50 mM, 
hence, as previously reported, research on biocatalysis focused more on developing efficient 
methods for the direct asymmetric synthesis of NCAAs. 
 
Scheme 1.21 The bifunctional NAAAR is able to catalyse the racemization of N-acyl amino acid (top 
reaction) and the syn dehydration of SHCHC (bottom reaction), an intermediate of menaquinone 
(vitamin K12). 
The lack of activity of NAAAR towards N-Ac-AAs was rationalised by Gerlt,97 he proposed that 
the racemization of acylated amino acids was not the “correct” function of this class of 
enzymes. Indeed, NAAAR shows a degree of promiscuity, being able to catalyse two different 
reactions: the stereoinversion of N-acetyl-AAs with a kcat of 10 s-1 and the syn dehydration of 
2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate (SHCHC) to form o-succinylbenzoate 
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(OSB) with higher efficiency, a kcat of 120 s-1 (Scheme 1.20). The SHCHC syn dehydration 
reaction is typically catalysed in bacteria by OSB synthase (OSBS) enzymes; however, no osbs 
gene was found in Amycopatosis genome, suggesting that NAAAR was actually the enzyme 
involved in OSB production in these microorganisms, which would explain the higher activity 
of the enzyme toward the OSBS reaction. Furthermore, the racemase preference towards N-
succinylated substrates, with the isomerization of these substrates proceeding 10-fold faster 
than that of N-acetyl-AAs, lead Gerlt97 to conclude that NAAAR is a bifunctional member of 
the enolase superfamily, possessing both OSBS and N-succinyl-amino acid racemase (NSAAR) 
activity. To avoid confusion, in this work the term NAAAR will be used to denote the 
bifunctional enzymes belonging to the OSBS/NSAAR subgroup. 
 
Scheme 1.22 Examples of reactions catalysed by various members of the enolase superfamily. From 
the top dehydration of 2-phosphoglycerate, 1,2-ammonia elimination of 3-methyl aspartate, 
lactonization and racemization of L-Ala-L-Glu dipeptide. 
1.4.2 The enolase superfamily 
The enolase superfamily consists of over 8000 members, these enzymes are characterised by 
a highly conserved three-dimensional structure despite having diverse amino acid sequences 
and mechanisms (Scheme 1.21).77 
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The structural domains conserved in the enolase superfamily are an α+β capping domain 
(Figure 1.11 A and B) involved in substrate recognition and a (β/α)7β-barrel domain, a 
variation of the common (β/α)8-barrel (TIM-barrel) motif, found in ~10% of the crystal 
structures published in the protein data bank (PDB). The (β/α)7β-barrel (Figure 1.11 A and C) 
contains the catalytic acid/base and metal binding residues which form the active site of 
these enzymes.97,98 
 
Figure 1.11 The A. sp TS1-60 NAAAR crystal structure (1SJC) in complex with Mg2+ (red sphere) and 
N-succinyl methionine (grey). A) Structure of NAAAR monomer divided in two section; B) α+β 
capping domain (upper section) containing the 20s (magenta) and 50s (blue) loops and C) the 
(β/α)7β-barrel domain (lower section). 
Members of the superfamily are able to catalyse a wide range of reactions, such as 
racemization, β-elimination, lactone formation, and syn dehydration. However, all these 
biotransformations start with a common step: the formation of an enolate intermediate with 
the abstraction of the alpha-proton of the substrate (Scheme 1.22).99 This mechanism also 
suggests a key role for a metal ion (Mg2+) to stabilize the enolate via coordination and have 
substrates with a C-H in alpha position in a carboxylate group, which decrease the pKa of the 
α-proton and stabilise the intermediate via resonance. The deprotonation step is carried out 
by an amino acid residue which acts as general acid/base catalysts, these residues are not 
highly conserved in the family, which is actually divided in various subgroups based on the 
number and nature of catalytic amino acids employed for the enolate formation. Mandelate 
racemases (MR) use a Lys and His, while enolases use only a Lys and muconate lactonizing 




Scheme 1.23 Mechanism of base-mediated and metal-assisted α-proton abstraction of carboxylic 
acid substrates employed by the members of the enolase superfamily. 
Given their conserved architectural motifs and mechanistic diversity, the enolase superfamily 
was extensively studied by the Gerlt group in order to understand how enzymes can acquire 
new functions in nature during evolution.98,100 According to the divergent evolution theory, 
all members of this superfamily derive from a common ancestor with the ability to abstract 
the α-proton of carboxylic substrates. This ancestor then acquired new functions via 
selection of mutant variants; with the advantageous mutations being passed down various 
generations, eventually forming the enolase superfamily we know today. Evidence of this 
process occurring can be found within the family itself, since its members possess a certain 
degree of “flexibility” being able to acquire or lose a particular function with just a slight 
variation in their amino acid sequences. By inserting a single point mutation in the sequence 
of E. coli epimesare AEE and Pseudomonas sp. P51 MLE II, two mutants (AEE D297G and MLE 
II E323G), able to catalyse both their natural reaction and the syn dehydration of SHCHC were 
isolated and characterised. To be noted that the two wild type (WT) enzymes did not show 
any activity for the OSBS reaction.101 Furthermore, the OSBS activity of E. coli D297G AEE was 
improved by 5-folds inserting a second mutation (I19F).102 While D297 and E323 are located 
on the (β/α)7β-barrel, I19 is part of the capping domain; however, all three residues are 
involved in substrate recognition and binding, suggesting that changing substrate specificity 
is the first step taken during divergent evolution to allow the development of novel enzyme 
functions. A similar example was recently reported by Glasner et al.; where a mutation at the 
Y299 position of Alicyclobacillus acidocaldarius OSBS resulted in the isolation of a bifunctional 
enzyme with both OSBS and NSAAR activity.103 
1.4.3 Role, structure and mechanism 
The recognised biological role of NAAAR is to catalyse the formation of OSB, the fourth step 
in the biopathway for the synthesis of menaquinone (vitamin K12, Scheme 1.20).104 However, 
it is still not clear why some OSBS enzymes acquired additional NSAAR activity through 
evolution. Analysis of the genome of the microorganisms containing NSAAR/OSBSs revealed 
that the gene of this bifunctional enzymes is usually incorporated in an operon containing a 
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N-succinyl D-amino acid transferase (NSAT) and a M20 hydrolase.105 These three enzymes 
may work together to form a pathway for the detoxification of D-amino acids; which are first 
succinylated by NSAT and then converted to N-succinyl-L-AAs by the bifunctional NAAAR; in 
the last step the hydrolase remove the succinyl group and release the free L-amino acids 
(Scheme 1.23).96 Another possible role for NAAAR is to intervene in the synthesis of D-AAs, 
since these compounds are fundamental in bacteria, as an essential component of 
peptidoglycans, which contribute to cell wall formations.106 
 
Scheme 1.24 Proposed tri-enzymatic pathway for the detoxification of D-amino acids in 
microorganisms encoding a NSAT and a NSAAR/OSBS bifunctional enzyme. 
The three-dimensional structure of NAAAR closely resembles that of the other members of 
the enolase superfamily; the central (β/α)7β-barrel domain is highly conversed in the family 
and contains the two catalytic residues, Lys 163 and Lys263 for A. sp. TS1-60 NAAAR, located 
at the opposite sides of the active site (Figure 1.12 A). The D189, E214 and D239 metal 
binding residues can also be found in the barrel domain. Following the coordination of the 
substrate carboxylate to the metal cofactor (Mg2+) the  NH2-group of highly conserved 
lysines act as general acid/base catalysts for the abstraction of the proton from the α-C to 
generate the planar enolate intermediate. This intermediate can be protonated on the same 
face by Lys163 or on the opposite face by Lys263, to form the second stereoisomer in a 
“mirror-like” mechanism (Scheme 1.24).91,107 
 
Figure 1.12 A. sp TS1-60 NAAAR crystal structure (1JSC) in complex with N-succinyl methionine NSM 
(grey) and magnesium (red sphere). A) NAAAR active site with the two catalytic lysine K163 and K263 
(orange) and Mg(II) binding residues D189, E214 and D239 (magenta). B) Substrate binding pocket; 
R299 (yellow) interacts with the carboxylate of the succinyl group via H-bonds formation with two 
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water molecules, while residues F19, F23, Y55 of the capping domain and G291, M292 and I293 of 
the (β/α)7β-barrel create a hydrophobic pocket to accommodate the substrate side chain. 
The succinyl side chain of N-succinyl-AAs interacts with the R299 residue via formation of 
bridging H-bonds with two molecules of water (Figure 1.12 B). Furthermore, the substrate 
bound crystal structure (PDB entry code 1SJC) of these enzymes shows two disordered loops 
in the α+β-capping domain, formed by residues 18-26 (20s) and 45-55 (50s), which seem to 
play a role in the recognition of N-acyl amino acid side chains.107 When the enzyme is free in 
solution, the two loops are disordered; however, upon addition of the substrate, these 
residues close around the molecule shielding it from the solvent. The aromatic or aliphatic 
AAs side chain upon binding to the enzyme, is surrounded by the residues F19, F23, Y55, 
G291, M292 and I293, which form a hydrophobic pocket (Figure 1.12 B). While the 50s loop 
is well conserved in the enolase superfamily, the 20s loop is quite diverse.100 However, the 
relevance of its role for the activity of OSBS/NSAAR bifunctional enzymes has been recently 
proved by Glasner et. al.108 Introducing mutations at position F19, R20, S22 and F23; the 
catalytic efficiency of A. sp. TS1-60 NAAAR was greatly reduced; interestingly the S22R and 
F23A mutations had a different effect on the two reactions. The arginine mutant showed 
higher activity for the OSBS reaction, while the NSAAR catalytic efficiency was improved in 
the F23A mutant. Generally, changes in the 20s loop region affected more markedly the KM 
of the racemization reaction, suggesting that the residues of the 20s loop are fundamental 
for OSBS/NSAAR activity and likely mutations in this region have played a role during the 
evolution of the OSBS family. 
 
Scheme 1.25 Mechanism employed by NAAAR for the racemization of N-acyl amino acids. 
1.4.4 Application 
The classic application of NAAAR in the synthesis of α-amino acids via DKR is a well-
established process, which take advantage of the use of enzymes with wide substrate scopes. 
These racemases are able to bind various N-acylated amino acids without showing particular 
preference for the L or D isomer and being able to accept a range of N-acyl moieties, such as 
acetyl, chloro-acetyl, propionyl, butyryl, formyl, benzoyl and succinyl; however, their activity 
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is affected by the nature of the AA side chain with low tolerance for the polarity from charged 
groups.88 The thermostable A. sp. TS1-60 NAAAR was particularly promising as coupling 
partner of an acylase enzyme, since it retains complete activity up to a temperature of 60°C. 
Tokuyama co-immobilised this racemase, along with either an L- or D-selective aminoacylase, 
on DEAE-Toyopearl columns to create two bioreactor for the efficient continuous synthesis 
of L and D-methionine respectively.109 Various NAAARs were employed in the development 
of similar DKRs80, an example is the use of an overexpressed NAAAR and L-acylase from D. 
radiodurans for the production of L-homophenylalanine (HPA) in a whole cell process, which 
yielded L-HPA with a 99% ee.110 Unfortunately, the low activity and stability of the L-acylase 
prevents an efficient re-use of the recombinant cells, with a loss of 65% of the total activity 
by the third cycle. Several patents describing the application of these racemases for the 
production of optically pure α-amino acids have also being published.111–120 
 
Figure 1.13 Crystal structure of the acyl binding pocket of A) NAAAR G291D F323Y (4A6G) in complex 
with N-acetyl methionine (NAM). H2O and H-bonds represented as red spheres and yellow dashed 
lines respectively and B) NAAAR WT (1SCJ) in complex with N-succinyl methionine (NSM).121 
The low activity of NAAARs towards N-acetylated substrate remains the main limitation of 
these processes. However, enzyme engineering can be employed to overcome this lack of 
catalytic efficiency. Baxter et al.121 reported in 2012 the isolation of the A. sp. TS1-60 NAAAR 
G291D F323Y double mutant, characterised by a 6-fold enhancement in activity for various 
N-acetylated canonical and non-canonical amino acids compared to the wild type enzyme. 
Directed evolution along with an in vivo selection system, based on a methionine auxotroph 
E. coli strain, were employed to engineer NAAAR; the improved variant was successfully 
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employed with a D-acylase in the DKR of D-allylglycine in large scale (50 g/L) with 89% isolated 
yield and 99% ee.  
The enhancement of NAAAR activity was rationalised by resolving the NAAAR G291D F323Y 
crystal structure in complex with N-acetyl methionine (PDB entry code 4A6G). The formation 
of two new hydrogen bond interactions was observed in the acyl binding pocket of the 
enzyme between the β-carboxylate of D291 and the p-OH of Y323 and between the β-
carboxylate of D291 and the guanidinium group of R299 (Figure 1.13 A). These new 
interactions mimic the bridging H-bonds formed by the R299 side chain and the water 
molecule with the carboxylate group of the succinyl moiety, found in the WT structure in 
complex with N-succinyl-methionine (Figure 1.13 B). However, the acetate moiety lacks this 
acidic group, resulting in the lower activity of NAAAR WT towards acetylated amino acids. 
 
Scheme 1.26 Continuous high-throughput coupled L-AAO assay for the screening of NAAAR activity 
towards N-acetyl canonical and non-canonical amino acids. Picture of an assay plate with constant 
enzymes loadings and increasing substrate concentration.122 
The potential for NAAAR evolution was limited in Baxter’s work121 by the use of a selection 
system based on a bacterial strain with a methionine deficiency; only NAAAR variants with 
improved activity towards N-Ac-D-Met could be isolated using this system. To obtain a more 
efficient biocatalyst, which could be employed in the synthesis of a wide range of NCAAs, a 
more generic screening protocol is required. A second work published by the Campopiano 
group122 covers the development of a high-throughput continuous colorimetric assay which 
couples the NAAAR and L-acylase with a FAD dependant L-amino acid oxidase (AAO) to 
produce hydrogen peroxide in the reaction mixture, which can be easily detected via 
oxidation of o-dianisidine, catalysed by the horseradish peroxidase. The oxidised form of o-
dianisidine possess a dark orange/red colour in solution (Scheme 1.25) with a strong 
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absorbance at 436 nm (8700 M-1cm-1). This robust continuous assay can be employed to 
measure NAAAR variants activity for various N-acetyl NCAAs. 
Variants of the classic acylase DKR process were developed by coupling NAAAR with various 
hydrolase enzymes. The Geobacillus stearothermophilus NAAAR was coupled with the 
Cupriavidus sp. P4-10-C N-succinyl-D-amino acid desuccinylase for the synthesis of D-
phenylalanine and D-tryptophan.123,124 N-carbamoyl-L-amino acids amidohydrolases125 have 
also been employed in these kind of processes. D. radiodurans NAAAR and Bacillus 
kaustophilus L-carbamoylase were co-expressed in E. coli cells; following permealisation with 
toluene treatments,126 these cells were employed in a whole-cell DKR process for the 
production of L-HPA. Recovery and recycling of the biocatalyst was extremely efficient, with 
a conversion > 90% retained after eight cycles. A similar process for the biocatalytic synthesis 
of L-HPA was described by Lin et al.,127 where the D. radiodurans NAAAR and B. kaustophilus 
L-carbamoylase were immobilised and packed in a bioreactor, for continuous flow 
production; however, the low stability of the amidohydrolase complicates the process. 
Unfortunately, large excess of the carbamoylase was required to extend the reactor 
operational time. More successful was the application of the G. kaustophilus NAAAR/ G. 
stearothermphilus L-carbamoylase couple for the production of L-aromatic and aliphatic 
amino acids starting from racemic N-carbamoyl and N-formyl derivatives.128,129 The co-
immobilised enzymes were able to yield an average of 80.5% pure L-norleucine, with only a 
decrease of 3% in activity per cycle (75% overall activity maintained after 10 cycles). 
 
Scheme 1.27 The double racemase hydantoinase process for L-amino acid production, obtained by 
coupling two racemase (hydantoin racemase and NAAAR) and two hydrolytic enzymes with opposite 
stereospecificity (D-hydantoinase and L-carbamoylase). 78,128,129 
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NAAARs applications have expanded in the last five years by employing the racemase in 
multiple enzyme cascades. As previously mentioned, the “hydantoinase process” is a well-
established protocol for the production of D-amino acids, given the prevalent isolation of D-
selective hydantoinase;79,130 however, this classic process was recently re-designed by 
coupling the G. kaustophilus NAAAR with a hydantoin racemase, a D-hydantoinase and an L-
carbamoyl amino acid amidohydrolase, in a four-enzymatic double racemase DKR (Scheme 
1.26).78 In this revised system, after formation, the D-carbamoyl amino acid intermediate 
undergoes racemization, catalysed by the promiscuous NAAAR, followed by hydrolysis by the 
L-enantioselective carbamoylase to form pure L-AAs. This double racemase hydantoinase 
process was successfully employed for the preparation of various L-amino acids: norleucine, 
norvaline, 2-amminobutarric acid and HPA. To scale up the process the four proteins were 
efficiently immobilised, retaining their stability and activity; unfortunately, intermediate 
accumulation and incomplete hydrolysis lead to a maximum conversion of 64% when the 
immobilised enzymes were coupled together.131,132 
A second interesting tri-enzymatic cascade was reported by Kourist;133 where the classic DKR 
of N-Ac-AAs, catalysed by engineered NAAAR G291D F323Y and L-acylase, was coupled with 
a stereoselective leucine dioxygenase from Bacillus thuringiensis (Scheme 1.27). This family 
of dioxygenases are Fe(II)/α-ketoglutarate dependant enzymes which catalyse the oxidation 
at the γ-position of amino acids. Starting from a cheap racemic N-acetylated derivative, this 
system can produce highly valuable hydroxy and oxo-amino acids with high diastereomeric 
excess (de). Operating under optimal conditions S,S-γ-hydroxy leucine, norleucine and 
norvaline were synthesised and L-methionine-(S)-sulfoxide was isolated in 97% yield and 95% 
de. 
 
Scheme 1.28 Tri-enzymatic cascade for the synthesis of diastereopure A) (S,S)-methionine sulfoxide 




The overall aim of this work is the development of an efficient DKR system for the biocatalytic 
production of L-phosphinothricin and other NCAAs. The first and second sections focus on 
the application of two hydrolytic enzymes, for the synthesis of L-amino acids from N-
acetylated derivatives. 
1) E. coli N-acetyl-L-ornithine deacetylase (ArgE). 
• Expression and purification of E. coli ArgE. 
• Enzyme characterization. 
• Kinetic analysis. 
• Quantitative assay development for reaction monitoring. 
• Substrate screening. 
• Structural and mechanistic studies. 
• Enzyme engineering. 
2) S. viridochromogenes N-Ac-PTT deacetylase (SvDea). 
• Expression and purification of S. viridochromogenes Dea. 
• Enzyme characterization. 
• Kinetic analysis. 
• Substrate screening. 
• Structural studies. 
The third section will focus on the coupling of the acylase enzymes with engineered NAAAR 
variants and the optimization and scale up of the biocatalytic DKR process. 
3) Amycolaptopsis sp TS1-60 N-acetyl amino acid racemase (NAAAR). 
• Expression and purification of A. sp TS1-60 NAAAR. 
• Kinetic analysis. 
• Coupling of NAAAR and aminoacylase in a DKR. 
• Substrate screening. 




3 The N-acetyl-L-ornithine deacetylase ArgE 
Currently, the Thermococcus litoralis L-Acylase (E.C. 3.5.1.14)134–136, developed by Littlechild 
and colleagues, is used in combination with Amycolaptopsis NAAAR121 for the dynamic kinetic 
resolutions (DKR) of amino acids. However, the intellectual property (IP) surrounding this 
enzyme is held by Dr Reddy’s Laboratories and not available for a PhD project sponsored by 
Syngenta (Jealott's Hill, UK). Furthermore, while the L-Acylase has shown activity towards 
aliphatic and aromatic N-acetylated amino acids, poor to no activity was reported towards 
charged and polar substrates.134 In order to develop an efficient DKR for the production of L-
phosphinothricin (PT), a new L-Acylase (amide hydrolase), that can be efficiently coupled 
with Amy NAAAR, needs to be identified and characterised. 
The Escherichia coli N-acetyl L-ornithine deacetylase (ArgE) was reported to be active 
towards N-Ac-L-PT in a patent from Bartsch et al.137 Indeed, it was successfully used for the 
creation of various transgenic plants with male sterility including tobacco138 and rice.139 By 
expressing the argE gene in the tapetum tissues of these organisms pollen maturation was 
disrupted. In another application the gene was introduced in perennial ryegrass29 to create 
an efficient and selective elimination system for this weed, to reduce its growth in golf 
courses and tennis courts. These results reported in the literature strongly suggest that ArgE 
is an ideal candidate for the DKR of L-PT, having a complementary substrate scope compared 
to Dr. Reddy’s L-Acylase, which displays greater activity for hydrophobic N-acetylated 
derivatives. 134 
 
Scheme 3.1 Bacterial biosynthetic pathway to L-arginine. ArgE (in green) catalyses the fifth step, the 
deacetylation of N-acetyl-ornithine. 
57 
 
The enzyme named ArgE, first isolated from E. coli in 1992,140 is a zinc dependant metallo-
protein, that is member of the M20A peptidase superfamily (EC 3.5.1.16).141 This class of 
enzymes catalyses the fifth step (acetylornithine hydrolysis) in the bacterial biosynthesis of 
arginine from glutamic acid (Scheme 3.1).142 The intermediate L-ornithine is of fundamental 
importance for these organisms, since it used not only for the production of L-Arg but also in 
the synthesis of polyamines; making the ArgE class a target for the production of new 
inhibitors.143 
3.1 Aims 
The aims of this project were to express, purify and characterize E. coli ArgE and to assay its 
activity and enantioselectivity for the resolution of L-PT and other non-canonical amino acids 
(NCAAs). We also planned to optimize the coupling of ArgE with NAAAR to develop a DKR. To 
achieve this goal a quantitative assay for monitoring the deacetylation reaction was 
optimised. Furthermore, to elucidate the mechanism of the enzyme and investigate which 
residues are involved in substrate binding, the crystal structure of ArgE requires to be 
resolved. 
3.2 Expression and purification of un-tagged ArgE. 
The full length argE gene, cloned into the expression vector pET28a using the NcoI and XhoI 
restriction sites, was ordered from GenScript (Uniprot code: P23908). The un-tagged pET28a-
ArgE construct was transformed in E. coli BL21 (DE3) cells and a series of expression tests 
were carried out to optimise the incubation temperature and isopropyl β-D-1-
thiogalactopyranoside (IPTG) concentration used for the enzyme production. All samples 
were analysed via SDS-PAGE electrophoresis. The gels show a low yield of soluble protein, 




Figure 3.1 12% SDS-PAGE gel of un-tagged ArgE expression tests. Lane 1 low molecular weight 
marker LMWM (M), lane 2-7 soluble (Lys) and 8-13 insoluble (Ins) fractions of samples 1 (0.0 mM 
IPTG), 2 (0.1 mM IPTG), 3 (0.2 mM IPTG), 4 (0.4 mM IPTG), 5 (0.8 mM IPTG) and 6 (1.0 mM IPTG), 
incubated A) at 20°C for 20 h and B) at 30 °C for 4 h. 
Since ArgE is a zinc dependant metallo-enzyme, it was thought that the addition of Zn(II) in 
the media may increase the yield of soluble protein. A second series of expression tests were 
carried out by adding various concentrations of ZnSO4 in the samples. The SDS-PAGE gels 
show a general increase in the yield of soluble ArgE (Figure 3.2) and the best conditions 
selected for scale-up were: 0.1 mM ZnSO4, 0.2 mM IPTG at 20°C for 20 h. 
 
Figure 3.2 12% SDS-PAGE gel of un-tagged ArgE expression tests. Lane 1 LMWM (M), lane 2-13 
soluble (S) and insoluble (I) fractions of samples 1 (0.0 mM ZnSO4), 2 (50 μM ZnSO4), 3 (0.1 mM 
ZnSO4), 4 (0.25 mM ZnSO4), 5 (0.5 mM ZnSO4) and 6 (1.0 mM ZnSO4), incubated at 20°C for 20 h with 
0.2 mM IPTG. 
Un-tagged ArgE was purified following a two-step protocol; the cell free extracts (CFEs) were 
applied to an anion exchange Q Sepharose Fast Flow (QFF) column with the enzyme eluting 
at ~300 mM NaCl (0.1-1.0 M NaCl gradient). These fractions were collected and concentrated 
before separated on a pre-calibrated Sephacryl S300 size exclusion chromatography (SEC) 
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column. The gel filtration chromatogram shows two main peaks at 40 mL and 65 mL 
respectively, however SDS-PAGE analysis confirms that the enzyme (band at ~42 kDa) eluted 
on the shoulder of the second peak at 73 mL (Figure 3.3 A and B), which corresponds to a 
molecular weight (MW) of 85 kDa for native ArgE (homodimer). After purification, the un-
tagged ArgE purity was ~70% (estimated by gel electrophoresis), unsuitable for mass 
spectrometry analysis and further applications. To optimize the purification, protocol the 
arge gene was subcloned to obtain a histidine tagged construct. 
 
Figure 3.3 Untagged E. coli ArgE purification. A) Size exclusion chromatogram for un-tagged ArgE on 
a Sephacryl S300 column. The arrow points to the acylase peak. B) 12% SDS-PAGE gel of un-tagged 
ArgE purification: lane 1 LMWM (M), lane 2 CFE (L), lane 3 insoluble fraction (P), lane 4-7 QFF 
fractions (5 mL each) and lane 8-12 S300 fractions (3 mL each). Untagged ArgE eluted in fraction 25 
at 73 mL elution volume, on the shoulder of the second peak. 
3.3 Expression and purification of N-HisTag ArgE 
The arge gene was sub-cloned into a pETHISTEV plasmid, using the NcoI/XhoI restriction sites, 
to obtain a construct with an N-terminal tobacco etch virus (TEV) cleavable hexahistidine tag. 
The protein was expressed using the optimised protocol and purified via metal ion affinity 
chromatography (IMAC) with a HisTrap Fast Flow 1 mL column, followed by SEC (Superdex 
S200 column). The SEC absorbance chromatogram, registered at 280 nm, shows a single peak 
at an elution volume of 75 mL (Figure 3.4 A), which corresponds to a molecular weight of 90 




Figure 3.4 Purification of N-His tagged ArgE. A) Size exclusion chromatogram for tagged ArgE on a 
Superdex S200 column. The arrow points to the acylase peak. B) 12% SDS-PAGE gel of N-HisTag ArgE 
purification: lane 1 LMWM (M), lane 2 CFE (L), lane 3 insoluble fraction (P), lane 4 HisTrap flow 
through (FT), lane 5-8 HisTrap fractions (3 mL each, enzyme elution start at ~200 mM imidazole) and 
lane 9-12 S200 fractions (3 mL each). 
After purification ArgE was obtained with a purity of ~95% (Figure 3.4 B) and an average yield 
of 15 mg per L of culture. To confirm that the correct construct was expressed and purified, 
the molecular weight of ArgE was calculated using denaturing liquid chromatography 
electrospray-mass spectrometry (LC ESI-MS). The resulting spectrum displayed several peaks, 
representing the many charge states of the protein. The observed MW of 45369.00 ± 0.90 Da 
(Figure 3.5 B), was in accordance with the theorical MW minus the initial methionine: 
45369.50 Da, calculated from the protein sequence with the ExPaSy ProtParam tool 
(https://web.expasy.org/protparam). The loss of the initial methionine is a very common 
post-translational modification.144 
 
Figure 3.5 Denaturating LC ESI-MS of ArgE (20 μM) with a mass of 45369.00 ± 0.90 Da, in accordance 
with the MW calculated from the sequence (45369.50 Da). The values reported are m/z with the 
charges in brackets. 
61 
 
3.3.1 High-throughput colorimetric L-amino acid oxidase assay 
The high-throughput continuous L-amino acid oxidase (L-AAO) assay reported by 
Campopiano et. al.122 was employed for the kinetic analysis of ArgE (Scheme 3.2). The N-Ac-
L-AA substrate is converted by the acylase to the L-AA; which is oxidised by the commercial 
Crotalus adamanteus L-AAO (lyophilised venom from Sigma-Aldrich) to form the 
corresponding α-keto acid (α-KA), plus ammonia. The L-AAO is a flavoprotein and during the 
oxidation FAD is reduced to FADH2, which is promptly re-oxidised by oxygen, producing 
hydrogen peroxide (H2O2) as a reaction by-product. Finally, H2O2 reacts with horseradish 
peroxidase (HRP) in the presence of o-dianisidine, which in its oxidised form has a strong 
red/orange colour and absorbance at 436 nm (ε = 8700 M-1cm-1), easily monitored 
spectrophotometrically. 
 
Scheme 3.2 Reaction scheme of the ArgE/L-AAO continuous assay. The oxidised from of o-dianisidine 
has a strong absorbance at 436 nm and can be easily monitored via UV-Vis on a 96-wells microplate 
reader. 
The assay was employed to measure the kinetic parameters of ArgE towards N-Ac-L-Met, 
which is reported to be the best substrate for this acylase.141 A set of reactions at increasing 
substrate concentrations were incubated at 40°C and the absorbance of o-dianisidine(ox) was 
monitored at 436 nm every 30 s for 1 h. The initial reaction rates were calculated from the 
linear portion of the absorbance curves and fitted using the Michaelis-Menten non-linear fit 
with Lab Origins software (Figure 3.6 A and B). The calculated kinetic parameters show that 
ArgE has a strong affinity (KM = 2.4 ± 0.2 mM) and high turnover number (TON, kcat = 4.58 ± 
0.07 s-1) for N-Ac-L-Met. Hence, this enzyme has potential for biocatalytic applications, as 
suggested by its high catalytic efficiency (kcat/ KM = 1759.653 ± 0.001 M-1s-1).  
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Similar results have already been reported by Blanchard et. al.,141 however the catalytic 
constant reported in literature (1700 ± 40 s-1) deviates highly from the value calculated with 
the L-AAO assay. This discrepancy can be explained by the difference in assays employed to 
assess the enzyme activity. Blanchard et al.141 performed the kinetic analysis by directly 
monitoring the change in the absorbance of the amide bond (ε = 103 M-1cm-1). Alternately, 
the L-AAO assay relies on a cascade of reactions to couple the deacetylation step with the 
formation of o-dianisidine(ox) (ε = 8700 M-1cm-1).122 
 
Figure 3.6 Determination of E. coli ArgE kinetic parameters via L-AAO continuos assay. A) Typical raw 
data profile for the formation of o-dianisidineox over time at various substrate (N-Ac-L-Met) 
concentrations. B) Michaelis-Menten plot of ArgE for N-Ac-L-Met. Initial rates calculated from the 
linear portion of the absorbance curves and fitted with the OriginLab software. The reaction mixture 
contained: N-Ac-L-Met (0-20 mM), ArgE 10 μg/mL, CoCl2 100 µM, L-AAO 70 mU/mL, HRP 10 U/mL 
and o-dianisidine 0.1 mg/mL in NaPi buffer 0.1 M pH 8. The plate was incubated at 40°C for 1 h and 
absorbance measured at 436 nm every 30 s. Reactions repeated in triplicates, error bars calculated 
as the standard deviations. 
3.3.2 ArgE kinetic analysis 
The L-AAO assay proved to be a quick and efficient method to measure enzymatic activity; as 
reported by Campopiano et. al.,122 the L-AAO used possesses quite a broad substrate scope, 
being able to accept both natural (methionine or phenylalanine) and non-natural 
(phenylglycine or 2-naphtylalanine) amino acids. However, the full potential of this oxidase 




Figure 3.7 Screening of L-AAO activity towards the 20 canonical L-amino acids, plus phosphinothricin 
(DL-PT) and ornithine (L-Orn). Water and D-methionine used as controls. The assay mixture 
contained: AA 10 mM, CoCl2 100 µM, L-AAO 100 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 mg/mL 
in NaPi buffer 0.1 M pH 8. The plate was incubated at 40°C for 1 h and absorbance measured at 436 
nm every 30 s. 
A series of reactions were set up using the 20 proteogenic L-amino acids, plus 
phosphinothricin (PT, 2a) and L-ornithine (L-Orn, 2d), to determine the substrate range and 
the optimal concentration of the enzyme to use in the reaction mixture. For this initial activity 
screening a concentration of AAs of 10 mM and of L-AAO of 100 mU/mL was used. 
N-Ac: KM (mM) kcat (s-1) kcat/KM (M-1s-1) 
L-Met 2.4 ± 0.2 4.58 ± 0.07 1759.653 ± 0.001 
L-Ala 9.91 ± 0.04 0.077 ± 0.002 7.773 ± 0.001 
L-Leu 8.3 ± 0.6 1.18 ± 0.02 142.72 ± 0.01 
L-Ile 22.1 ± 0.8 0.69 ± 0.03 31.153 ± 0.001 
L-Val 60 ± 6 0.107 ± 0.003 1.792 ± 0.002 
L-Phe - - - 
L-Tyr N.D. N.D. N.D. 
L-Trp N.D. N.D. N.D. 
L-His 0.96 ± 0.02 0.126 ± 0.003 131.7512 ± 0.0006 
L-Arg 24 ± 4 0.070 ± 0.005 2.93 ± 0.001 
L-Lys 5.2 ± 0.7 0.185 ± 0.009 36.423 ± 0.006 
L-Gln 12.6 ± 0.9 0.65 ± 0.04 51.735 ± 0.004 
DL-Ser 15 ± 5 0.011 ± 0.001 0.78 ± 0.04 
L-Thr - - - 
Table 3.1 Kinetic parameters of ArgE for fourteen N-Ac-AAs obtained with the continuous L-AAO 
assay The reaction mixture contained: N-Ac-AA various concentrations, CoCl2 100 µM, L-AAO 100-
300 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 mg/mL NaPi buffer 0.1 M pH 8. The plate was 
incubated at 40°C for 1 h and absorbance measured at 436 nm every 30 s. 
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As shown in Figure 3.7 the oxidase is active for most hydrophobic and positively charged 
amino acids, with a few exceptions (proline, glycine and asparagine). The oxidase is also able 
to accept some polar amino acids (serine and threonine), as substrates, while no activity was 
detected for: aspartic acid, glutamic acid and PT, it is clear that the L-AAO does not tolerate 
AAs with negatively charged side chains. Unfortunately, this assay cannot be used to screen 
for acylase activity towards N-Ac-PT (1a), however by optimizing the loading of the oxidase, 
the assay was employed to measure the kinetic parameters of ArgE towards fourteen of the 
twenty canonical N-Ac-L-AAs (Table 3.1). 
The substrate scope of the enzyme was wider than anticipated; being able to accept N-acetyl-
L: lysine, arginine, histidine, valine, threonine and phenylalanine, while no activity was 
detected towards N-acetyl-L-tyrosine and tryptophan. However, the kinetic parameters for 
N-acetyl-L-phenylalanine and threonine could not be determined, since the kinetic curves did 
not reach saturation, even at high (> 200 mM) substrate concentration. Interestingly, no 
activity was previously reported towards all these substrates by Blanchard et. al.,141 another 
advantage of the higher sensitivity of the L-AAO assay. 
3.4 Kinetic resolution of N-acetyl methionine 
To obtain an efficient kinetic resolution or DKR of N-acetyl AAs, it is necessary to employ a 
highly stereoselective acylase. A chiral HPLC assay, previously optimised by Baxter,121 was 
employed to test ArgE stereoselectivity towards N-Ac-Met. Standards of: N-Ac-L-Met, N-Ac-
D-Met, L-Met and D-Met were run on a Chirobiotic T (Teicoplanin) column with an isocratic 
gradient of a 0.025% triethylammonium acetate (TEAA) : MeOH = 75:25 mixture as eluent. 
The four isomers were separated with good retention times: 3.0, 4.3, 5.6 and 6.7 min, 
respectively (Figure 3.8 A) and four calibration curves were produced to allow quantitative 
analysis. (Appendix 19). 
A kinetic resolution (KR) was set up with 60 mM N-Ac-DL-Met, 100 µM CoCl2 and 10 µg/mL 
of ArgE in Na phosphate buffer (NaPi) 0.1 M pH 8. Given ArgE high turnover number (TON) 
for this particular substrate, the acylase concentration had to be kept low, to be able to 
monitor the reaction conversion over time. The biotransformation was incubated at 40°C for 
24 h; samples were taken over time and quenched by 1:40 dilution into the eluent mixture 




Figure 3.8 KR of N-Ac-DL-Met catalysed by ArgE. A) HPLC profile for the resolution of both 
enantiomers of the starting material: N-Ac-L-Met (blue), N-Ac-D-Met (red) and product: L-Met 
(green), D-Met (purple). Standards samples at a concentration of 25 mM. B) HPLC curves of time 
point samples of the biocatalytic KR of N-acetyl methionine (scale of grey). C) Conversion of N-Ac-L-
Met (blue) into L-Met (green) over time, N-Ac-D-Met (red) concentration remains constant over time 
and no trace formation of D-Met (purple) was detected. All samples analysed by HPLC on a 
Chirobiotic T (Teicoplanin) column, isocratic gradient: elution phase 0.025% TEAA and MeOH (75/25 
ratio), flow 1.0 mL/min, T = 40°C and λ = 210 nm. Reactions repeated in duplicates, error bars 
calculated as standard deviations reported only for triplicates. 
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As expected, the reaction was very fast with full conversion (50%) achieved in only 30 
minutes with the complete disappearance of the N-Ac-L-Met peak at 3.0 min (Figure 3.8 B). 
Furthermore, ArgE showed complete stereoselectivity towards L-Met formation (ee > 99.9%), 
while N-Ac-D-Met concentration remained constant over time and no traces of D-Met 
formation were observed in the HPLC traces (Figure 3.8 B and C). 
3.5 Metal binding studies 
3.5.1 Metal content of purified ArgE 
ArgE belongs to the di-zinc dependant M20 metallo peptidase family; all members of this 
family have highly conserved metal-binding residues in their active sites and can accept, as 
cofactors, zinc or other divalent small transition metal ions, such as Co(II) or Mn(II).142 Indeed, 
preliminary studies conducted by Holz et. al.145 suggest that ArgE is able to coordinate up to 
two Zn2+ or Co2+ ions per monomer (Table 3.2) and both metals cations assume a distorted 
penta-coordinated geometry, upon binding to the active site residues. 
 Zn
2+ Co2+ 
kd1 (μM) 2.7 0.4 
kd2 (μM) 51 153 
Table 3.2 Dissociation constants (kd1 and kd2) for ArgE with Zn2+ and Co2+ ions, calculated by 
isothermal titration calorimetry (ITC) by Holz et. al.145 
To determine the metal content of ArgE a sample of purified enzyme (1 mg/mL, ~20 μM) was 
analysed via inductively coupled plasma-mass spectrometry (ICP-MS), while a second ArgE 
sample (10 mg/mL, ~200 μM) was analysed using a newly developed method reported by Dr. 
Wong146 for the determination of the metal/protein stoichiometry via Thin-Film Energy 
Dispersive X‑ray Fluorescence Spectroscopy (EDXRF). The EDXRF analysis was run by Silvia 
Fruncillo, Dr Wong group, University of Manchester. The two analyses gave concordant 
results: one equivalent of zinc is bound per ArgE monomer, while no traces of cobalt were 
detected; only the [Zn(ArgE)] species is present in solution after protein purification. The data 
obtained and the dissociation constants (kd1 and kd2) values reported in literature (Table 3.2) 
suggest that while one zinc ion is tightly bound to the enzyme (kd1 = 2.7 μM) and probably 
plays an essential role during catalysis, the second metal binding site (kd1 = 51 μM) is probably 
just partially occupied in physiological condition and has mainly a structural role.  
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It has been reported that cobalt bound ArgE, [Co(ArgE)] is 2.4 times more active then 
[Zn(ArgE)];145 this species is usually prepared by incubation of APO ArgE with an excess of 
CoCl2. The APO enzyme is obtained by dialysing the purified protein against a buffer 
containing EDTA. However, this process is quite lengthy and has a poor yield, since a good 
percentage of enzyme precipitates after CoCl2 addition. To obtain [Co(ArgE)] the enzyme was 
expressed using the optimised protocol (Chapter 6.3.4) but supplementing the media with 
0.1 M of CoCl2, instead of ZnSO4. The purified protein, analysed by IPC-MS, contained 0.5 eqv 
of zinc bound per ArgE monomer: [Zn(ArgE)2], while no traces of Co(II) were detected by the 
instrument. The enzyme favourably binds to the zinc ions, which are present at low 
concentration in the LB media, as a consequence half of the protein is expressed in its APO 
form, which would explain the poor yield (3 mg per L of culture) obtained from this batch. 
The direct production of [Co(ArgE)] is quite challenging, it may be achieved but the protocol 
needs optimisation, for instance: by changing the expression media or using another salt as 
cobalt source. Since the purified [Zn(ArgE)] already presents a high catalytic efficiency, this 
species was used for future studies. 
3.5.2 Effect of Zinc and Cobalt on ArgE activity 
To understand if an increase of enzymatic activity can be achieved by addition of metal to 
the reaction mixture; a kinetic study of: [Zn(ArgE)] and [Zn(ArgE)2] was conducted, employing 
the continuous L-AAO assay. The kinetic parameters of the two enzyme species were 
determined by varying the metal content in the assay reaction mixture: CoCl2 100 μM, ZnCl2 
100 μM and a control without metal addition. 
 
Figure 3.9 Michaelis-Menten plot for the kinetic analysis of A) [Zn(ArgE)] and B) [Zn(ArgE)2] with N-
Ac-L-Met in the presence of various metal ions: Co2+ (purple), Zn2+ (grey) and no metal addition 
(black). All reactions contained various concentrations of N-Ac-L-Met, CoCl2/ZnCl2 100 µM, L-AAO 70 
mU/mL, HRP 10 U/mL and o-dianisidine 0.1 mg/mL in NaPi buffer 0.1 M pH 8. The plate was 
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incubated at 40°C for 1 h and absorbance measured at 436 nm every 30 s. Reactions repeated in 
triplicates, error bars calculated as the standard deviations. 
As shown in Figure 3.9 A the addition of Co(II) to the reaction mixture caused a slight increase 
in [Zn(ArgE)] activity (1.4-fold), while an excess of Zn(II) inhibited the enzyme, a phenomenon 
already observed for other zinc metallo-proteins with a binuclear site.142 As expected, 
without any metal addition to the reaction mixture, the activity of [Zn(ArgE)2] is halved 
compare to [Zn(ArgE)]. However full activity can be regained by addition of Co2+ (Figure 3.9 
B). 
 
Figure 3.10 Inhibition study of ArgE using A) ZnCl2 (scale of red) and B) CoCl2 (scale of blue). Each 
kinetic curve was obtained using a reaction mixture with various concentrations of N-Ac-L-Met, 
CoCl2or ZnCl2 0-750 µM, L-AAO 70 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 mg/mL in NaPi buffer 
0.1 M pH 8. The plate was incubated at 40°C for 1 h and absorbance measured at 436 nm every 30 s. 
Reactions repeated in triplicates, error bars calculated as the standard deviations. 
The inhibitory effect of zinc was further studied by determining the kinetic profile of the ArgE 
catalysed hydrolysis of N-Ac-L-Met at various ZnCl2 concentrations (0, 5, 50, 100, 250 μM). 
The derived Michaelis-Menten curves (Figure 3.10 A) show a typical competitive reversible 
inhibition profile, with a constant Vmax and an increase of the apparent KM at increasing Zn(II) 
concentrations. A similar behaviour has been previously reported for the carboxypeptidase 
A enzyme (M24 family),147 another zinc dependant hydrolase, active towards ester and amide 
bonds. Hypothetically, the excess zinc ions could bind to some residues in the active site, 
which are normally involved in substrate recognition, leaving the Zn2+ and substrate to 
compete for the active site, inhibiting the reaction. This scenario can explain why zinc acts as 
a competitive inhibitor for the two hydrolases. However, no inhibition was observed even at 
high CoCl2 concentrations (750 μM, 5 times higher than kd2) in the reaction mixture (Figure 
3.10 B).  
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Since Co2+ ions act as ArgE activator, a slight excess of CoCl2 will be used in all future 
experiments to achieve the highest possible reaction conversion and enzymatic activity. 
3.6 ArgE Thermostability 
3.6.1 Thermal Denaturation Assay 
Thermostable proteins are usually favoured for biocatalytic applications, being easier to 
handle and use in industrial scale process.148 To determine the ArgE transition unfolding 
temperature (melting temperature, Tm) a thermal denaturation assay (TDA) was run on a 
reverse transcription polymerase chain reaction (RT-PCR) machine. In a typical TDA149,150 the 
enzyme is incubated with a fluorophore, as SYPRO-orange149 (λex 470 nm /λem 570 nm) and 
the assay temperature is increased constantly over time. The dye fluorescence is quenched 
by water, but as the protein start to unfold and expose on the surface its hydrophobic 
residues; SYPRO-orange binds to these regions restoring its fluorescence (Figure 3.11 A). 
The assay was run on a 96 well plate and ArgE melting curves (Figure 3.11 A) were recorded 
in twelve different conditions: 0.1 M Na citrate (pH 3.0, 3.5, 4.0, 4.5, 5.0 and 5.5), 0.1 M NaPi 
(pH 6.0, 6.5, 7.0, 7.5 and 8.0) and 0.1 Na carbonate (NaCi) pH 9.0. The enzyme’s Tms were 
calculated from the second derivative of the corresponding melting curves. 
As shown in Figure 3.11 B, ArgE thermal stability (Tm  ~35°C) is very low at acidic pH, however 
it significantly increase towards neutral and basic pH values, stabilising at around a Tm of 
65°C. Thermostable proteins usually have melting temperatures higher than 80°C, thus ArgE 
cannot be classified as such. However, it is stable at neutral and basic pH up to a temperature 
of 60°C, which may increase the chance of protein crystal formation.151 
 
Figure 3.11 Analysis of ArgE thermostability at various pHs via TDA. A) ArgE melting curve at pH 6.5 
(25-75°C). At low temperature the enzyme is stable in solution and SYPRO-orange fluorescence is 
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completely quenched (a), as the temperature increase the protein start to unfold and the dye binds 
to the hydrophobic residues (b). The fluorescence intensity reaches its maximum when the enzyme 
is completely unfolded (c); as the protein starts to aggregate the dye dissociates and the florescence 
intensity is quenched (d). The flex point of the melting curve corresponds to the enzyme Tm. B) ArgE 
melting temperatures at various pH (3-9); the assay mixture contained ArgE 2.0 µM (0.1 mg/mL), 5X 
SYPRO orange in DMSO and 50 mM buffer at various pHs. The melting curves were obtained 
measuring the fluorescence of SYPRO orange between 25 and 75°C with a gradient of 1°C/min. 
Reactions repeated in triplicates, error bars calculated as the standard deviations. 
3.6.2 Correlation between reaction temperature and ArgE activity 
 
Figure 3.12 ArgE specific activity for N-acetyl L-methionine at 25°, 30°, 40° and 50°C measured via 
the continuous L-AAO. The assay mixture contained various concentration of N-Ac-L-Met, CoCl2 100 
µM, L-AAO 70 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 mg/mL in NaPi 0.1 M pH 8. The plate was 
incubated at the chosen temperature for 1 h and absorbance measured at 436 nm every 30 s. The 
specific activity is expressed in Unites per milligram of enzyme, with one unit referring to the μM of 
substrate the enzyme turns over in one minute. Reactions repeated in triplicates, error bars 
calculated as the standard deviations. 
ArgE activity was monitored at four different temperatures; the continuous L-AAO was 
employed to determine the specific activity of the enzyme for N-Ac-L-Met at: 25°, 30°, 40° 
and 50°C. According to Figure 3.12, ArgE shows high activity (> 25000 U/mg) in this 
temperature range with an optimal reaction temperature of 40°C (32700 U/mg). Still, the 
enzyme retained 96% of its activity at 50°C, suggesting that with some optimization it may 






3.7 ArgE activity towards N-Ac-PT 
3.7.1 Synthesis and Crystal Structure 
 
Scheme 3.3 Acetylation protocol for DL-phosphinothricin. 
The free racemic PT amino acid (gifted by Syngenta, Jealott's Hill, UK), was acetylated with 
an excess of acetic anhydride in the presence of triethylamine at room temperature (r.t.) 
over twenty hours (Scheme 3.3). This protocol gave pure N-Ac-DL-PT (1a) triethylammonium 
with a yield of 73%.83 
 
Figure 3.13 N-Ac-PT crystallization study. A) Resolved X-ray structure and B) schematic 
representation of N-Ac-PT (1a). C) Three-dimensional arrangement inside the unit cell with the 
formation of intermolecular H-bonding. Carbon in grey, hydrogens in white, oxygens in red, nitrogen 
in blue, phosphorus in purple and H-bonds in yellow. N-Ac-PT molecules (represented as sticks). 
 
A sample of the product was recrystallized by the slow evaporation of a mixture of water and 
acetone, to give single colourless plate-shaped crystals. The crystals were sent to the X-ray 
facility of the University of Edinburgh and the X-ray structure was solved with ShelXT 
(Sheldrick, 2015) structure solution program using the Intrinsic Phasing solution method 
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(Figure 3.13 A). An extended three-dimensional intermolecular H-bond network was 
observed (Figure 3.13 B). 
3.7.2 Kinetic Resolution of N-Ac-PT 
The KR of N-Ac-PT was set up by incubating the substrate with ArgE and CoCl2 in NaPi 0.1 M 
pH 8 at 40°C (250 rpm) for 24 h. Eight biotransformations were run simultaneously varying 
the concentration of the three reaction components, as shown in Table 3.3. The commercially 
available Amano Acylase and Dr Reddy’s T. litoralis L-Acylase were also tested. All samples 
were analysed by LC-TOF MS, but no product formation was detected. 
These results were unexpected, since the ArgE catalysed N-acetyl PT deacetylation had been 
previously observed in literature via radioactive assay138 and exploited for creation of 
transgenic plants.29,138,139 However, Flashel et. al. conducted in 2005152 a study aimed to 
understand the stability of the N-acetyl PT amide bond under various conditions. The data 
collected suggests that higher temperature, basic pH and the presence of particular micro-
organism in the sample determine an increase in the free PT concentration over time. These 
results call into question the data described in the literature, regarding the specific activity 











20 100 1.0 N.D. 
20 200 1.0 N.D. 
20 200 5.0 N.D. 
20 200 10 N.D. 
40 200 5.0 N.D. 
40 200 5.0 N.D. 
10 200 5.0 N.D. 
T.litoralis L-Acylase 20 200 10 N.D. 
Amano Acylase 20 200 10 N.D. 
Table 3.3 KR of N-Ac-PT, optimization of the substrate, enzyme and cofactor loadings. No product 
formation detected at the TOF MS. 
3.7.3 Inhibition tests 
3.7.3.1 Inhibition studies with N-Ac-PT and racemic PT 
The natural role of L-PT is as a potent inhibitor of the enzyme glutamine synthase in bacteria 
and plants.30 It is possible for this amino acid to act in a similar way towards ArgE, with the L-
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PT released in solution, binding to the enzyme and inhibiting the reaction, which would 
explain the low specific activity of ArgE reported for this substrate in the literature.152  
 
Figure 3.14 Absorbance curves of o-dianisidineox at 436 nm over time. The L-AAO reaction mixture 
contained N-Ac-L-Met 1 mM, ArgE 10 µg/mL, various concentrations of A) PT or B) N-Ac-PT, L-AAO 
70 mU/mL, CoCl2 100 µM, HRP 10 U/mL and o-dianisidine 0.1 mg/mL in NaPi buffer 0.1 M pH 8. The 
reactions were incubated at 40°C and Abs red at 436 nm every 30 s for 2 h. 
To test this theory the rate of a set of ArgE-catalysed N-Ac-L-Met hydrolysis reactions were 
monitored, exploiting the high-throughput L-AAO assay (Scheme 3.3); each reaction was 
incubated with increasing concentrations (0-10 mM) of either PT (2a), or N-Ac-PT (1a). 
However, no sign of inhibition was detected up to 10 mM concentration of either of these 
molecules, suggesting that ArgE does not favourably bind these molecules (Figure 3.14 A and 
B). 
3.7.3.2 Inhibition studies with L-methionine sulfoxide and sulfone 
To understand why ArgE has such a low binding affinity for N-Ac-PT, the same inhibition 
studies were repeated using, as inhibitor candidates, two L-amino acids structurally 
analogous to PT: L-methionine sulfoxide (L-MetO, 2b) and L-methionine sulfone (L-MetO2, 
2c). These three AAs have polar side chains of similar length, furthermore, the sulfoxide, 
sulfone and phosphonic acids group share a similar sizes and same tetrahedral geometry 
(Figure3.15). 
 
Figure 3.15 Comparison between phosphinothricin (2a), L-methionine sulfoxide (L-MetO, 2b) and L-
methionine sulfone (L-MetO2, 2c) structures. 
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As shown in Figure 3.16 A and B, neither L-MetO, or L-MetO2 produced an evident inhibitory 
effect on N-Ac-L-Met hydrolysis. However, the reaction control of both assays (which 
contained 1 mM of 2b and 2c, but no substrate) shows a significant background absorbance, 
suggesting that the L-AAO is active towards the two methionine derivatives. This hypothesis 
was successfully tested (data not shown) and the L-AAO assay was subsequently used to 
screen ArgE activity towards these two new potential substrates.  
 
Figure 3.16 Absorbance curves of o-dianisidineox at 436 nm over time. The L-AAO reaction mixture 
contained N-Ac-L-Met 1 mM, ArgE 10 µg/mL, various concentrations of A) L-MetO or B) L-MetO2, L-
AAO 70 mU/mL, CoCl2 100 µM, HRP 10 U/mL and o-dianisidine 0.1 mg/mL in NaPi buffer 0.1 M pH 8. 
The reactions were incubated at 40°C and Abs red at 436 nm every 30 s for 2 h. Reaction curves in 
black, control in red. 
N-Ac-L-MetO (1b) and N-Ac-L-MetO2 (1c) show a high affinity for ArgE, with a kcat of 1.97 ± 
0.08 s-1 and 0.36 ± 0.02 s-1 and a KM of 26 ± 3 mM and 3.4 ± 0.9 mM, respectively (Figure3.17 
A and B). By comparing the difference in ArgE catalytic activity for substrates 1a, 1b and 1c, 
it is clear that the low affinity of this enzyme towards N-Ac-PT is probably caused by the 
presence of a negatively charged group (phosphinic acid, pKa ~1.0) on the amino acid side 
chain, which is the main difference between the three structurally analogous substrates 
(Figure 3.15). 
This preliminary screen shows that ArgE has a much wider substrate scope than expected, 
being able to accept some N-acetylated NCAAs. Further studies are required to understand 




Figure 3.17 Michaelis-Menten plot of ArgE for A) N-Ac-L-MetO and B) N-Ac-L-MetO2. Initial rates 
calculated from the linear portion of the absorbance curves and fitted with the OriginLab software. 
The reaction mixture contained: ArgE 0.1 mg/mL, CoCl2 100 µM, L-AAO 70 mU/mL, HRP 10 U/mL and 
o-dianisidine 0.1 mg/mL in NaPi 0.1 M pH 8. The plate was incubated at 40°C for 1 h and absorbance 
measured at 436 nm every 30 s. Reactions repeated in triplicates, error bars calculated as the 
standard deviations. 
3.8 Development of a quantitative assay for ArgE 
3.8.1 Marfey’s Reagent Derivatization 
The chiral HPLC assay has been useful to monitor the KRs of N-Ac-methionine, however only 
a few amino acids (as Phe, Tyr and Trp) have a suitable absorbance in the UV-Vis spectrum. 
A more comprehensive approach is required to efficiently study the biocatalytic potential of 
ArgE towards non canonical N-Ac-AAs.  
Various HPLC pre-column derivatization methods, such as: ninhydrin153 o-phthalaldehyde 
(OPA)154,155 and 4-chloro-7- nitrobenzo-2-oxa-1,3-diazole (NBD),156 have been developed over 
the years to quantify amino acids. However, the Marfey’s reagent (MR) protocol was 
particularly attractive, given the chiral nature of the derivatization reagent. Marfey’s reagent, 
or (S)-2-((2,4-difluoro-5-nitrophenyl)amino)propenamide (FDAA),157 possesses a chiral center 
on its structure, thus it can react with a racemic mixture of amino acids to form two 
diastereoisomers (Scheme 3.4), which can be easily separated on a C18 column by reverse 
phase HPLC. This method would be extremely useful, not only to determine the 
biotransformations conversions, but also to measure the enantiomeric excess (ee) of the 
products. Furthermore, N-Ac-AAs will not interfere with the derivatization reaction since 
FDAA reacts exclusively with free amines. MR derivatives have a strong absorbance at 360 
nm and can be easily detected by LC-MS on positive ion mode.158 They degrade quickly if 




Scheme 3.4 Marfey’s reagent (FDAA) derivatization of a standard solution of racemic allylglycine 
(2f).This results in the formation of two diastereoisomers: L-3f (S,S) and D-3f (R,S). 
FDAA is commercially available but expensive (100 mg for 157 £ by Merck). Since large 
amounts of the reagents are required, to carry out all the appropriate test to optimize the 
assay protocol, a batch of MR was prepared in house. FDAA was synthesised following the 
original protocol reported in 1984 by Marfey157 (Scheme 3.5) via a nucleophilic aromatic 
substitution of one of one of the fluorine of 1,5-difluoro-2,4-dinitrobenzene (DFNB) by the 
amino group of (S)-2-aminopropanamide in the presence of a strong base. Pure MR crystals 
were isolated with a yield of 47.7%.  
 
Scheme 3.5 Synthesis of FDAA from DNFB and L-alanine amide. 
The derivatization protocol was tested by reacting FDAA with a standard solution of the 
amino acid allylglycine (2f), using the protocol reported by Wu (Scheme 3.5).159 The 
derivatization mixture was filtered and analysed by HPLC. The absorbance chromatogram, 
recorded at 360 nm, shows two peaks which eluted with a retention time of 23.6 min for L-
3f (S,S) and 26.7 min for D-3f (R,S) (Figure 3.18).160 Analysis by LC-TOF MS confirmed the 




Figure 3.18 HPLC absorbance traces of MR derivatization mixture of a standard L-allylglycine 2f 
solution (black) and a reaction mixture (red). The samples eluted on a C18 column with a linear 
gradient of 15% to 50% ACN 0.1% FA in water 0.1% FA, over 30 minutes. Flow 1.0 mL/min and λ = 
360 nm at r.t. 
N-Ac-allylglycine (1f) was used as substrate for ArgE KR, the reaction was incubated for 24 h 
at 40°C and product 2f formation was confirmed by TOF MS analysis. The MR protocol was 
further tested by reacting FDAA with N-Ac-allylglycine KR reaction mixture (Scheme 3.6). The 
derivatization solution was analysed by HPLC and LC-TOF MS, however no traces of 
allylglycine-MR derivatives were detected by either technique (Figure 3.18). 
 
Scheme 3.6 N-Ac-allylglycine (1f) was hydrolysed in a KR with ArgE (0.25 mg/mL) in NaPi buffer 0.1 M 
pH 8. The KR was incubated 24 h at 40°C; after quenching the biotransformation a sample was 
derivatised with MR to give as expected product the FDAA derivative L-3f (S,S) diastereoisomer. 
Attempts to optimise the reaction protocol by changing the incubation temperature, the 
derivatization time, the reagents concentration, the base and buffer used, did not prove 
successful. 
The assay reproducibility is quite poor, especially when a reaction mixture is used for the 
derivatization, instead of a standard amino acid solution. To be reliable, the MR 
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derivatization protocol requires a long optimization. Another more immediate solution was 
selected to monitor the hydrolysis conversions.157 
3.8.2 1H-NMR assay 
3.8.2.1 Proof of concept 
1H-NMR spectroscopy is a good candidate as a technique to monitor the enzyme catalysed 
deacetylations. The 1H-NMR spectra of free and N-acetylated amino acids have at least two 
very distinctive signals, which undergo a shift during hydrolysis. The C-α-proton shifts from 
4-5 ppm to 3-4 ppm and the acetate methyl group shifts from 2.1-1.9 ppm to 1.9-1.8 ppm 
following deacetylation. By comparing the integrals of these signals, it should be possible to 
calculate the relative conversion of the reaction.161–163 
For proof of concept, a biotransformation was set up, incubating N-Ac-L-ornithine (1d, 20 
mM) with ArgE (0.25 mg/mL) and CoCl2 (100 μM) at 40°C for 24 h in a final volume of 500 μL 
(Scheme 3.7). The formation of the product 2d was confirmed by LC-TOF MS analysis. The 
biotransformation was quenched by addition of HCl conc. to precipitate the enzyme. 100 μL 
of D2O was mixed in an NMR tube with 400 μL of reaction mixture. The 1H-NMR spectrum of 
the sample was recorded on an AVA 500 (500 MHz) NMR, with a solvent signal suppression 
experiment (16 scans).  
 
Scheme 3.7 Scheme for the ArgE catalysed deacetylation of N-Ac-L-Orn (1d).The hydrogens of 
substrate and products are colour coded and reported in: green (α), red/yellow (β/γ), blue (δ) and 
orange (acetate CH3 group). 
As shown in Figure 3.19, the biotransformations reached completion after 24 h incubation 
and the C-α-proton and acetate signals can be potentially used to monitor the conversions. 
However, the α-proton signal of N-acetylated amino acids falls close to the residual solvent 
peak of D2O (4.79 ppm). Depending on the nature of the amino acid side chains, the two can 
overlap or the intensity of the signal can potentially be altered during the solvent suppression 
experiment. The acetate signal falls far from the water peak and can be used to obtain a more 
accurate estimate of the deacetylation conversion. Furthermore, the acetate peak is formed 
by three equivalent protons, which should give a better intensity/noise ratio and higher assay 
sensitivity; indeed, sodium acetate is a common internal standard used for quantitative 
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Figure 3.19 1H-NMR spectrums with colour coded signals of A) N-Ac-L-Orn (1d) standard, B) L-Orn 
(2d) standard and C) ArgE biotransformation reaction mixture with L-Orn formation (2d). The proton 
signals are reported in: green (α), red/yellow (β/γ), blue (δ) and orange (acetate CH3 group). 
3.8.2.2 Conversion of canonical N-Acetyl-L-Amino Acids 
Having successfully used N-Ac-L-Orn (1d) as proof of concept, we then set up nineteen 
biotransformations using N-acetylated L-amino acids 20 mM (with the exception of serine, 
used as a racemic mixture), ArgE 0.25 mg/mL and CoCl2 (100 μM) and incubated at 40°C for 
24h (Scheme 3.8). The reactions were quenched by addition of HClconc and centrifuged to 
separate the precipitated enzyme from the supernatant. A 1H-NMR spectrum was recorded 




Scheme 3.8 Reaction scheme of the ArgE catalysed N-acetyl-L-amino acids hydrolysis. 
The conversions, reported in Table 3.4, agreed with the kinetic data determined with the L-
AAO assay (Table 1.1), with low to no activity detected for aromatic substrates and a 
preference for hydrophobic or basic groups on the N-Ac-AA side chains. In addition, N-Ac-L-
cysteine and proline were identified as ArgE substrates, while no activity was detected 
towards N-Ac-L-Asp and Glu. These results were expected, since ArgE already showed a low 
tolerance for N-acetylated amino acids with negatively charged groups on the side chain, as 
PT. 
L-AA Conv (%) m/z [M+H]+ 
Ala 93.9 90.0 
Ile 98.3 132.1 
Leu 99.3 132.1 
Pro 53.7 116.0. 
Val 85.4 118.1 
Phe 2.10 166.1 
Tyr N.D. N.D. 
Trp N.D. N.D. 
Asp N.D. N.D. 
Glu N.D. N.D. 
Arg 99.3 124.1 
His 96.1 156.1 
Lys 98.8 147.0 
Ser 44.9 106.1 
Thr 27.3 147.1 
Cys 77.8 120.1 
Met 100 122.1 
Asn 95.4 150.1 
Gln 60.6 133.1 
Table 3.4 ArgE biotransformation products conversion percentages calculated from the 1H-NMR 
spectrums and m/z values from TOF-MS analysis on positive ionization modes. 
3.8.2.3 Time dependant experiment 
The 1H-NMR assay can potentially be exploited to monitor the reaction conversion over time. 
For the time dependant experiment N-Ac-L-Val was chosen as substrate, since this compound 
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has another signal, the isopropyl group at ~1 ppm, which falls close to the acetate peak and 
shifts in the spectrum during the hydrolysis. 
 
Scheme 3.9 Reaction scheme of the ArgE catalysed N-Ac-L-Val hydrolysis for the time dependant 1H-
NMR experiment. The hydrogens of substrate and products are colour coded and reported in: blue 
and green for the iPr group and purple and red for the acetate CH3 group. 
Two enzymatic reactions were set up at 30 mM substrate concentration in NMR tubes using 
D2O as solvent (Scheme 3.9). Since ArgE is a hydrolytic enzyme and its rate limiting step is the 
water deprotonation, as reported by Blanchard et. al.,141 a higher enzyme concentration (0.5 
mg/mL) was employed for these experiments, to compensate for the loss of activity due to 
the solvent isotopic effect. 
.  
Figure 3.20 Superimposition of 1H-NMR spectra of the N-Ac-L-Val hydrolysis at 40°C during 
incubation times 15 to 125 min. The spectra intensity values were normalised between 0 and 100. 
The proton signals of the starting material (purple and blue) and the product (red and green) 
monitored during the reaction, are colour coded as described in Scheme 3.9. Data intensity 
normalised against the free acetate singlet peak. 
The two reactions were incubated at 25°C and 40°C respectively and a 1H-NMR spectrum was 
recorded on an AVA 400 (400 MHz) NMR every 10 minutes for 2.5 h (Figure 3.20), starting 
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after 15 min from the addition of ArgE. This lag phase was necessary to set up the experiment 
and to give enough time to the NMR probe and the reaction to reach the desired temperature 
By analysing the superimposed 1H-NMR spectra it is easy to monitor the progress of the 
reactions with the N-acetate peak intensity (2.16 ppm) decreasing over time, while the free 
acetate signal (2.0 ppm) grows in a time-dependant manner; the isopropyl group signal for 
starting material and product follow the same pattern (Figure 3.20). Conversions were 
calculated from the integrals of the free (2.0 ppm) and N-bound acetate peaks (2.16 ppm). 
As expected, given ArgE’s optimal reaction temperature, the reaction at 40°C is favoured. It 
reaches full conversion after 2 h incubation, compared to the 81% conv. obtained for the 
hydrolysis incubated at room temperature (Figure 3.21).  
The reported 1H-NMR assay is reliable and reproducible, plus it does not require the 
preparation of a calibration curve to obtain quantitative analysis and the samples are easy to 
prepare. This assay will be employed in all future experiments to measure the conversion of 
acylase catalysed hydrolysis reactions. 
 
Figure 3.21 Formation of L-Val over time from the ArgE catalysed biotransformations incubated at 
40°C (blue) and 25°C (orange). Conversion percentages calculated from the integrals of the acetate 
signals from the 1H-NMR spectrums. 
The results obtained employing the 1H-NMR assay are concordant with the data collected on 
ArgE thermostability and substrate scope, using the spectrophotometric L-AAO assay 
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(Section 3.3 and 3.6.), proving that 1H NMR spectroscopy can be employed to efficiently 
monitor enzymatic reactions and to obtain reliable data. Furthermore, the new assay can 
potentially be applied for the determination of the acylase kinetic parameters, by reducing 
the 15 min lag phase between the start of the reaction and first spectrum recorded, to obtain 
a better estimate the initial rate values.  
3.9 Expanding ArgE substrate scope  
3.9.1 Non canonical N-acetyl amino acid library synthesis 
The novel 1H-NMR assay was further employed to expand ArgE substrate scope by screening 
a library of N-Ac-NCAAs. The N-acetyl amino acids (1a and 1e-t) were prepared from their 
respective free AAs or derivatives, a gift from Syngenta (Jealott's Hill, UK), with the exception 
of N-acetyl-2-amino-3-(1H-1,2,4-triazol-1-yl)propanoic acid (1i), which was obtained in its 
acetylated form (gifted by Syngenta, Jealott's Hill, UK). While, N-acetyl: L-MetO (1b), L-MetO2 
(1c), L-Orn (1d), 4-F-Phe (1u), 3-F-Phe (1v) and 2-F-Phe (1w) were purchased from Sigma-
Aldrich. 
 
Scheme 3.10 Deprotection of FMOC-AAs. 
The FMOC AAs (4e-h) were deprotected using an excess of piperidine in DMF, the reaction 
was complete after 2 h at room temperature with stirring (Scheme 3.10). While the methyl 
and ethyl esters (5j-l) were hydrolysed overnight under reflux with 6M HCl (Scheme 3.11) to 




Scheme 3.11 Protocol for ester hydrolysis. 
The free amino acids and 2e-u were acetylated with the same protocol used for 2a (Section 
3.7.1): treatment with acetic anhydride (1.2 eqv) and excess NEt3 (2.1 eqv), overnight with 
stirring (Scheme 3.3). It was noted that product 1l was isolated as a 1:1 mixture of cis and 
trans stereoisomers. 
3.9.2 ArgE catalysed biotransformations 
The first set of reactions was prepared by mixing 1b-q (20 mM), ArgE (0.25 mg/mL) and CoCl2 
(100 μM) in 0.1 M NaPi buffer pH 8. The biotransformations, along with positive and negative 
controls were incubated for 24 h at 40°C (Scheme 3.12). After quenching the reactions with 
the addition of HCl conc., the 1H-NMR spectrum of the reaction mixtures was registered, and 
the reaction conversions calculated (Figure 3.22). 
 
Scheme 3.12 Protocol for the ArgE catalysed hydrolysis of N-Ac-L-NCAAs. 
ArgE accepted most of the N-Ac-NCAAs, with the exception of the sterically hindered 
substrate: N-Ac-tert-Leu (1p) and N-Ac-tert-Bu-Ala (1q). The enzyme was not able to accept 
N-acetyl methyl-L-alanine (1e), however it is active towards other substrates with tertiary 





Figure 3.22 1H-NMR calculated conversions for the enzymatic deacetylation of the N-Ac-NCAA 
library. 
One of the lowest conversions (20.6%) was obtained using N-acetyl (E)-2-amino-5-
methylhex-3-enoic acid (1l) as the substrate; this compound is present in solution as a 
mixture 44:56 of two amide rotamers, cis and trans (Figure 3.23 A).165 The presence of a 
mixture of rotamers was confirmed by conducting a complete NMR charachterization at 
various temperatures of an 1l standard sample, which excluded the presence of a mixture of 
E,Z stereoisomers, see Appendix 22. Instead, rotamers formation due to the presence of the 
acetamide group is suggested by the coalescence of the 1H-NMR peaks at high temperature 
(Appendix 22 D). For this compound it was deduced that the trans is the major rotamer in 
solution, since this particular conformation can be stabilised by the formation of an 
intramolecular H-bond between the amide N-H and the carboxylic acid group, which should 
be deprotonated in the reaction conditions (buffer pH 8). By analysing the 1H NMR of the 
biotransformation mixture in the double bond region it was deduced that only the cis minor 
rotamer is accepted by ArgE. As reported in Figure 3.23, the trans signal (in blue) remains 
unaltered after the enzymatic reaction. However, a new peak appears at 5.92 ppm (purple), 





Figure 3.23 A) Reaction scheme for the biocatalytic hydrolysis of (E)-2-acetoamido-5-methylhex-3-
enoic acid (1l). B) Double bond region (5-6 ppm) of the 1H-NMR spectrum of 1l reaction mixture after 
24 h incubation at 40°C with ArgE (0.25 mg/mL) and CoCl2 (100 μM). C). Double bond region (5-6 
ppm) of the 1H-NMR spectrum of (E)-2-acetoamido-5-methylhex-3-enoic acid (1l). The two double 
bond protons (Ha and Hb) are reported in two shades of: blue (the starting material trans rotamer), 
green (the starting material cis rotamer) and purple (the product trans isomer) 
 
3.9.3 PT and Glu Studies 
The results reported in Section 3.7.2, 1.7.3 and 3.8.2.2 suggest the lack of activity towards N-
Ac-PT 1a is caused by the presence of the phosphinic acid moiety on the side chain of the N-
Ac-AA. Indeed, ArgE showed a high activity for two substrates structurally analogous to N-
Ac-PT, 1b and 1c, but it was completely inactive towards other N-acetyl amino acids with 
negatively charged groups in their structure, such as N-Ac-Glu and Asp (Figure 3.24). 
To definitively prove this hypothesis, the activity of ArgE for three new 1a analogues: N-Ac-
L-Glu, N-Ac-L-5-methoxy-Glu (1r) and N-acetyl dimethyl L-glutamate (1s), was tested. The 




Figure 3.24 Comparison between ArgE activity towards N-Ac-L-Glu, N-Ac-L-5-methoxy-Glu (1r) and N-
acetyl dimethyl L-glutamate (1s). Conversion measured by 1H-NMR spectroscopy and m/z values 
obtained via LC TOF-MS. 
No conversion was detected for N-Ac-L-Glu and for the di-methyl ester substrate 1s. 
Formation of product 2r (c = 22.5%) was observed by 1H-NMR spectroscopy and LC TOF-MS. 
By “hiding” the negative charge of glutamate side chain, via methyl ester formation (1r), the 
enzyme was able to recognise and bind this substrate, catalysing the formation of the γ-
methyl ester product (2r) However, this newfound activity is completely lost when both 
carboxylic groups of glutamate are methylated. These data suggest that an α free carboxylic 
acid group is required for substrate recognition, while the presence of a negatively charged 
group on the side chain of the substrate is not tolerated by ArgE. 
3.9.4 Kinetic Resolution on N-Ac-NCAAs 
Up to this point only enantiopure substrates were used for screening, with the exception of 
1a. The second section of the N-Ac-NCAAs library is made up by racemic compounds, which 
were employed to perform an ArgE catalysed kinetic resolution; the protocol reported in 
Section 1.9.2 was employed to run these reactions (Scheme 3.13). 
 
Scheme 3.13 ArgE catalysed kinetic resolution of racemic N-acetyl NCAAs. 
As reported in Figure 3.25, ArgE shows great affinity for unsaturated amino acids derivatives 
(1f and 1g) and is able to accept N-acetyl heterocyclic amino acids (1h-j) with good to 
moderate activity. As expected, no product formation was detected using phenylalanine 




Figure 3.25 1H-NMR calculated conversions for the enzymatic KR of the racemic N-Ac-NCAA.ee 
percentages calculated by chiral HPLC analysis on a Chirobiotic T (Teicoplanin) column, isocratic 
gradient: elution phase 0.025% TEAA and MeOH (60/40 ratio), flow 0.5 mL/min, T = 40°C and λ = 210 
nm. Reactions repeated in duplicates, error bars calculated as standard deviations reported only for 
triplicates. 
The chiral HPLC assay was exploited to estimate ArgE enantioselectivity towards these 
substrates. Product 2h, 2j and 2t have a weak absorbance at 210 nm (Figure 3.26 A and B), 
thus it was possible to calculate their enantiomeric excess (> 99%).  
The amino acids 2f, 2g and 2i do not absorb in the UV-Vis spectrum, however it was still 
possible to determine the stereoselectivity of the enzyme by observing the change in their 
respective N-Ac-AA peaks; after 24 h incubation the peak of the L-isomer decrease in 
intensity, disappearing completely for some samples, while the peak of the D-isomer remains 




Figure 3.26 Example of chiral HPLC traces employed to study the enantioselectivity of ArgE KR 
reactions. Comparison between A) 1h (blue) and 2h (red) standards, and B) a sample of 1h kinetic 
resolution reaction mixture in black. Comparison between C) 1f (blue) standard, and D) a sample of 
1f kinetic resolution reaction mixture in black. Chiral HPLC analysis on a Chirobiotic T (Teicoplanin) 
column, isocratic gradient: elution phase 0.025% TEAA and MeOH (60/40 ratio), flow 0.5 mL/min, T = 
40°C and λ = 210 nm. Reactions repeated in duplicates, error bars calculated as standard deviations 
reported only for triplicates. 
To improve the reaction conversions, two new kinetic resolution batches were set up with 
0.50 mg/mL and 1.00 mg/mL of enzyme, respectively. An increase in the conversion values 
can be noted for the three heterocyclic substrates: especially 1h (43%) and 1i (52%), while 
no traces formation of 2u, 2v, or 2w was detected by either 1H-NMR spectroscopy or LC-TOF 
MS, even at the highest enzyme concentration (Figure 3.27).  
The best results were obtained using the highest ArgE concentration tested (1 mg/mL); since 





Figure 3.27 Comparison between the conversion values calculated with the 1H-NMR assay for the 
kinetic resolution of 1f-j and 1u-w at increasing enzyme loading: 0.25 mg/mL (blue), 0.50 mg/mL 
(orange) and 1.00 mg/mL (grey). The reactions contained: substrate (20 mM), ArgE (0.25 mg/mL) and 
CoCl2 (100 μM) in 0.1 M NaPi buffer pH 8. The KRs were incubated at 40°C, 250 rpm for 24 h. 
Reactions repeated in duplicates, error bars calculated as standard deviations reported only for 
triplicates. 
3.9.5 Determination of kinetic parameters of ArgE 
The NCAAs library was screened for activity with the commercial L-AAO. With the exception 
of L-tert-leucine (2p), the oxidase was active for all NCAAs (Figure 3.28). However, this lack 
of activity of the L-AAO did not cause any drawbacks for the determination of ArgE kinetic 
parameters. As reported in Figure 3.22 and Figure 3.25, no conversion was measured for ArgE 
towards the acetylated derivative of L-tert-leucine and other steric hindered amino acids. 
 
Figure 3.28 Screening of L-AAO activity towards the non-canonical amino acid library. Water used as 
control. The assay mixture contained: AA 10 mM, CoCl2 100 µM, L-AAO 100 mU/mL, HRP 10 U/mL 
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and o-dianisidine 0.1 mg/mL in NaPi buffer 0.1 M pH 8. The plate was incubated at 40°C for 1 h and 
absorbance measured at 436 nm every 30 s. Structures of the amino acids are reported in Figure 
3.22 and Figure 3.25. 
The kinetic parameters of ArgE for the N-acetyl NCAAs library were determined with the 
continuous L-AAO assay (Table 3.5); it must be noted that ArgE shows a higher activity for N-
Ac-L-Met (kcat = 4.58 s-1), compared to N-Ac-L-Orn (1d), its natural substrate. Furthermore, a 
TON of 0.15 s-1 was calculated for substrate 1j, 5-fold higher than the kcat obtained for 
compound 1i (3·10-2 s-1); however, a 52% conversion was reported for 2i formation, while the 
maximum conversion achieved for 2j at the highest enzyme loading was 10%. ArgE activity 
may be inhibited by the presence of either substrate (1j) or product (2j) in high concentration, 
which could explain this gap registered between TON and reaction conversions. Further tests 
are required to confirm this theory. 
N-Ac: KM (mM) kcat (s-1) kcat/KM (M-1s-1) 
1d 3.0 ± 0.3 0.106 ± 0.008 35.250 ± 0.008 
1f 2.4 ± 0.2 0.34 ± 0.02 267.870 ± 0.003 
1g 1.29 ± 0.08 0.12 ± 0.01 6.47 ± 0.03 
1h - - - 
1i 36 ± 3 0.0298 ± 0.0008 0.836 ± 0.002 
1j 10.03 ± 0.07 0.147 ± 0.002 14.6276 ± 0.0001 
1k 2.7 ± 0.1 0.170 ± 0.002 64.3415 ± 0.0005 
1l 2.7 ± 0.1 0.170 ± 0.002 64.3415 ± 0.0005 
1m 4.1 ± 0.3 0.152 ± 0.009 37.006 ± 0.005 
1n 6.2 ± 0.5 0.28 ± 0.02 44.688 ± 0.004 
1o 0.4 ± 0.1 0.26 ± 0.01 676.84 ± 0.01 
1r 5 ± 1 0.44 ± 0.03 88.78 ± 0.02 
1t 12.5 ± 0.4 0.311 ± 0.007 24.8651 ± 0.0008 
Table 3.5 Kinetic parameters of ArgE for N-Ac-NCAAs. The reaction mixture contained: various 
substrate concentrations, CoCl2 100 µM, L-AAO 100-300 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 
mg/mL NaPi buffer 0.1 M pH 8. The plate was incubated at 40°C for 1 h and absorbance measured at 
436 nm every 30 s. Reactions repeated in triplicates. 
3.10 Homology model and Mechanistic Studies 
3.10.1 Homology Model 
To complement the activity and substrate screenings performed, a structural study was 
conducted. Since the ArgE crystal structure has not been resolved, a homology model was 
built with the free access RaptorX software (Figure 3.29)166 using the enzyme amino acid 
sequence. Five homologues with a resolved X-ray structure were used as templates: DapE 
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from Haemophilus. influenzae (31.5 % sequence identity, PDB entry code 3IC1), DapE from 
Neisseria meningitis (29.0 % sequence identity, PDB entry code 1VGY), carboxypeptidase G2 
from Pseudomonas sp. (30.3 % sequence identity, PDB entry code 1CG2), N-acetyl-ornithine 
deacetylase from Rhodopseudomonas palustris (27.5 % sequence identity, PDB entry code 
3PFO) and N-acetyl-ornithine deacetylase from Spaerobacter thermophilus (29.0 % sequence 
identity, PDB entry code 4Q7A). These proteins, like ArgE, are members of the M20 peptidase 
superfamily and are di-zinc dependant hydrolases. Furthermore, they are homodimers and 
each monomer contains a catalytic and a dimerization domain.167 
 
Figure 3.29 E. coli ArgE homology model built with the free access software RaptorX, based on the 
crystal structure of: DapE from H. influenzae (3IC1), DapE from N. meningitis (1VGY), 
carboxypeptidase G2 from Pseudomonas sp. (1CG2), N-acetyl-ornithine deacetylase from R. palustris 
(3PFO) and N-acetyl-ornithine deacetylase from S. thermophilus (4Q7A). Catalytic domain in green 
and dimerization domain in silver. 
In the catalytic domain each metal ion is coordinated to a glutamate and a histidine residue, 
with a bridging aspartic acid and water molecule completing the penta-coordination. These 
residues are involved in maintaining the enzyme’s structural integrity but they also play a 
role during catalysis; additionally, another residue (Glu or Asp) acts as general acid/base, 
deprotonating the water and starting the reaction.167 Sequence alignment of ArgE with its 
five homologues (Chapter 8.6) shows that the residues H80, D112, E144, E145, E169 and 
H355 (H67, D100, E134, E135, E163 and H349 for H. influenzae DapE) are highly conserved in 




Figure 3.30 Superimposition between the active site of E. coli ArgE (in green) and its closest 
homologue: H. influenzae DapE (silver) in complex with two Zn(II) ions (grey spheres); the bridging 
water is represented as a blue sphere. 
The role of residues H80 and H355 was investigated by Holz et. al.168 These two His residues 
were mutated to Ala. While the H80A mutant was completely insoluble the H355A mutant 
was successfully expressed and purified, however the mutation caused a significant loss in 
ArgE activity (measured as the decrease of L-Orn production over time per milligram of 
enzyme) and an increase in the second kd. This data suggest that H355 is involved in catalysis 
and occupies the second (weaker) metal binding site. 
The role of the three highly conserved glutamate residues has yet to be clarified. As shown 
in Figure 3.30, E145 and E169 are in proximity of the two zinc ions and suggests that they are 
involved in the metal binding. However, E144 is quite distant from both Zn2+ and it probably 
acts as a general acid/base, deprotonating the water to start the reaction.  
The sequence alignment also revealed the presence of another highly conserved residue in 
the family. H195, which is located on the dimerization domain, far from the catalytic site. The 
role of this residue during catalysis was first suggested by Holz et. al.169 by resolving the 
crystal structure of the H. influenzae DapE enzyme in complex with the reaction products: 
succinic acid (SNA) and L,L-di-amino pimelic acid (L,L-DAP), PDB entry code 5VO3. The H. 
influenzae DapE is a di-zinc metalloprotein which shares 31% sequence homology with ArgE 




Figure 3.31 Comparison between A) open (3IC1) and B) close (5VO3) conformation of H. influenzae 
DapE crystal homodimeric structures (chain A in red, chain B in gold, L,L-DAP in yellow, SNA in cyan 
and Zn(II) ions in grey). 
Upon comparing the DapE free (PDB entry code 3IC1,) and products L,L-diaminopimelic acid 
(L,L-DAP)/succinic acid (SNA)-bound structures (Figure 3.31), a significant conformational 
change is noted with the catalytic domain twisting and flexing (50° rotation and 10 Å shift)169 
to pass from an open to a close conformation during substrate binding. Holz suggested that 
this conformational change is caused by the formation of two new interactions between one 
of the succinic carboxylate groups with Zn(II) and H194 (H195 for ArgE), which would bring 
the dimerization domain of chain B, where H194 is located, close to the catalytic domain of 
chain A (Figure 3.32). Another interaction involved in substrate binding stabilization, is 
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formed between the R258 (R264 for ArgE) guanidinium group and the alpha carboxylate of 
the substrate (Figure 3.32). 
To verify if ArgE follows a reaction mechanism and substrate binding/stabilization mode 
analogous to H. influenzae DapE (31% sequence homology), single point mutants of D112, 
E144, E145, E169, H195 and R264 were prepared and their activity tested using ArgE WT best 
substrate: N-Ac-L-Met. 
 
Figure 3.32 H. influenzae DapE dimeric structure (chain A in gold and chain B in red) in complex with 
two Zn(II) ions (grey spheres), succinic acid SNA (cyan) and L,L-diaminopimelic acid L,L-DAP (yellow). 
Residues H194:B and R258:A involved in substrate binding and stabilization by H-bonds formation. 
3.10.2 ArgE E144A, E145A and E169A Characterization 
Mutagenesis primers were designed for the mutants E144A, E145A and E169A, using the 
method described by Lin and Naismith.170 The pETHISTEV-ArgE vector was used as a template 
for site directed mutagenesis (SDM) and the whole plasmid was amplified with the primers 
incorporating the mutations into the gene. The presence of the desired mutation was 
confirmed by sequence analysis. 
ArgE E144A, E145A and E169A were expressed using the standard ArgE protocol (Chapter 
6.3.4), however SDS-PAGE analysis of ArgE E145A and E169A expression test samples, 
revealed that the mutants were completely insoluble (Figure 3.33 A). ArgE E144A was 
successfully expressed and purified with a final yield of 10 mg per L of culture; the SEC 
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absorbance chromatogram shows a single peak at 72 mL (Figure 3.33 B), indicating the 
presence of a homodimeric protein in solution. 
 
Figure 3.33 Expression and purification of ArgE E144A, E145A and E169A mutants. A) 12% SDS-PAGE 
gel of ArgE E145A and E169A expression tests: lane 1 LMWM (M), lane 2 E145A pellet sample (P), 
E169A pellet sample (P), lane 4 E145A soluble fraction (L) and lane 5 E169A soluble fraction (L). B) 
SEC chromatogram for ArgE E144A purification on a S200 SEC column. 
The SDS-PAGE gel shows a strong band at 45kDa (Figure 3.34 A) and ICP-MS analysis confirm 
the presence of one zinc bound per unit of enzyme. To further verify the presence of the 
mutation, a sample of purified protein was analysed using denaturing LC ESI-MS. The 
observed MW of 45312.77 ± 2.08 Da (Figure 3.34 B) was in accordance with the theoretical 
MW (45311.47 Da) of the enzyme minus the initial methionine, calculated from the amino 
acid sequence. 
 
Figure 3.34 Characterization of purified ArgE E144A. A) 12% SDS-PAGE gel of ArgE E144A 
purification: lane 1 LMWM (M), lane 2 CFE (L), lane 3 HisTrap flow through (FT), lane 4-7 HisTrap 
fractions (3 mL each, enzyme elution start at ~200 mM imidazole) and lane 8-12 S200 fractions (3 mL 
each). B) Denaturating LC ESI-MS of ArgE E144A (20 μM) with a mass of 45312.77 ± 2.08 Da, in 
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accordance with the MW calculated from the sequence (45311.47 Da). The values reported are m/z 
with the charges in brackets. 
ArgE E144A kinetic parameters for N-Ac-L-Met as substrate were obtained employing the 
high-throughput L-AAO assay (Figure 3.35 A). The mutant was almost completely inactive 
(Figure 3.35 B); this loss in activity is caused by a significant decrease of the kcat (0.019 ± 0.002 
s-1), 250-fold lower than the value calculated for the WT (4.58 ± 0.07 s-1), while the mutant is 
still able to efficiently bind the substrate, since the KM, suffered just a slight decrease from 
2.4 ± 0.2 mM (WT) to 1.3 ± 0.7 mM (E144A). 
 
Figure 3.35 Kinetic analysis of ArgE E144A via the HT L-AAO assay. A) Michaelis-Menten plot of ArgE 
E144A for N-Ac-L-Met. Initial rates calculated from the linear portion of the absorbance curves and 
fitted with the OriginLab software. The reaction mixture contained: various substrate 
concentrations, ArgE 10 μg/mL, CoCl2 100 µM, L-AAO 70 mU/mL, HRP 10 U/mL and o-dianisidine 0.1 
mg/mL in NaPi 0.1 M pH 8. The plate was incubated at 40°C for 1 h and absorbance measured at 436 
nm every 30 s. B) Comparison between the Michaelis-Menten curve of ArgE WT (black) and E144A 
(red) obtained for N-Ac-L-Met. Reactions repeated in triplicates, error bars calculated as the 
standard deviations. 
The data collected suggest that the E144 residue assumes a catalytic role in ArgE, acting as a 
general acid/base catalyst during the water deprotonation step. While the E145 and E169 
residues are not directly involved in catalysis, however the insolubility of the two alanine 
mutants demonstrate the importance of these two residues for cofactor binding and for 
maintaining the structural integrity of the catalytic site. 
3.10.3 ArgE D112A, H195I and R264A Characterization 
Mutagenesis primers were designed for the mutants D112A, H195I and R264A, using the 
method described by Lin and Naismith.170 The pETHISTEV-arge vector was used as template 
for SDM and the whole plasmid was amplified with the primers incorporating the mutations 
into the gene. The presence of the desired mutation was confirmed by sequence analysis. 
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ArgE D112A, H195I and R264A were expressed using the standard ArgE protocol. The three 
mutants were purified via metal affinity chromatography and the fractions containing the 
enzymes were collected and dialysed overnight at 4°C against storage buffer (50 mM 
tris(hydroxymethyl)aminomethane TRIS pH 8 and 150 mM NaCl). SDS-Page and denaturating 
LC-ESI MS analysis were carried out to confirm the presence of the desired mutations. 
Additionally ICP-MS analysis was performed to quantify the zinc concentration bonded to the 










D112A 3.9 45325.07 ± 1.03 45325.49 1 
H195I 12 45316.00 ± 2.75 45319.44 1 
R264A 13 45281.21 ± 1.52 45284.40 1 
Table 3.6 Yield, MW calculated from amino acid sequence, MW observed by denaturing LC-MS and 
Zn(II) content determined via ICP-MS for ArgE D112A, H195I and R264A mutants. 
The activity of the mutants towards N-Ac-L-Met was explored employing the continuous L-
AAO assay (Table 3.7); the Michaelis Menten curve of ArgE R264A did not reach saturation 
even at high substrate concentration, however the curvature was sufficient to estimate the 
kinetic parameters of the mutant. 
Mutant KM (mM) kcat (s-1) kcat/KM (M-1s-1) 
WT 2.4 ± 0.2 4.58 ± 0.07  1759.653 ± 0.001 
D112A 5.0 ± 0.2   0.353 ± 0.002 70.293 ± 0.002 
H195I 10 ± 1 0.384 ± 0.004 7.58 ± 0.01 
R264A 59 ± 16 0.11 ± 0.01 1.91 ± 0.04 
Table 3.7 Comparison between the kinetic parameters obtained for ArgE WT, D112A, H195I and 
R264A with the continuous L-AAO assay using N-acetyl-L-methionine as substrate. 
As shown in Table 3.6, the enzyme’s zinc and substrate binding were not disrupted by the 
mutation of the bridge ligand D112; however, the TON of D112A (0.353 ± 0.002 s-1) is 13-
folds lower compared to ArgE WT (4.58 ± 0.07 s-1). In the absence of the bridging ligand, the 
Zn(II) ion is possibly forced to assume a distorted tetracoordinated conformation, similar to 
those assumed by the cofactor in zinc metalloproteins with a catalytic active site;171 this 
change in the geometry may explain the loss in activity detected.  
A 13-fold decrease in the kcat was also calculated for the H195I mutant (0.384 ± 0.004 s-1), 
along with a 5-fold increase in the KM (10 ± 1 mM). While the kinetic parameters obtained for 
ArgE R264A shows a TON 40-times lower (0.11 ± 0.01 s-1) and a KM 25-times (59 ± 16 mM) 
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higher compared to the WT. The data collected suggest that these two residues are 
important for the enzyme activity and do play a role in substrate binding; in accordance with 
the proposed role for the DapE H194 and R258 residues, based on the product-bound 
structure of H. influenzae DapE; suggesting that E. coli ArgE and potentially other members 
of the M20 peptidase family, not only follow the same reaction mechanism, but undergo an 
analogue conformational change upon substrate binding. 
3.10.4 Proposed Mechanism 
The data collected from the SDM studies, along with the results previously reported in 
literature141,145,168 suggest that ArgE presents a typical co-catalytic binuclear zinc binding 
site142,172 and follow a hydroxide mechanism,167,169,173 as other members of the members of 
the M20 peptidase family. 
 
Figure 3.36 Schematic representation of ArgE active site with the Zn2+ (grey) and Co2+ (purple) bound 
and E144 ready for catalysis upon substrate binding. 
It was noted that after purification ArgE contains only a zinc bound to the “strong” binding 
site (higher affinity) formed by the E169 and H80 residues; the data reported by Holz145,168 
and the results of the metal binding studies conducted in Section 3.5 suggests that after 
addition of CoCl2 to the reaction mixture the enzyme will bind a Co2+ ion, which is going to 
occupy the weak binding site, with E145 and H355 acting as ligands (Figure 3.36). 
As reported in Scheme 3.14, the reaction starts with substrate recognition and binding; the 
enzyme undergoes a conformational change, passing from an “open” to a “closed” active 
conformation. It is probable that, similarly to H. influenzae DapE, various ArgE residues, 
which are going to form the substrate binding site, are involved in this step. The results of 
the SDM studies suggest that R264 from chain A of the dimer and H195 from chain B (R258·A 
and H194·B for DapE) are involved in the N-Ac-amino acid stabilization with the guanidinium 
group of R264 forming an hydrogen bond with the α-carboxylate of the substrate, while the 
acetate C=O, coordinated with the Co2+ ion, interacts via a H-bond with the imidazole of H195 
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from chain B, forming an oxyanion hole and increasing the electrophilicity of the carboxylate. 
The hydroxide is formed from the deprotonation of the bridging water by E144 in the rate 
limiting step of the reaction;141 the Zn2+ ion acts as a Lewis acid by decreasing the pKa of the 
water and stabilizing the hydroxide ion, which attacks the electrophilic carboxylate of the 
acetate. The tetrahedral intermediate, stabilized by coordination to the Zn(II) and Co(II) ions 
and by a H-bond with H195, collapses thanks to a proton transfer delivered from E144. The 
amino acid product is released with the enzyme returning to an “open” conformation and a 
new water molecule substitutes the acetate as bridging ligand reforming the catalytic active 
site. 
 
Scheme 3.14 Proposed ArgE hydrolysis mechanism of N-acetyl-L-ornithine, adapted from the H. 
influenzae reaction mechanism described by Holz et. al.169 
In the absence of CoCl2 the enzyme still retains 70% of its activity (Section 3.5.2). The second 
metal ion is not fundamental for this class of enzymes,167,169 since the reaction mechanism 
can proceed in a similar fashion with the carboxylate group of the acetate being stabilised by 
hydrogen bonding with H355 and H195.  
 
3.11 Crystal Trials 
The homology model built and the SDM studies conducted clarified the role of the active site 
residues involved in metal binding, water deprotonation and intermediate stabilization. 
However, to fully comprehend ArgE’s substrate selectivity and identify the residues involved 
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in the amino acid side chain recognition, a substrate bound crystal structure is required. 
Various ArgE constructs were prepared and tested for the crystal trials. 
3.11.1 N-HisTag ArgE WT 
N-HisTag ArgE, purified as described in Chapter 6.4, at a concentration of 10 mg/mL was 
employed to screen 672 conditions with the crystallization kits: MIDAS, STRUCTURE 1+2, PEG 
ION, Index, PACT, CSS1+2 and JCSG+; all crystallographic studies were conducted in York in 
collaboration with Prof. Grogan. Unfortunately, only plate shaped salt crystals were obtained 
from this initial screening. 
3.11.2 C-HisTag ArgE WT 
The stop codon of the pET28a-ArgE construct was removed by SDM and the arge gene was 
subcloned into a pEBSRCTEVC10HIS plasmid (a gift from Prof. Naismith) using the NcoI and 
XhoI restriction sites, to obtain a construct with a TEV cleavable 10xHisTag at the C terminus 
of the protein. pEBSRCTEVC10HIS-ArgE was expressed using the standard ArgE protocol 
(Chapter 6.3.4), however SDS-page analysis revealed that the protein did not express in these 
conditions. 
The presence of the long 10xhistidine tag at the C-terminus is not tolerated by ArgE; no 
further attempts were made to improve the construct expression yield. 
3.11.3 Non-Tagged ArgE WT 
The pETHISTEV-ArgE construct possess a TEV cleavable hexa-histidine tag; TEV protease was 
expressed and purified as reported in Chapter 6.4 and employed to obtain pure non-tagged 
ArgE with a four steps purification protocol. The N-His tagged ArgE cell free extract was 
purified via nickel affinity chromatography and the fractions containing the enzyme were 
collected and incubated with 2 mg/mL of TEV for 16 h and dialysed against ArgE storage 
buffer (TRIS 50 mM pH 8 and 150 mM NaCl). The untagged protein was separated from TEV 
by a second nickel affinity chromatography step, the flow-through containing ArgE was 
collected, concentrated and injected on a pre-calibrated Superdex S200 column. A single 
peak eluted at 70 mL (Figure 3.37 A), indicative of the presence of a homodimer in solution. 
ICP-MS and SDS-PAGE analysis (Figure 3.37 B) were performed, confirming that a protein 
with a MW of ~42 kDa eluted with only 1 eqv of Zn2+ bound per monomer, indeed it is possible 
to clearly observe the ArgE MW loss after overnight dialysis with TEV, with the enzyme band 
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shifting from 45 kDa to 42 kDa on the gel. An observed MW of 42533.08 ± 1.42 Da was 
obtained by denaturating LC-MS analysis (Figure 3.38 A), matching the predicted MW of 
42532.53 Da calculated from the amino acid sequence. 
 
Figure 3.37 Purification of untagged ArgE, following N-His tag cleavage. A) SEC chromatogram for 
untagged ArgE purification on a S200 column. B) 12% SDS-PAGE gel of untagged ArgE purification: 
lane 1 LMWM (M), lane 2 CFE (L), lane 3 insoluble fraction (P), lane 4-7, lane 8 sample after overnight 
dialysis (D) and lane 9-13 S200 fractions (3 mL each). 
An activity assay on non-tagged ArgE was performed via the high-throughput L-AAO assay. 
The kinetic parameters calculated for N-Ac-L-Met (Figure 3.38 B) match the values obtained 
for the N-HisTag ArgE construct. The presence of a His tag at the N-terminus of ArgE, does 
not influence the enzyme activity and stability, a problem found observed for other metallo-
proteins.174–176 
 
Figure 3.38 Characterization of purified untagged ArgE, following N-His tag cleavage.A) Denaturating 
LC ESI-MS of untagged ArgE (20 μM) with a mass of 42533.08 ± 1.42 Da, in accordance with the MW 
calculated from the sequence (42532.53 Da). The values reported are m/z with the charges in 
brackets. B) Michaelis-Menten plot of untagged ArgE for N-Ac-L-Met. Initial rates calculated from the 
linear portion of the absorbance curves and fitted with the OriginLab software. The reaction mixture 
contained: various substrate concentrations, ArgE 10 μg/mL, CoCl2 100 µM, L-AAO 70 mU/mL, HRP 
10 U/mL and o-dianisidine 0.1 mg/mL in NaPi 0.1 M pH 8. The plate was incubated at 40°C for 1 h 
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and absorbance measured at 436 nm every 30 s. Reactions repeated in triplicates, error bars 
calculated as the standard deviations. 
Freshly purified protein at a concentration of 11 mg/mL was employed for crystallization 
screening. The crystal plates were incubated at 18°C and after three days protein crystals, 
with a singular prism shape (Figure 3.39), formed for two of the conditions screened: Na 
formate 0.8 M + TRIS 0.1 M pH 8 + 10% polyethylene glycol (PEG) 8K + 10% PEG 1K and Na 
formate 0.8 M + TRIS 0.1 M pH 8 + 8% PEG 20K + 8% PEG 550 MME. These crystals were 
fished, frozen in cryoprotectant and sent to the Diamond Light synchrotron, Harwell for X-
ray diffraction analysis. However, the quality (6 Å) and reproducibility of the crystals were 
very poor. To improve the quality and reproducibility of the protein crystals, non-tagged ArgE 
E144A was prepared. 
 
Figure 3.39 Untagged ArgE crystals obtained from a 1 to 1 dilution of freshly purified enzyme at 10 
mg/mL in Na formate 0.8 M + TRIS 0.1 M pH 8 + 10% PEG 8K + 10% PEG 1K. 
3.11.4 Crystal Optimization 
The M20 peptidase family members undergo a significant conformational change upon 
substrate binding and during catalysis,169 which may impact the crystals resolution and 
reproducibility. However, due to the lower activity of the E144A mutant (250-fold less than 
the WT), coupled with its high affinity for N-Ac-AAs, this mutant may yield diffraction quality 




Figure 3.40 Purified untagged ArgE E144A characterization A) 12% SDS-PAGE gel of untagged ArgE 
E144A purification: lane 1 LMWM (M), lane 2 CFE (L), lane 3 insoluble fraction (P), lane 4-7, lane 8 
sample after overnight dialysis (D) and lane 9-12 S200 fractions (3 mL each). B) Denaturating LC ESI-
MS of untagged ArgE (20 μM) with a mass of 42476.02 ± 1.86 Da, in accordance with the MW 
calculated from the sequence (42474.49 Da). The values reported are m/z with the charges in 
brackets. 
Non-tagged ArgE E144A was purified as described for the non-tagged ArgE WT. SDS-PAGE 
and denaturing LC-MS analysis show that the correct construct had been expressed (Figure 
3.40 A and B). Freshly purified enzyme at a concentration of 15 mg/mL was employed to set 
up 48 wells crystallization plates via the hanging drop method, using the conditions found 
whilst screening the non-tagged ArgE WT. 
 
Figure 3.41 Picture of untagged ArgE E144A, crystals obtained from a 1 to 1 dilution of freshly 
purified enzyme at 15 mg/mL in Na formate 0.8 M + TRIS 0.1 M pH 8 + 10% PEG 8K + 10% PEG 1K 
with the hanging drop method (drop size 4 μL). 
Prism shaped protein crystals (Figure 3.41) were obtained in both plates and sent to the 
Diamond facility; unfortunately, the best resolution obtained was ~4.0 Å. The DapE crystal 
structure (PDB entry code 3ISZ and 3IC1) was used as model for molecular replacement with 
the X-ray data available (Chapter 8.14). However, according to Prof. Grogan the electron 
density map is too disperse to properly resolve the ArgE crystal structure.  
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During crystallization a fraction of the enzyme precipitates from the solution, this precipitate 
forms a glue-like film over the drop (Figure 3.41); this film makes crystal fishing quite 
challenging and may be responsible for the poor crystal quality. To minimize the precipitation 
and improve the crystal resolution various: purification buffers, cosolvents, additives, ligands 
and metal ions were tested, but no improvement was obtained. Without a crystal structure 
available a random mutagenesis approach was employed to engineer ArgE. In conclusion for 
the first time we reported the formation of ArgE crystals, however to resolve the enzyme 
structure the crystal quality needs improvement. A possible solution is to change structure, 
maybe truncate the enzyme or add solubility tags or try to improve stability via mutations 
and surface entropy reduction. 
 
3.12  Engineering of ArgE via random mutagenesis 
In the absence of a crystal structure error prone PCR (ep-PCR)48,177 was employed in an effort 
to create an active mutant towards N-Ac-PT. Random mutagenesis techniques generate large 
mutant library and a high-throughput assay is required to efficiently screen all variants for 
activity (Figure 3.42). 
 
Figure 3.42 Schematic representation of a directed evolution process: from the template protein a 
mutant library is generated, and the mutants are expressed on a small scale and screened for 
activity. A high-throughput assay is employed to monitor product formation. 
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However, none of the assays available can be employed for this task. The development of a 
new high throughput assay is needed. 
3.12.1 In vivo Arabidopsis thaliana assay 
One option would be to test the ArgE mutants activity using an in vivo assay, since L-PT is a 
potent herbicide, while no plant toxicity has been reported for 1a. Arabidopsis thaliana are 
often employed for these toxicity assays since they grow in a relatively short period and do 
not require particular conditions. This work was developed on placement at Syngenta 
(Jealott's Hill, UK). 
A control plate was prepared with Arabidopsis seeds incubated with various concentrations 
of racemic 1a and 2a, mixed with minimal agar. The plate was incubated at 20°C with an 8 h 
light/ 16 h darkness cycle. As shown in Figure 3.43, at increasing D,L-PT concentrations an 
increase in plant death can be clearly observed, while no toxicity was observed even at the 
highest N-Ac-PT concentration employed. 
 
Figure 3.43 Picture of the Arabidopsis assay control plate after one-week incubation at 20°C. 
Comparison between racemic PT and N-Ac-PT induced toxicity at increasing compounds 
concentration. Blank samples contained NaPi buffer 0.1M pH 8. 
The Arabidopsis assay is reliable and robust with a good limit of detection (LOD) around 3-6 
ppm; however, a week is required for the plant to grow. Given the long incubation time an 
alternative was sought. 
3.12.2 OPA Assay 
OPA,154 along with ninhydrin, is one of the oldest derivatization agents used for amino acid 
analysis. The OPA reagent readily reacts with any free primary amine groups, however is 
completely inactive towards N-protected amino acids, making this assay ideal for monitoring 
the hydrolysis of N-Ac-AAs. The primary amines group of an amino acid reacts with OPA in 
the presence of a thiol, 2-mercaptoethanol or N-acetyl cysteine for instance, at basic pH; the 
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reaction is instantaneous and the isoindole product has a strong absorbance at 340 nm and 
fluorescence at 460 nm (Scheme 3.15).178  
 
Scheme 3.15 OPA derivatization reaction in the presence of an L-amino acid and a thiol at basic pH 
for the formation of a fluorescent isoindole derivative. 
This protocol is advantageous for pre- or post-column derivatization and HPLC analysis, since 
the derivatives have the same extinction coefficient (6000 M-1cm-1), independently of the 
amino acid side chain. The main drawback of this assay is the short half-life of the isoindoles, 
which are dependent on the nature of the functional groups on the amino acid chain, the pH 
of the solution and the thiol used.179 
In 2019 a new OPA derivatization protocol, optimised for the high-throughput screening of 
PT 2a, was published.178 The authors used the -SH group of N-Ac-L-Cys to catalyse the 
isoindole formation and since the thiol employed is enantiopure, it will form a diastereomeric 
mixture upon reacting with a racemic amino acid, as reported in (Scheme 3.16). Similarly, to 
MR derivatization, this OPA assay protocol allows for a rapid determination of the amino acid 
enantiopurity, since the diastereoisomers formed can easily be separated on a C18 column 
by HPLC analysis.  
 
Scheme 3.16 Diastereoselective version of the OPA assay; enantiopure N-Ac-L-Cys is used as thiol to 
produce a 50:50 mixture of two diastereoisomers (R,S and S,S) upon reaction with a racemic amino 
acid. 
The isoindole derivatives of PT were prepared using the optimised protocol reported by 
Zheng et. al.178 and their stability was tested by monitoring the absorbance at 340 nm of the 
reaction mixture with a micro-plate reader; no variations in Abs intensity were recorded for 
over one hour at r.t. (Figure 3.44 A). Unfortunately, the linear range of the assay is quite 
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narrow (Figure 3.44 B), thus its application for quantitative analysis is limited, but it still is 
very effective to measure a relative increment in enzymatic activity. 
 
Figure 3.44 Formation of amino acid isoindoles derivatives via OPA assay. A) Absorbance at 340 nm 
over time of OPA-PT derivatives. B) OPA assay calibration curve for PT, fluorescence intensity 
recorded at 460 nm (excitation at 340 nm). The OPA assay mixture contained 15 mM OPA and 30 
mM N-Ac-L-Cys diluted in 50 mL of NaBi 0.14 M pH 9.5. Reactions repeated in triplicates, error bars 
calculated as the standard deviations. 
The optimised OPA assay protocol was employed for the screening of the mutant library. 
3.12.3 ArgE mutant library creation and screening 
Of the possible mutagenesis methods we selected ep-PCR. ep-PCR was employed to insert 
point mutations into the arge gene at random positions. The amplified gene library was 
ligated back into the pETHISTEV plasmid backbone via MEGAWHOP PCR180,181 (Figure 3.45) 
and the reaction mixture was transformed with BL21 (DE3) E. coli cells for screening, however 
this protocol yielded a low number of colonies.  
 
Figure 3.45 Two-step protocol for the creation of ArgE mutant library via EP- and MEGAWHOP-PCR. 
The arge gene (blue) is amplified by ep-PCR to generate a library of mutants (red, green, light blue), 
which are ligated back into the expression vector backbone (yellow) via MEGAWHOP-PCR. 
Any attempts in optimising the MEGAWHOP PCR step was not fruitful, hence a new ligation 




Figure 3.46 Three-step protocol for the creation of ArgE·X mutant library. ep-PCR and HF-PCR 
employed to insert random mutations in the arge gene and amplify the vector backbone, 
respectively. The gene library is ligated into the vector in the third step via Gibson assembly. 
Two sets of primers with overlapping ends (10-20 bp) were designed.The first set was used 
to amplify the arge gene via EP-PCR to create the mutagenesis library. The second set was 
employed to amplify the pETHISTEV plasmid backbone with high-fidelity PCR. The two PCR 
products were purified and mixed with the Gibson assembly master mix to ligate the gene 
back into the backbone in a tri-enzymatic process: the exonuclease degrades the DNA 
fragments at the 5’ end, the single helix fragments binds to each other thanks the overlapping 
portions on their sequence and the DNA polymerase start to add the nucleotides; finally, the 
ligase binds the fragments and seal the nicks in the sequence (Figure 3.47).  
A sample of the Gibson assembly reaction mixture was 
transformed and the BL21 (DE3) E. coli colonies (~200) 
used for screening. The colonies were picked and the 
mutant library (ArgE·X) grown on small scale (1 mL LB 
media) in 48 well sterile plates at 37°C, until OD600 = 
0.6-1.0; protein expression started by addition with 
0.2 mM IPTG and 0.1 mM ZnSO4. The plates were 
incubated for 20 h at 20°C and harvested by 
centrifugation, cell free extract was prepared by 
addition of BugBuster reagent (primary amine free). 
ArgE·X CFE activity was screened against substrate 1a 
(2 mM) by setting up analytical scale reactions in a 96 
well plate (Vf = 200 μL), as shown in Scheme 3.17.  
Figure 3.47 Gibson assembly 
mechanism for the ligation of two DNA 
strands with overlapping segments. 
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After 24 h incubation a sample of the reaction mixture was derivatised via OPA assay and the 
isoindole’s fluorescence at 460 nm (λex = 340 nm) was recorded, unfortunately no increase in 
activity was detected. 
 
Scheme 3.17 Reaction conditions used during ArgE·X screening foe 1a activity. 
Despite the negative results obtained from the first screening, an efficient protocol for ArgE 
directed evolution was optimised. However, more time is required to create and screen 
mutants for N-Ac-PT activity. 
 
3.13 Conclusion and Future Work 
This work proves that E. coli ArgE has great potential for biocatalytic application thanks to its 
high TONs, stereoselectivity and wide substrate scope for both N-acetylated canonical and 
NCAAs; unfortunately, no activity was detected for N-Ac-PT target and protein engineering 
along with structural studies are required to increase the enzyme affinity for this particular 
substrate. 
The N-His tagged ArgE construct (pETHISTEV-ArgE) was successfully expressed, purified and 
characterised; ICP-MS and EDXRF146 confirm the presence of only one Zn2+ ion bound for ArgE 
monomer, while any attempt to directly express the enzyme bound to Co2+ was unfruitful. 
A series of assays were tested to find the best protocol to observe the amino acid formation 
in solution and calculate ArgE catalytic activity. The MR protocol was quite effective for the 
analysis of standards solution, unfortunately the results were not reproducible when 
employed for the derivatization of enzymatic reaction mixtures. Hence the chiral HPLC 
assay121 was exploited to study the stereoselectivity of the enzyme by either observing the 
direct formation of the product (amino acid with an UV-Vis absorbance) or the disappearance 
of the starting material (amide bond absorbance at 210 nm) in a kinetic resolution. However, 
to quantify the reaction conversion, an efficient 1H-NMR assay was developed; by recording 
a 1H-NMR spectrum of the reaction mixture, the relative conversion of the biotransformation 
can be easily obtained by comparing the integrals of the CH3-group for the free and N-bound 
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acetate. This assay can be employed to directly monitoring hydrolysis and to optimise 
reaction conditions, however, since the ArgE rate limiting step is the H2O hydrolysis and the 
assay requires the use of D2O as solvent, the enzyme kinetic parameters cannot be accurately 
determined via 1H-NMR spectroscopy. Instead the L-AAO assay reported by Dr Sànchez-
Carròn122 was employed in the kinetic and activity study of ArgE for both N-acetyl 
proteinogenic and non-proteinogenic amino acids, thanks to the wide substrate scope of the 
oxidase. 
Activity and stability (TDA) studies showed that the best reaction conditions for the enzyme 
are: neutral or basic pH, a temperature of 40°C and addition of CoCl2. Even if not classified as 
thermostable (Tm of 60°C, at neutral and basic pH), the E. coli ArgE still retains 96% of its 
activity at 50°C, showing potential to be coupled with the thermostable NAAAR in a KDR. 
While Co(II) ions cause a 1.4-fold increase in enzyme activity, the addition of ZnCl2 strongly 
inhibits the enzyme, with Zn2+ acting as a reversible competitive inhibitor; a similar case was 
already reported for at least one other zinc dependant hydrolase.147 
Racemic PT was chemically acetylated to form its N-acetylated derivative 1a in good yields 
(73%);83 this protocol was also employed for the acetylation of non-canonical amino acids to 
create a library of substrates, which was subsequently screened for activity with ArgE. The 
results obtained with the 1H-NMR and chiral HPLC assays show that the enzyme possesses a 
wide substrate scope and high stereoselectivity towards the L-isomer. The best conversion 
percentages were obtained by increasing the loading of ArgE up to 1 mg/mL, however even 
at high concentration only a 10% conversion was calculated for 1j and no activity was 
detected for 1a. 
Activity studies conducted with various N-Ac-PT structural analogues suggest that the 
enzyme substrate binding site is able to bind polar groups, such as the sulfoxide and sulfone 
in 1b and 1c, but does tolerate the presence of a negative charge on the amino acid side 
chain (the phosphinic and carboxylic acid of 1a and Glu). 
With a lack of structure, we are not sure which residues are involved in the recognition of 
the substrate side chain. Protein engineering is required to obtain an ArgE variant active 
towards N-Ac-PT. Various ArgE constructs were expressed and purified (N-HisTag ArgE WT, 
C-HisTag ArgE WT, non-tagged ArgE WT and non-tagged ArgE E144A) to screen for crystal 
formation; prism shaped protein crystals were obtained using the two non-tagged constructs 
with the best resolution (4 Å) achieved using the mutant enzyme. The crystal structure of 
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ArgE’s closest homologue (H. influenzae DapE, PDB 3IC1) was employed to resolve ArgE 
structure via molecular replacement, unfortunately the electron density map was too 
dispersed. The ArgE crystal quality needs to be improved to obtain a better dataset; a surface 
entropy reduction strategy may prove fruitful in this instance. 
Sequence alignment and homology model studies were employed to identify various 
residues involved in catalysis, cofactor binding and substrate stabilization in ArgE. These 
residues were mutated into alanine via SDM, expressed, purified and their activity tested 
with the L-AAO assay. E144, H195 and R264 appear to play a fundamental role in the reaction 
mechanism, as previously suggested by Holz169 with the glutamate acting as general 
acid/base catalyst, the histidine activating the acetate carboxylate via hydrogen bond 
formation and the arginine stabilizing the substrate binding by interacting with the amino 
acid α-carboxylate.  
Since the ArgE crystal structure was not available a random mutagenesis strategy was 
employed to evolve the enzyme. An optimised directed evolution protocol (EP-PCR and 
Gibson assembly)177,182 along with the high-throughput OPA assay178 were employed to 
create and screen a ArgE·X mutant library for 1a activity. Unfortunately, no improved activity 
variants were isolated and more time is required to efficiently generate and screen a large 




4 The N-acetyl-bialaphos deacetylase (SvDea) 
Unfortunately, the Escherichia coli ArgE was inactive towards N-Ac-L-PT and attempts to 
engineer the enzyme by rational design or directed evolution were not fruitful. However, this 
deacetylase proved to have good potential for the KR of N-acetyl non-canonical amino acids 
(NCAAs). 
Therefore, a second hydrolytic enzyme was selected as a candidate for the DKR of N-Ac-L-PT; 
the Streptomyces viridochromogenes N-acetyl bialaphos deactylase (SvDea) has been 
proposed to catalyse the last step in the synthesis of the natural herbicide tripeptide 
bialaphos (L-PTT), the deacetylation of the N-acetyl-L-PTT precursor (Scheme 4.1). The gene 
encoding SvDea is found within the operon, which contains 16 genes involved in the 
bialaphos biosynthesys (Figure 1.5 and Table 1.1). This enzyme has been described in the 
literature,23,25,26,183 however it has never been isolated or characterised, thus no background 
information on substrate specificity was available. Since most hydrolases display quite a wide 
substrate scope and can accept non-natural substrates, SvDea may be able to efficiently 
catalyse the hydrolysis of N-Ac-L-PT. 
 
Scheme 4.1 The predicted last step in the biosynthesis of the non-ribosomal tripeptide bialaphos, 
the SvDea catalysed deacetylation of N-Ac-L-PTT. 
 
4.1 Aims 
The aims of this part of the overall project were to express, purify and characterize the novel 
Streptomyces viridochromogenes Tü494 SvDea and to assay its activity for the deacetylation 
of the natural herbicide L-PTT and for the NAAAR DKR of L-PT. To achieve this goal the 
optimised 1H NMR assay described in the previous chapter was employed to monitor acetate 
production, along with LC-ESI MS analysis; while a colorimetric assay was used to determine 
the kinetic parameters of the enzyme. Sequence alignment, homology modelling and crystal 
114 
 
trials were also performed to obtain some structural and mechanistic insights of this novel 
deacetylase. 
4.2 Expression and purification of N-His tagged SvDea. 
The full length S.v. dea gene, cloned into the pUC57 plasmid was ordered from GenScript 
(Uniprot code: Q56171). The gene was subcloned into the expression vector pET28a using 
the NdeI and XhoI restriction sites, the N-hexahistidine tagged pET28a-SvDea construct was 
transformed in E. coli BL21 (DE3) cells and a series of expression tests were carried out to 
select the best media and optimise the IPTG concentration used for the enzyme production. 
All samples were analysed via SDS-PAGE. A low yield of protein expression was obtained 
using three different media: LB, sorbitol media and sorbitol media prepared in 0.1 M 
phosphate buffer pH 7.8;184 however, overnight expression (~20 h) in terrific broth (TB) with 
0.4 mM IPTG yielded a good amount of soluble SvDea (Figure 4.1). These optimised 
conditions were employed for scale-up expression. 
 
Figure 4.1 15% SDS-PAGE analysis of N-His tagged SvDea expression tests. Lane 1 low molecular 
weight marker LMWM (M), lane 2-7 LB-media soluble (S) and insoluble (I) samples and 8-13 lane TB-
media soluble (S) and insoluble (I) samples. Protein expression was induced with 0.1 mM, 0.2 mM 
and 0.4 mM IPTG for samples 1, 2 and 3, respectively with incubation at 20°C for 20 h. The SvDea 
band is at ~ 35 kDa. 
For SvDea purification we used the two-step protocol described for the isolation of N-His tag 
ArgE; the harvested cells were resuspended in lysis buffer (Tris 50 mM pH 8) and lysed via 
sonication treatment for 15 minutes (30s ON/30s OFF. These steps were particularly tricky, 
given the gelatinous consistency of the cells it was not possible to obtain a homogenous 
suspension; furthermore, following lysis a clouded solution was obtained, instead of a clear 
dark lysate. This suspension was centrifuged, filtered and loaded on a HisTrap Fast Flow 1 mL 
column. N-His tagged SvDea eluted at 140 mM imidazole (Figure 4.2 A); analysis via SDS-PAGE 
electrophoresis and denaturing LC-ESI MS of the collected fractions confirmed the isolation 
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of the correct enzyme with an observed MW of 34201.25 ± 0.33 Da (Figure 4.2 B), which was 
in accordance with the theorical MW minus the initial methionine: 34203.39 Da, calculated 
from the protein sequence with the ExPaSy ProtParam tool. Unfortunately, the final yield of 
expressed enzyme after just a single purification step was very low: 1 mg per L of culture.  
However, the expression test SDS-PAGE (Figure 4.1) indicates the production of a good level 
of soluble protein; thus, the loss of enzyme must occur during one or more purification steps. 
Before testing the enzyme’s activity, further optimization of the CFE preparation and 
purification protocols are required to increase the yield of soluble protein isolated. 
 
Figure 4.2 Purification and characterization of SvDea. A) IMAC chromatogram for N-His tagged SvDea 
on an FF HisTrap (1 mL) column recorded at 280 nm. The arrow points to the deacetylase peak. B) 
Denaturating LC ESI-MS of SvDea (20 μM) with a deconvoluted mass of 34201.25 ± 0.33 Da, in 
accordance with the MW calculated from the sequence (34203.39 Da). The values reported are m/z 
with the charges in brackets. 
 
4.3 Thermal denaturation assay (TDA) 
This is the first report of recombinant S. viridochromogenes Dea isolation and expression, 
hence no prior knowledge was available regarding the optimal conditions for the enzyme 
stability. Since Tris pH 8 is a common buffer used for the purification of various enzymes, 
including E. coli ArgE, it was also selected to purify SvDea. However, given the low yield of 
pure protein obtained, a TDA was run to determine the best buffer to employ to increase 
protein stability during purification. A 0.1 mg/mL SvDea solution (3 μM) was used to run the 
assay on a 96 well plate; the enzyme melting curves were recorded in twelve different 
conditions: 0.1 M Na citrate (pH 3.0, 3.5, 4.0, 4.5, 5.0 and 5.5), 0.1 M NaPi (pH 6.0, 6.5, 7.0, 
7.5 and 8.0) and 0.1 M Na carbonate (NaCi) pH 9.0.  
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As reported in Figure 4.3 A, the melting temperatures of SvDea are consistently low, between 
35° and 40°C, across a wide range of pHs, but start to increase in alkali solutions, reaching a 
Tm of 61°C in 0.1 M NaCi pH 9.0. Considering this first set of results, it was clear that the 
enzyme stability is higher at basic pHs. A second TDA was run to compare SvDea’s melting 
temperatures for two alkali buffers, 0.1 M NaCi and 0.1M N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS). A constant Tm of 65°C between pH 8 and 11 was obtained 
using CAPS, thus this buffer was selected to carry out the purification and store the protein. 
 
Figure 4.3 TDA analysis of SvDea. A) SvDea melting temperatures at various pH; the assay mixture 
contained SvDea 3.0 µM (0.1 mg/mL), 5X SYPRO orange in DMSO and 50 mM buffer at various pHs. 
B) Comparison between SvDea melting temperatures at alkali pH using an organic (blue bars) and 
inorganic (grey bars) buffer; the assay mixture contained SvDea 3.0 µM (0.1 mg/mL), 5X SYPRO 
orange in DMSO and 0.1 M buffer at various pHs. The melting curves were obtained measuring the 
fluorescence of SYPRO orange between 25 and 75°C with a gradient of 1°C/min. Reactions repeated 
in triplicates, error bars calculated as the standard deviations. 
 
4.4 Optimization of the purification of N-HisTag SvDea 
The SvDea was expressed using the optimised protocol (Chapter 6.3.5), the harvested cells 
were resuspended in 0.1 M CAPS buffer pH 9.5. Given their gelatinous consistency and the 
low protein yield obtained previously during purification using sonication, two alternative 
techniques were tested to break down the cell walls: French press and overnight treatment 
with lysozyme at 4°C. Precipitation was observed using the high pressure treatment with the 
formation of a cloudy lysate, while the chemo-lysis method resulted more effective; 
however, the resulting suspension had quite a dense consistency and could not be efficiently 
filtered. The overexpression of SvDea in the cytosol may have tampered with the biosynthesis 
of the cell membrane or wall components, which would explain the higher viscosity of the 
CFE. To proceed with the purification via IMAC the lysate was incubated for 2 h with Ni2+ resin 
117 
 
at 4°C on an orbital shaker (150 rpm) and loaded onto a column; the protein was eluted 
manually with 0.1 M CAPS buffer pH 9.5 with 500 mM imidazole. Bradford assay was used to 
determine which fractions contained the enzyme (Figure 4.4 A), these were collected, 
concentrated and loaded on a Superdex S75 column. 
 
Figure 4.4 Isolation of SvDea A) 96-well plate used to run a qualitative Bradford assay to identify the 
IMAC fractions containing SvDea, tubes 1-6 (blue) were collected and used to carry out the second 
purification step. B) Size exclusion chromatogram for N-His tag SvDea on a Superdex S75 column. 
The arrow points to the deacetylase peak. C) 15% SDS-PAGE gel of N-HisTag SvDea purification: lane 
1 LMWM (M), lane 2-7 manual Ni2+ resin column fractions (~7 mL each) and lane 8-10 S75 fractions 
(3 mL each). 
The SEC absorbance chromatogram, monitoring at 280 nm, shows a single peak at an elution 
volume of ~55 mL (Figure 4.4 B), which corresponds to a molecular weight of 35 kDa, this 
suggest the presence of a monomeric hexa-His tagged SvDea in solution. The enzyme was 
obtained with a purity of >95% (Figure 4.4 C) and an average yield of 15 mg per L of culture. 
Both SDS-PAGE analysis and denaturing LC-ESI MS analysis confirm that the desired construct 
was expressed and isolated. 
 
4.5 Assaying SvDea activity and kinetic analysis 
4.5.1 The p-NO2 phenol esterase assay 
A sequence homology study revealed that SvDea shares between 25-50% identity with four 
esterases, belonging to the hormone-sensitive lipase family (EC 3.1.1.79, HSL). A common 
colorimetric assay used to measure these enzymes activity is the p-NO2 phenol (pNP) assay185 
(Scheme 4.2), where various p-NO2 phenol esters are employed as substrate for the enzyme. 
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Following hydrolysis, p-nitro phenol is released in solution, which is deprotonated in alkali 
conditions (pH > 7.8); this negatively charged form is characterised by a bright yellow colour 
(λmax = 405 nm, ε = 18500 M-1 cm-1), easily detected via UV-Vis spectroscopy. 
 
Scheme 4.2 Reaction scheme of the pNP continuos assay for SvDea hydrolysis of four pNP esters. The 
deprotonated form of p-NO2 phenol has a bright yellow colour and a strong absorbance at 405 nm, 
which can be easily monitored via UV-Vis on a 96-wells microplate reader. 
The continuous pNP assay was employed to test SvDea activity towards four p-NO2 phenol 
esters: acetate (pNPA), butyrate (pNPB), octanoate (pNPO) and palmitate (pNPP). Following 
20 minutes incubation at 25°C, only the pNPA reaction mixture developed a yellow colour 
(Figure 4.5 A). This suggests that the enzyme is very specific towards the acyl moiety of the 
substrate, with only the shorter acetate ester being recognised by SvDea. Furthermore, the 
pNP assay was employed to determine the best temperature for SvDea activity, which was 
monitored at 25°, 30°, 40° and 50°C; four sets of reactions containing pNPA, each incubated 
at a different temperature, were prepared and their absorbance measured over time at 405 
nm, the specific activities were calculated dividing the maximum rate (Vmax) of the hydrolysis 
with the enzyme loading employed (mg). According to Figure 4.5 B, SvDea’s activity is not 
particularly affected by the reaction temperature, however the highest value (2100 ± 100 




Figure 4.5 SvDea activity test via pNP assay. A) Comparison between the absorbance curves at 405 
nm for the enzymatic hydrolysis of pNPA (green), pNPP (blue), pNPO (red) and pNPB (black). B) 
Specific activity of SvDea for pNPA at 25°, 30°, 40° and 50°C measured via the continuous pNP assay. 
The reactions contained various substrate concentrations and 0.1 mg/mL SvDea in NaPi 0.1 M pH 8, 
plate incubated at the desired temperature for 30 minutes and absorbance measured at 405 nm 
every 30 s. The specific activity is expressed in units per milligram of enzyme, with one unit is 
referring to the μM of substrate converted per minute. Reactions repeated in triplicates, error bars 
calculated as the standard deviations. 
The continuous pNP assay reported was further employed for the kinetic analysis of SvDea 
towards pNPA. A set of reactions at increasing substrate concentrations were incubated at 
50°C in 0.1 M NaPi buffer pH 8 and the absorbance of p-NO2 phenol was monitored at 405 
nm every 30 s for 1 h. Since pNPA is prone to auto-hydrolysis in these reaction conditions, 
the substrate stock was prepared in acetonitrile to increase its stability and various dilutions 
into the reaction buffer were tested; surprisingly SvDea resulted quite tolerant to the 
presence of organic solvent, no decrease of activity was detected up to 10% ACN in the 
reaction mixture. For the kinetic analysis a set of control reactions (without enzyme) was also 
prepared and their absorbance measured over time; the final absorbance for each time-point 
was calculated subtracting the Abs of the enzymatic reaction from the Abs of the control. The 
initial reaction rates were obtained from the linear portion of the absorbance curves and 
fitted using the Michaelis-Menten non-linear fit with the Lab Origins software (Figure 4.6 A 
and B). The calculated kinetic parameters show that SvDea has a strong affinity (KM = 250 ± 
30 μM) and high catalytic efficiency (kcat/ KM = 2052.837 ± 0.008 M-1s-1) for pNPA, with a TON 




Figure 4.6 SvDea kinetic analysis via pNPA. A) Typical raw data profile for the formation of p-NO2 
phenol over time at various substrate (pNPA) concentrations. B) Michaelis-Menten plot of SvDea for 
pNPA. Initial rates calculated from the linear portion of the absorbance curves and fitted with the 
OriginLab software. The reaction mixture contained: various substrate concentrations and SvDea 50 
μg/mL in NaPi 0.1 M pH 8. The plate was incubated at 50°C for 30 minutes and the absorbance 
measured at 405 nm every 30 s. Reactions repeated in triplicates, error bars calculated as the 
standard deviations. 
4.5.2  The L-AAO/HRP coupled assay 
As well as the pNP assay to monitor ester hydrolysis, we also found the L-AAO assay122 proved 
to be a quick and efficient method to measure the activity of deacetylases towards a wide 
range of N-acetylated canonical and NCAAs, as reported in Chapter 3. This high-throughput 
assay was employed to test the hydrolytic activity of SvDea using ten N-acetylated-L-amino 
acids. Each reaction contained 10 mM substrate and 0.4 mg/mL enzyme; following 1 h 
incubation at 50°C, no sign of activity was detected in any sample as shown in Figure 4.7, 
with the exception of the assay positive control (10 mM L-Met). These results suggest that 
the SvDea enzyme has a very narrow substrate scope, being extremely selective towards both 
the amino acid moiety and the acyl chain of the substrate, being able to recognise only the 
acetylated pNP ester. 
 
Figure 4.7 Screening of SvDea activity towards ten N-acetylated L-amino acids via L-AAO assay. 
Water and L-methionine used as negative (- Ctrl) and positive (+ Ctrl) controls respectively. The assay 
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mixture contained: N-acetyl-L-AA 10 mM, SvDea 0.4 mg/mL, L-AAO 100 mU/mL, HRP 10 U/mL and o-
dianisidine 0.1 mg/mL in NaPi 0.1 M pH 8. The plate was incubated at 50°C for 1 h and absorbance 
measured at 436 nm every 30 s. 
4.6 Kinetic resolution of N-acetyl PT and derivatives 
4.6.1 Substrate synthesis 
The racemic ethyl 2-amino-4-(ethoxy(methyl)phosphoryl) butanoate (2y) and a sample (~2 
mg) of the natural product L-PTT (2z) were gifted by Syngenta (Jealott's Hill, UK) and 
acetylated following the same protocol employed for the preparation of 1a (Scheme 4.3).83 
Ethyl 2-acetamido-4-(ethoxy(methyl)phosphoryl) butanoate (1y) was isolated with a yield of 
11.5% and characterised by NMR spectroscopy and LC-ESI MS spectrometry, the low yield is 
caused by the partial hydrolysis of the ester bonds, which spontaneously occur during 
acetylation. Given the low amount of natural product available a full characterization of N-
Ac-L-PTT (1z) could not be obtained. Following the acetylation work-up, the product was 
freeze-dried and full conversion of the tripeptide was confirmed by LC-ESI MS analysis; the 
mass spectrum recorded on a positive ion mode showed two peaks at m/z of 366 and 388, 
corresponding to the protonated [M+H]+ and sodium adduct [M+Na]+ species respectively. 
 
Scheme 4.3 Chemical acetylation protocol for the synthesis of N-acetyl-DL-phosphinothricin (1a) and 
derivatives (1y and z). 
4.6.2 Biotransformations 
At first SvDea activity was tested towards N-Ac-PT; a set of four reactions at increasing 
enzyme concentrations (0.00, 0.25, 0.50 and 1.00 mg/mL) were incubated at 50°C for 24 h 
(Scheme 4.4). The biotransformations were quenched by addition of 20 μL of HClconc., 
centrifuged and the supernatant analysed via 1H-NMR spectroscopy and LC-TOF MS; no 




Scheme 4.4 SvDea catalysed hydrolysis of N-Ac-PT and derivatives 1a, 1y and 1z. Reactions repeated 
in triplicates. 
The protocol was repeated using compounds 1x and 1y as substrates. For the KR of 1x after 
24 h incubation, a mixture of starting material (30%) and partially hydrolysed substrate (70%) 
was obtained, but no formation of the deacetylated product was detected; however, it is not 
clear if the ester hydrolysis occurs spontaneously or is mediated by SvDea. While the 
formation of traces amount of 2y were observed by LC-MS analysis of the samples of the 
reactions of N-Ac-L-PTT with 0.50 and 1.00 mg/mL SvDea. The product peak in the mass 
spectrum had a low intensity; to obtain more conclusive results, it is necessary to synthesize 
the natural substrate 1y in higher quantities and scale up the biotransformations to be able 
to run a proper NMR characterization. 
 
Figure 4.8 1H-NMR of the SvDea (1 mg/mL) catalysed deacetylation of 20 mM N-Ac-PT (1a). 
Following 24 h incubation at 50°C (250 rpm), only the substrate was present in the reaction mixture. 
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Unfortunately, SvDea cannot be employed for the DKR of L-PT; it appears, based on its 
proposed role within the biosynthetic pathway, that SvDea is highly selective towards the 
intermediate N-Ac-L-PTT intermediate, with no activity detected towards any other N-
acetylated amino acids tested. However, since the enzyme is active towards pNPA, it will be 
interesting to test the enzyme in the deacetylation of other small aromatic esters or 
derivatives to prove if SvDea is able to catalyse amide hydrolysis (Figure 4.9). 
 
Figure 4.9 Various acetyl ester, thioester or amides with an aromatic, aliphatic or unsaturated chain 





4.7 Structural studies. 
4.7.1 Crystal Trials 
Given the limited substrate scope of the WT enzyme, the resolution of SvDea crystal structure 
could give new insights on the residues involved in ligands recognition and possibly help in 
designing mutants with higher biocatalytic potential on L-PTT derivatives.  
The current pET28a-SvDea construct available encodes for an N-His tagged enzyme with the 
S.v. dea gene cloned using the NdeI and XhoI restriction sites; to obtain a non-tagged 
construct the gene was amplified via PCR, using the forward plasmid to change the NdeI site 
into a NcoI. The PCR product was purified via agarose gel electrophoresis, digested and 
ligated into the pETHISTEV vector, which possess a N-terminal TEV cleavable hexa-histidine 
tag, using the NcoI and XhoI restriction sites. 
The pET28a-SvDea and pETHISTEV-SvDea constructs were expressed using the optimised 
SvDea protocol (Chapter 6.3.5). The N-His tagged SvDea was purified using the two-step 
protocol described in Section 4.4. To obtain the untagged enzyme, following IMAC the 
pETHISTEV-SvDea fractions were collected and incubated with 2 mg/mL of TEV protease for 
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16 h at 4°C and dialysed against SvDea storage buffer (CAPS 0.1 M pH 9.5 and 150 mM NaCl). 
Unfortunately, the protein completely precipitated during overnight incubation, leaving only 
the protease in solution, as shown in Figure 4.10. 
 
Figure 4.10 15% SDS-PAGE gel of untagged SvDea purification: lane 1 LMWM (M), lane 2-3 IMAC flow 
through (FT), lane 3-4 manual Ni2+ resin column fractions (~7 mL each) and lane 5 protein sample 
following overnight incubation with the TEV protease(D). 
The initial crystal trials were performed employing the freshly purified N-His tag SvDea at a 
10 mg/mL concentration; ~300 conditions were screened using the crystallization kits: PACT, 
CSS1+2 and JCSG. Unfortunately, only plate shaped salt crystals were obtained from this 
initial screening, further studies are required. Trying different crystallization screens and 
changing the enzyme concentration may deliver more positive results. However, the 
optimization of the untagged SvDea purification protocol and possibly the creation of a C-His 
tag construct may be required to obtain positive hits during crystal trials. 
4.7.2 Homology Model 
Given the high time-demand required to obtain and optimise protein crystals and the lack of 
information on this novel deacetylase, a sequence alignment and homology model were built 
to understand which residues are involved during hydrolysis. 
The SvDea sequence was aligned using the Clustel Omega186 and ESPrit3187 softwares with 
four homologues microbial esterase from the HSL family with a resolved structure: Est22 
(27.4 % sequence identity, PDB entry code 5HC0), Pyrobaculum calidifontis PestE188 (33.8 % 
sequence identity, PDB entry code 3FAK), EstE5 (48.8 % sequence identity, PDB entry code 
3FAK) and microbial E40189 (49.4 % sequence identity, PDB entry code 4XVC). The two closest 
homologues (EstE5 and E40) were further employed to build a homology model with the free 
access RaptorX software.166 
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According to the sequence analysis the SvDea belongs to the HSL family, which is 
characterised by a hydrolytic mechanism based on a catalytic triad formed by conserved Ser, 
His and a Glu/Asp residues. As shown in Figure 4.11, H267 and E237 are highly conserved 
between the homologous, along with the amino acid motif GXSXG (from position 141 to 145), 
where X could by any amino acid. This motif usually contains the nucleophilic serine (S143 
for SvDea) that is essential for the metabolism.189 
 
Figure 4.11 Sequence analysis of SvDea with other members of the HSL family. Sequence alignment 
between S. viridochromogenes Dea, Est22 (27.4 % sequence identity, PDB entry code 5HC0), 
Pyrobaculum calidifontis PestE (33.8 % sequence identity, PDB entry code 3FAK), EstE5 (48.8 % 
sequence identity, PDB entry code 3FAK) and microbial E40 (49.4 % sequence identity, PDB entry 
code 4XVC). White over red residues are conserved across all species, red on white are conserved 
across most while black on white are variable across species. The residues circled in black and 
underlined by a triangle are involved in the formation of the catalytic triad (S143, E237 and H267) 
and oxyanion hole (H73, G75 and G75). 
The homology model shows the typical structure for a member of the HSL family, with a 
monomer composed of a CAP domain, formed by three α-helixes connected by loops (in 
orange in Figure 4.12 A) and a catalytic domain with a α/β-hydrolase fold, formed by eight β-
strands and five α-helixes (in blue in Figure 4.12 A). This domain contains both the active site 
and the oxyanion hole, responsible for the stabilization of the reaction intermediate, which 
is usually formed by the HGG motif, His73-Gly74-Gly75 (Figure 4.11), in close proximity of the 




Figure 4.12 SvDea homology model built with the free access software RaptorX, based on the crystal 
structure of: bacterial EstE5 (3FAK) and microbial esterase E40 (4XVC). A) Tertiary structure of SvDea 
monomer; in blue the catalytic domain with an α/β-hydrolase fold and in orange the CAP domain. B) 
SvDea active site identified by sequence alignment; the E237, H267 and S143 residues form the 
catalytic triad, while the conserved H73, G74 and G75 motif generates the oxyanion hole. 
There is a conserved mechanism for this family of hydrolytic enzymes (Scheme 4.5). It begins 
with the conserved Glu-His-Ser triad, which is connected by a network of H-bonds, increasing 
the nucleophilicity of the Ser143 hydroxyl group and facilitating the attack on the carboxylate 
group of the substrate. The negatively charged tetrahedral intermediate, stabilised by 
interaction with the oxyanion hole, collapses and releases the free alcohol or amine, leaving 
the catalytic Ser acylated. A water molecule, activated by H-bonding with the imidazole group 
of His267, attack the carboxylate, forming a second tetrahedral intermediate, which collapse 




Scheme 4.5 The SvDea catalytic triad five-step reaction cycle for the hydrolysis of p-nitrophenol 
acetate. 
 
4.8 Conclusion and Future Work 
In this work the novel S. viridochromogenes Tü494 deacetylase (SvDea) was expressed, 
purified and characterised. Activity studies carried out employing the continuous 
colorimetric pNP and L-AAO assays revealed that the enzyme possess a narrow substrate 
scope, being able to accept only esters with a short acyl chain (pNPA), while no activity was 
detected for the biotransformations of N-acetylated canonical or NCAAs, including N-Ac-PT 
and derivatives. Only traces of L-PTT formation were detected by LC-ESI MS, however these 
experiments need to be repeated on a larger scale to obtain conclusive results. These 
preliminary data reveal that SvDea does not possess biocatalytic potential for the synthesis 
of amino acids, but further studies are required to understand if the enzyme can accept other 
acetylated esters or derivatives as substrates.  
Initial crystal trials, performed using an N-hexahistidine tagged construct, failed to deliver 
any positive hits; more screening will be required in order to obtain protein crystals and more 
constructs (untagged and C-His tag) needs to be prepared and tested, the first step will be 
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the optimization of the TEV protease protocol. It is clear that SvDea is not stable overnight in 
the conditions used for dialyses, a shorter incubation time for digestion may be more 
effective and still deliver a good yield of non-tagged enzyme. 
Sequence alignment and homology modelling revealed that SvDea belongs to the HSL family, 
has a structure formed by a capping and a catalytic α/β-hydrolase fold domains and uses a 
catalytic triad formed by the highly conserved S143, E237 and H267 residues to catalyse the 
deacetylation reaction. The primary function of the HSLs is to regulate the catabolism of 
triglycerides during fasting in many organisms,190 it is possible that SvDea carries out a similar 
function in Streptomyces since the overexpression of the enzyme in E. coli cells appears to 
affect the composition of the bacteria membrane and wall, giving the cells a viscous 
consistency, which prevent the formation of proper pellets during harvesting and hinder the 
preparation of cell free extracts during purification. Further studies are required to confirm 
this hypothesis, but it is possible that SvDea acts as a bifunctional enzyme, intervening in the 




5 The N-Acetyl Amino Acid Racemase (NAAAR) 
The Amycolatopsis sp TS-160 NAAAR was isolated by Tokuyama et al. in 199588 from a soil 
sample (Osaka). The enzyme selectively catalyses the racemization of N-acylated amino 
acids, but showed no activity for the free amino form of either L- or D-AAs. NAAAR has a wide 
substrate scope and can accept a range of aliphatic and aromatic amino acids with different 
N-acyl moieties: formyl (Fr), acetyl (Ac), chloro-acetyl (Cl-Ac), propionyl (Pr), succinyl (Sc), 
butyryl (Bt) and benzoyl (Bz).88,107 In addition to its favourable substrate scope, NAAAR also 
has high thermostability and a metal cation cofactor. Therefore, NAAAR has great potential 
coupled with an L- or D-acylase for the development of a dynamic kinetic resolution (DKR) 
for the production of L- or D-amino acids respectively (Scheme 5.1).109 
 
Scheme 5.1 Schematic representation of a NAAAR/L-Acylase catalysed DKR for the production of 
enantiopure L-AA with a theorical 100% conversion and ee, starting from a racemic mixture of N-Ac-
DL-AA. 
However, there are two main limitations of the WT NAAAR enzyme for industrial application 
in biocatalysis: substrate inhibition occurs at concentration > 50 mM and the enzyme has a 
preference towards longer acyl moiety (N-propionyl and N-succinyl AAs),88,107 which has 
limited its application for industrial scale synthesis. In an effort to obtain a NAAAR variant 
with higher racemase activity for N-acetylated substrates, the enzyme was subjected to 
rounds of directed evolution and mutagenesis coupled with a live/death selection system of 
methionine auxotrophic pressure, yielding the double mutant G291D F323Y (DM) with 6-fold 
higher catalytic activity towards N-Ac-Met than the WT.121 
The live/death assay was limited to methionine, so a novel colorimetric assay122 (Scheme 5.2, 
see below) was developed to be able to screen NAAAR activity towards a wide range of 
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substrates. After the development of a high-throughput assay122 for efficient screening of 
mutant libraries, a second round of mutagenesis was performed. This new “engineering” 
strategy was also guided by structural studies (Table 5.1). This led to the isolation of the 
quadruple mutant NAAAR Q26A M50I G291D F323Y (QM) with a 40-fold higher activity for 
N-Ac-Phe compared to the WT (data not published).191 
 
5.1 Aims 
The aim of this project was to express, purify and characterize the three active NAAAR 
constructs: WT, DM and QM (Table 5.1), in order to develop an efficient biocatalyst for the 
production of enantiopure non-canonical amino acids (NCAAs). Additionally, the conditions 
for the DKR will require optimisation alongside a wider study of the substrate scope for the 
mutants. 
NAAAR mutations Uniprot code PDB code Ligand bound  
WT - Q44244 1SJC N-Suc-Met 
DM G291D F323Y Q44245 4A6G N-Ac-Met 
QM Q26A M50I G291D F323Y Q44247 5FJU N-Ac-2-Nal 
Table 5.1 List of NAAAR variants, used in this work, with their mutations, Uniprot code, PDB entry 
code and the ligand bound in the crystal structure. With 2-Nal being the abbreviation for 3-(2-
Naphthyl)-alanine. 
 
5.2 NAAAR WT and DM purification and characterization. 
The codon optimised A.sp TS-160 naaar constructs: pET20b-NAAAR WT and pET22b-NAAAR 
DM, were expressed and purified using the optimised protocol reported by Sànchez-
Carròn.122 The two enzymes were expressed in Escherichia coli BL21 (DE3) cells in TB media 
with 0.4 mM IPTG at 20°C for 20 h. The stability of NAAAR construct is affected by the 
presence of hexa-histidine tags,192 either at the N- or C-terminus, therefore, all the 
recombinant proteins expressed are un-tagged; therefore to obtain the enzymes with a good 
purity level a three-step purification protocol was employed. NAAAR was separated from the 
more thermolabile proteins by subjection of the cell lysate to a thermal treatment at 60°C 
for 30 min, followed by anion exchange chromatography on a Q Sepharose Fast Flow (QFF) 
column with the enzymes eluting at a concentration of 0.3 M NaCl (Figure 5.1 A). Finally, size 
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exclusion chromatography (SEC) was performed on a pre equilibrated S300 Sephacryl SEC 
column.  
 
Figure 5.1 Purification of recombinant NAAAR DM. A) Anion exchange chromatogram for NAAAR DM 
purification, in black the UV-Vis traces and in red the elution profile expressed as gradient of %B. B) 
SEC chromatogram for NAAAR DM on a Sephacryl S300 column. The arrows point to the NAAAR 
elution peaks. 
The UV/Vis chromatogram recorded at 280 nm displayed two symmetrical peaks, however 
analysis via SDS-PAGE (Figure 5.2 A and Figure 5.3 A) electrophoresis confirms that NAAAR 
(band at ~39 kDa) is present only in the second peak, at an elution volume of 55 mL (Figure 
5.1 B), which corresponds to a molecular weight of ~300 kDa for native NAAAR (homo-
octamer). 
 
Figure 5.2 Characterization of NAAAR WT. A) 15% SDS-PAGE analysis of NAAAR WT purification: lane 
1 LMWM, lane 2 CFE after heat-treatment, lane 3 insoluble fraction, lane 4 QFF flow-through, lane 5-
8 QFF fractions (5 mL each) and lane 9-11 SEC fractions (3 mL each). B) Denaturating LC ESI-MS of 
NAAAR WT (20 μM) with a mass of 39406.02 ± 0.39 Da, in accordance with the MW calculated from 





Figure 5.3 Characterization of NAAAR DM. A) 15% SDS-PAGE analysis of NAAAR DM purification: lane 
1 the LMWM, lane 2 CFE after heat-treatment, lane 3 insoluble fraction, lane 4-9 QFF fractions (5 mL 
each, peak collected from ~225 to 275 mL) and lane 10-14 SEC fractions (3 mL each, ~45 to 65 mL). 
B) Denaturating LC ESI-MS of NAAAR DM (20 μM) with a mass of 39480.53 ± 0.41 Da, in accordance 
with the MW calculated from the sequence (39480.45 Da). The values reported are the m/z with 
their respective charges (z) in brackets. 
After three purification steps NAAAR WT and DM were obtained with a purity of ~95% and 
an average yield of 25 mg per L of culture. To confirm that the correct constructs were 
expressed and purified, the molecular weight of NAAAR WT and DM were obtained using 
denaturing LC ESI-MS. The observed MW of 39406.02 ± 0.39 Da and 39480.53 0.41 Da, for 
WT and DM respectively (Figure 5.2 B and Figure 5.3 B), were in accordance with their 
theorical MW: 39406.42 Da for WT and 39480.45 Da for DM, calculated from the protein 
sequence with the ExPaSy ProtParam tool (https://web.expasy.org/protparam). 
 
5.3 NAAAR WT and DM kinetic analysis 
The high-throughput continuous L-AAO assay reported by Sànchez-Carròn122 was employed 
for the kinetic analysis of NAAAR (Scheme 5.2). The N-Ac-D-AA substrate is converted by the 
racemase to the respective N-Ac-L-AA; which is hydrolysed by the Thermococcus litoralis L-
Acylase (obtained from Dr. Reddy’s Laboratories). The L-AA produced initiates a cascade of 
reactions, as described in Chapter 3.3.1, that results in the formation of an orange/red dye 




Scheme 5.2 Reaction scheme of the NAAAR/L-AAO continuos assay.122 The oxidised from of o-
dianisidine has a strong absorbance at 436 nm and can be easily monitored via UV-Vis on a 96-well 
microplate reader. 
The kinetic analysis was repeated in triplicates, at various substrate concentrations; the 
reactions were incubated at 50°C and the absorbance was recorded at 436 nm over 1 h on a 
microplate reader. As shown in Figure 5.4 A, the assay background is caused by the presence 
of the T. litoralis L-Acylase (a gift from Dr. Reddy’s Laboratories)134 in the reaction mixture. 
This enzyme was provided as lyophilized CFE and when dissolved in buffer is characterised 
by a faint orange colour. However, as the background absorbance is constant, the kinetic 
analysis is unaffected (Figure 5.4 B). 
 
Figure 5.4 Kinetic analysis of NAAAR DM with L-AAO/HRP assay. A) Typical raw data profile for the 
formation of o-dianisidineOx over time at various substrate (N-Ac-D-Met) concentrations. B) 
Michaelis-Menten plot of NAAAR DM for N-Ac-D-Met. Initial rates calculated from the linear portion 
of the absorbance curves and fitted with the OriginLab software. Reactions repeated in triplicates, 
error bars calculated as the standard deviations. 
The kinetic parameters calculated using the DM (Table 5.2) are in accordance with the data 
reported in the literature122 for N-Ac-D-Met, while for N-Ac-D-Phe a higher kcat (0.46 ± 0.04 s-
1) and lower KM (1.8 ± 0.5 mM) were obtained, compared to those reported by Sànchez 
Carròn: 0.104 ± 0.004 s-1 and 4.20 ± 0.39 mM.122 However, this difference can be explained 
by the presence of CoCl2 instead of MgCl2 in the reaction mixture, since it is known that 
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NAAAR has a higher activity when Co2+ is used as the cofactor instead of Mg2+.193 Overall, as 
expected, the DM showed a higher activity for both substrates compared to the WT enzyme 
(Table 5.2 and Figure 5.5). Furthermore, given the high kcat of NAAAR DM towards N-Ac-D-
Met (0.87 ± 0.05 s-1), this mutant was chosen for the coupling with the acylase ArgE. 
NAAAR WT DM 
N-Ac-D Met Phe Met Phe 
KM (mM) 3.7 ± 0.7 18 ± 3 4.7 ± 0.8 1.8 ± 0.5 
kcat (s-1) 0.095 ± 0.005 0.30 ± 0.04 0.87 ± 0.05 0.46 ± 0.04 
kcat/KM (M-1 s-1) 26.61 ± 0.01 17.07 ± 0.02 187.621 ± 0.005 243.03 ± 0.03 
Table 5.2 NAAAR WT and DM kinetic parameters for N-Ac-D: Met and Phe, calculated with the L-
AAO/HRP assay. Reactions repeated in triplicates, error bars calculated as the standard deviations. 
 
Figure 5.5 Kinetic curves of NAAAR WT and DM. Comparison between the Michaelis-Menten plots of 
NAAAR WT (red) and DM (blue) for A) N-Ac-D-Phe and B) N-Ac-D-Met. Reactions repeated in 
triplicates, error bars calculated as the standard deviations. 
 
5.4 NAAAR DM Reaction Monitoring 
The L-AAO assay provides a quick and efficient method to test NAAAR activity, nevertheless 
it relies on a system of coupled reactions. A more direct approach to monitor the 
racemization can be achieved via chiral HPLC, exploiting the amide bond absorbance at 210 
nm.141 
 
Scheme 5.3 Reaction scheme of the racemization of N-Ac-D-Met catalysed by NAAAR DM. 
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The racemization of N-Ac-D-Met (Scheme 5.2) was monitored over time using the same 
protocol described in Chapter 3.4 and 6.9.3. As shown in Figure 5.6, the racemization 
proceeds quite rapidly even at moderate enzyme loading (0.1 mg/mL) with a 42 % conversion 
of D- to L- in only 30 min; after one-hour incubation at 60°C, the enantiopure substrate was 
completely converted to a racemic mixture. 
 
Figure 5.6 Chiral HPLC analysis of N-Ac-D-Met racemization. A) Elution profile of N-Ac-L-Met 
standard with a retention time (R.T.) of 2.15 min. B) Elution profile of N-Ac-D-Met standard with a 
R.T. of 2.90 min. C) Analysis of N-Ac-D-Met racemization sample following 30 min incubation at 60°C 
with NAAAR DM. D) Conversion of N-Ac-D-Met into N-Ac-L-Met catalysed by NAAAR. Time-point 
samples were analysed by Chirobiotic T (Teicoplanin) column with an isocratic gradient: elution 
phase 0.025% TEAA and MeOH (50/50 ratio), flow 1.0 mL/min, T = 40°C and λ = 210 nm. In red N-Ac-
D-Met, in blue N-Ac-L-Met, in black the reaction mixture and in green triangles the solution ee. 
Reactions repeated in duplicates, error bars calculated as standard deviations reported only for 
triplicates. 
5.5 Coupling of ArgE and NAAAR DM 
5.5.1 DKR of N-Ac-DL-Met 
The NAAAR DM and E. coli ArgE have the potential to be coupled together in an efficient DKR: 
they both have high TONs and work in cooperative conditions; active at pH 8 and with high 
CoCl2 concentrations. However, a compromise had to be made on a reaction temperature of 
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50 degrees since ArgE (melting temperature of 65°C) is not a thermostable protein (Chapter 
3.6) and, at the same time, a reaction temperature of 40°C is far from ideal for NAAAR 
activity.88 To verify if ArgE still retained good activity at 50°C, an L-AAO assay was performed 
incubating various concentrations of NAAAR DM with 0.5 mg/mL ArgE, which replaced the T. 
litoralis L-Acylase in the assay mixture. As shown in Figure 5.7, ArgE is active and can couple 
efficiently with NAAAR DM at 50°C for the conversion of N-Ac-D-Met to L-Met. Furthermore, 
the biotransformation is very rapid, with the assay reaching saturation in less than 20 
minutes at higher DM concentrations. 
 
Figure 5.7 Coupling of NAAAR DM and ArgE monitored with the L-AAO assay. A) Raw data profile for 
the L-AAO assay, absorbance curves at 436 nm over time for the coupling reactions between ArgE 
0.5 mg/mL and NAAAR 0.0-0.8 mg/mL with 15 mM N-Ac-D-Met at 50°C. B) Saturation curves 
between [NAAAR] and reactions initial rates calculated from the initial linear portion of the 
absorbance curves. Reactions repeated in triplicates, error bars calculated as the standard 
deviations. 
Using these optimised conditions, a DKR of N-Ac-DL-Met (60 mM) was set up (Scheme 5.4). 
Reaction samples were taken over time, quenched by a 40-fold dilution into the chiral phase 
(75:25=0.025% TEAA:MeOH) and analysed by chiral HPLC. 
 
Scheme 5.4 DKR of N-Ac-DL-Met 60 mM with 0.1 mg/mL ArgE, 0.1 mg/mL NAAAR DM and CoCl2 100 
μM in NaPi 0.1 M pH 8. The reaction was incubated at 50°C for 24 h (250 rpm) and time points taken 




Figure 5.8 The DKR of N-Ac-DL-Met catalysed by NAAAR DM and ArgE. A) HPLC profile for the 
resolution of both enantiomers of the starting material: N-Ac-L-Met (blue), N-Ac-D-Met (red) and 
product: L-Met (green), D-Met (purple). Standards samples at a concentration of 25 mM. B) HPLC 
curves of time point samples of the biocatalytic DKR of N-acetyl methionine (scale of grey). C) 
Conversion of N-Ac-L-Met (blue) and N-Ac-D-Met (red) into L-Met (green) over time, no trace 
formation of D-Met (purple) detected. All samples analysed by HPLC on a Chirobiotic T (Teicoplanin) 
column, isocratic gradient: elution phase 0.025% TEAA and MeOH (75/25 ratio), flow 0.5 mL/min, T = 
40°C and λ = 210 nm. Reactions repeated in duplicates, error bars calculated as standard deviations 
reported only for triplicates. 
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As shown in Figure 5.8 the hydrolysis is very rapid, after 10 minutes incubation, all N-Ac-L-
Met starting material has been converted to L-Met. The racemization proceeds more 
gradually, but as soon as N-Ac-D-Met is converted by the DM into the L-stereoisomer, ArgE 
quickly hydrolyses it to form the final product, with the all process reaching completion in 
three hours. A faster DKR can be achieved by increasing the concentration of the two 
enzymes in the reaction mixture, however to effectively monitor the process by HPLC the DM 
and ArgE loadings have been purposely kept low. After 24 h incubation, the remaining 
reaction mixture was quenched by addition of HClconc and analysed by 1H-NMR spectroscopy, 
which confirmed complete conversion of the substrate to L-Met. 
5.5.2 Comparison between E. coli ArgE and T. litoralis L-Acylase 
A second DKR of N-Ac-DL-Met was set up, which involved coupling NAAAR DM with the T. 
litoralis L-Acylase from Dr. Reddy’s. Analysis by chiral HPLC again shows a fast hydrolysis and 
a gradual racemization with complete conversion achieved after 3 h incubation (Figure 5.9). 
Nevertheless, the process is slower compared to the DKR of N-Ac-methionine catalysed by 
NAAAR DM and ArgE. After the initial 10 minutes N-Ac-L-Met was still present in the reaction 
mixture and following 1 h incubation a conversion of just 77% was achieved, opposed to the 
90% conversion obtained with ArgE; an impressive result considering that the ArgE 
concentration in the reaction mixture (0.1 mg/mL) was much lower than Dr. Reddy’s L-
Acylase (1 mg/mL lyophilized CFE). To note that no D-Met was formed during the reaction. 
In conclusion T. litoralis L-Acylase has great potential application for the resolution of 
aromatic substrates, N-Ac: Phe, Tyr and Trp.134 While with E. coli ArgE it is possible to achieve 
a rapid and efficient resolution of aliphatic and charged N-Ac-NCAAs. Between the T. litoralis 
L-Acylase and the E. coli ArgE, it is possible to set up DKRs to cover a broad substrate profile, 




Figure 5.9 The DKR of N-Ac-DL-Met catalysed by NAAAR DM and T. litoralis L-Acylase. A) HPLC profile 
for the resolution of both enantiomers of the starting material: N-Ac-L-Met (blue), N-Ac-D-Met (red) 
and product: L-Met (green), D-Met (purple). Standards samples at a concentration of 25 mM. B) 
HPLC curves of time point samples of the biocatalytic DKR of N-acetyl methionine (scale of grey). C) 
Conversion of N-Ac-L-Met (blue) and N-Ac-D-Met (red) into L-Met (green) over time, no trace 
formation of D-Met (purple) detected. All samples analysed by HPLC on a Chirobiotic T (Teicoplanin) 
column, isocratic gradient: elution phase 0.025% TEAA and MeOH (40/60 ratio), flow 0.5 mL/min, T = 
40°C and λ = 210 nm. Reactions repeated in duplicates, error bars calculated as standard deviations 
reported only for triplicates. 
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5.5.3 DKR of N-Ac-Non-Canonical-AAs 
Given the promising results obtained in the DKR of N-Ac-Met, the NAAAR DM/ArgE couple 
was also employed for the resolution of N-Ac-NCAAs. It is known that NAAAR DM is able to 
accept a wide range of substrates, including some non-proteinogenic N-Ac-AAs (Scheme 5.5), 
such as: N-Ac-allylglycine (Alg), N-Ac-phenylglycine (N-Ac-Phg), N-Ac-4-F-Phg, N-Ac-4-NO2-
Phe and N-Ac-2-naphthylalanine (N-Ac-2-Nal).122,192,194 The activity of NAAAR with the new N-
Ac-NCAAs was also investigated. However, the enzyme loading for these experiments was 
increased from 0.5 mg/mL for the DM and ArgE to 1 mg/mL (the optimised enzyme 
concentration reported in Chapter 3.9.4, Scheme 5.5 A). The reactions were incubated for 24 
h at 50°C and subsequently quenched with HClconc and analysed by 1H-NMR spectroscopy (see 
Chapter 6.9.1). 
 
Scheme 5.5 Substrate profile of NAAAR DM/ArgE DKR. A) Schematic representation of a DKR of an N-
Ac-AA 50 mM catalysed by NAAAR DM 0.5 mg/mL and ArgE 1.0 mg/mL with 200 μM CoCl2 in NaPi 0.1 
M pH 8. Reaction incubated at 50°C 250 rpm for 24 h. All DKRs were quenched by HClconc addition 
and analysed by NMR spectroscopy and chiral HPLC. B) List of DM/ArgE DKR products with their 1H-
NMR spectroscopy conversions and ee. Reactions repeated in duplicates, error bars calculated as 
standard deviations reported only for triplicates. 
As shown in Scheme 5.5 B, average to excellent conversions were obtained; with the best 
values (c > 90%) calculated for N-Ac-propargylglycine (1g) and N-Ac-1-triazolylalanine (1i). 
However, N-Ac-citrulline (1t) gave only modest conversions despite ArgE previously showed 
excellent activity towards polar and positively charged N-Ac-AAs (Chapter 3.8 and Chapter 
3.9), suggesting it is NAAAR, which does not favourably bind to this polar substrate. The worst 
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conversion (c = 32.4%), “as expected”, was obtained for the reaction with N-Ac-(2-Me-
thiazolyl)-4-alanine (1h): indeed, ArgE presented low activity for this bulky heterocyclic 
substrate. However, there was an increase of 10% conversion upon the previous KR (Chapter 
3.9.4) to 32% for the DKR, indicates that the DM is able to bind to the substrate and the 
racemization equilibrium pushes the process towards the formation of L-2-Me-thiazolyl)-4-
alanine (2j). Samples of each reaction were also analysed by chiral HPLC (protocol reported 
in Chapter 6.9.3) and the ee percentages was calculated for the substrates with an 
absorbance at 210 nm. 
Protein precipitation was observed in all reactions after overnight incubation at 50°C, 
therefore, at high concentration (1 mg/mL), ArgE is most probably unstable under these 
biotransformation conditions. To optimize the process, a second set of DKRs were run at 40°C 
and at this temperature no precipitation was observed after 24 h incubation; however, with 
the exception of N-Ac-3-thienylalanine (1h c = 89.4%), all other 1H-NMR conversions gave 
lower values compared to the previous reaction set (Table 5.3). The decrease in temperature 
likely slowed the racemization, the limiting step of the process. Perhaps by increasing the 
reaction time and/or the NAAAR concentration it may be possible to obtain better results 
even at 40°C, however so far, the best results were obtained at a reaction temperature of 
50°C (Figure 5.10). 
 
Figure 5.10 Comparison between the NAAAR DM/ArgE performances at 40°C (blue bar) and 50°C (grey 
bar) for the DKR of N-Ac-NCAAs. Conversions calculated by 1H-NMR spectroscopy. Reactions repeated 




1H-NMR Conversion (%) 
T° = 40°C 50°C 
1f 82.1 84.3 
1g 95.8 95.7 
1h 89.4 82.7 
1i 72.2 94.1 
1j 8.7 32.4 
1t 51.7 70.7 
Table 5.3 NAAAR DM and E. coli ArgE DKR conversions calculated by 1H-NMR spectroscopy by 
monitoring the acetate peaks intensity for the reaction sets incubated at 40°C and 50°C. 
 
5.6 NAAAR QM expression, purification and characterization 
The NAAAR QM biocatalyst was expressed and purified using the standard NAAAR protocol 
(see Chapter 6.3 and 6.4).122 The SEC chromatogram shows a peak at 60 mL (Figure 5.11 B), 
which according to the calibration curve, correspond to a 300 kDa protein; like the other 
variants, the QM also forms a homo-octamer in solution. SDS-PAGE analysis (Figure 5.11 A) 
confirms the presence of the protein, the gel presents a band at ~39kDa, approximately the 
MW of the monomer. 
To further confirm the presence of the correct mutations, a sample of the purified enzyme 
was analysed via LC ESI-MS (Figure 5.11 C). The observed mass of 39409.38 ± 1.08 Da was in 
accordance with the theoretical MW (39405.37 Da) of the enzyme, calculated from the amino 
acid sequence. NAAAR QM was successfully purified with a yield of 20 mg per L of culture 




Figure 5.11 Purification and characterization of NAAAR QM. A) Size exclusion chromatogram for 
NAAAR QM on a Sephacryl S300 column. The arrow points to the NAAAR elution peak. B) 15% SDS-
PAGE analysis of NAAAR QM purification: lane 1 LMWM, lane 2 CFE after heat-treatment, lane 3 
insoluble fraction, lane 4-8 QFF fractions (5 mL each) and lane 9 S300 fraction (3 mL each). C) LC ESI-
MS of NAAAR QM (20 μM) with a mass of 39409.38 ± 1.08 Da, in accordance with the MW calculated 




5.7 Investigating the NAAAR QM substrate scope 
5.7.1 Synthesis of N-Ac-AAs substrates 
According to Sànchez-Carròn191 the introduction of the mutations Q26A and M50I into 
NAAAR DM, opened the enzyme active site, generating an increase in catalytic activity but 
also a higher affinity for aromatic substrates. To test the potential of the novel QM as 
biocatalyst, a range of 17 racemic N-Ac-AAs were selected to use in a DKR process with the 
NAAAR QM. However, not all substrates were commercially available; N-Ac: Phe, Tyr, Trp and 
Phg were purchased from Sigma Aldrich, N-Ac: 1-triazolylalanine, 3-F-Phe and 2-F-Phe were 
obtained from Syngenta, N-Ac-2,2-bypyridylalanine (BpyA) was a gift from Dr Richard 
Brewster (University of Edinburgh, School of Chemistry) and racemic N-Ac: citrulline (1t), 
allylglycine (1f), propargylglycine (1g), 3-thienylalanine (1h) and 2-Me-thiazolyl-4-alanine (1j) 
were prepared as described in Chapter 3.9.1. N-Ac: 4-NO2-Phe (1u), 4-F-Phe (1v), 4-Cl-Phe 
(10a) and 4-Br-Phe (10b) were prepared from their respective AA racemic mixtures by 
treatment with slight excess of acetic anhydride in presence of a strong base (Scheme 5.6). 
The products were isolated and characterised by NMR spectroscopy and MS (see 
Appendices). 
 
Scheme 5.6 Scheme for the acetylation reaction of phenylalanine analogues. The amino acid solution 
(0.1 M in 1:3=acetone:water) was reacted with Ac2O (1.5 eqv) and NaOH (2.0 eqv) for 20 h at r.t. 
5.7.2 Small scale screening 
A set of small scale (500 μL) DKRs was set up coupling NAAAR QM with T. litoralis L-Acylase 
(Scheme 5.7); interestingly precipitate formation was observed in almost all samples during 
the incubation. After isolating the solid by centrifugation; analysis with ESI-TOF MS revealed 
the precipitate to be the product which is insoluble in the reaction media. Potentially, the 





Scheme 5.7 Small scale DKR of N-Ac-AAs 50 mM with NAAAR QM CFE (1.0 mg/mL) and T. litoralis L-
Acylase (2.5 mg/mL with CoCl2 1 mM in NaPi 0.1 M pH 8. The reactions were incubated at 60°C, 250 
rpm for 24 h and quenched by addition of NaOH 5M. Analysis carried using 1H NMR and chiral HPLC. 
After 24 h incubation at 60°C, the DKR conversions were obtained by quenching the reaction 
mixture by addition 20 μL of NaOH (5M). The product was redissolved and the crude reaction 
mixture was analysed by NMR spectroscopy to determine conversion (see Chapter 6.9.1) and 
chiral HPLC (see Chapter 6.9.3) for the ee of the UV-active products (Figure 5.12). 
 
Figure 5.12 Summary of the of QM/ T. litoralis L-Acylase DKR substrate range (using sixteen N-Ac-
AAs). Reaction products reported with their 1H-NMR percentage conversions and ee. Reactions 
repeated in duplicates, error bars calculated as standard deviations reported only for triplicates. 
In order to test the efficiency of the process for the production of both L- and D-AAs, another 
set of small scale (500 μL) DKRs were set up coupling the NAAAR QM with Achromobacter 
xylosoxidans subsp. denitrificans ATCC 15173 D-Acylase (obtained as lyophilized CFE from Dr. 
Reddy’s Laboratories).195 As with the T. litoralis L-Acylase reactions, the same protocol was 
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employed for the DKRs with A. xylosoxidans D-acylase, changing only the incubation 
temperature from 60° to 37°C, the ideal temperature reported for this D-Acylase.195 As 
described in Section 5.5.3, a decrease of NAAAR performance has to be expected at T < 50°C. 
However, the high enzyme loading and longer incubation time will hopefully reverse any 
previously observed loss in activity. 
 
Figure 5.13 Summary of QM/ A. xylosoxidans D-Acylase DKR substrate range (using sixteen N-Ac-
AAs). Reaction products reported with their 1H-NMR percentage conversions and ee. Reactions 
repeated in duplicates, error bars calculated as standard deviations reported only for triplicates. 
Across the sixteen substrates tested, good to excellent conversions were obtained for most 
substrates, using either the T. litoralis L-Acylase (Figure 5.12) or A. xylosoxidans D-Acylase 
(Figure 5.13) as the coupling enzyme, with the exception of 1t which gave the lowest c and 
ee values. This suggests the NAAAR QM is not particularly active towards this polar amino 





Figure 5.14 Structure of L and D-BpyA, no traces of either enantiomers detected from the DKR 
reaction mixtures after analysis by NMR, HPLC or TOF-ESI MS. 
No activity was detected either by NMR spetroscopy, HPLC, or TOF-ESI MS for the resolution 
of N-Ac-BpyA (Figure 5.14), no traces of product detected by either: NMR, HPLC and TOF-ESI 
MS. Possibly the larger sterically hindered substrate cannot access the catalytic site of the 
enzymes or it may bind but not in the right conformation for the catalysis to occur. A similar 
case was reported by Sànchez-Carròn191 for N-Ac-2-Nal; NAAAR QM showed poor activity 
towards this bulky amino acid, but the substrate was still able to efficiently bind to the 
mutant, indeed a ligand bound X-ray structure of QM in complex with N-Ac-2-Nal (PDB code 
5FJU) was resolved. 
 
Figure 5.15 Comparison between the ee values obtained from the NAAAR QM DKR screening with 
the T. litoralis L-Acylase (blue bar) and A. xylosoxidans D-Acylase (grey bay). No results reported for 
2f, 2g and 2j, because the low UV-Vis absorbance of these AAs prevented analysis by chiral HPLC. 
In general, better selectivity (ee > 90%) was obtained using the T.litoralis L-Acylase coupling 
enzyme than the A. xylosoxidans deacetylase (Figure 5.15). However, this factor is not 
indicative of a poor NAAAR QM performance, as this enzyme simply catalyses the 
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racemization equilibrium of N-Ac-AAs, but it is correlated with the enantioselectivity of the 
acylase used in the process. 
 
5.8 DKR Scale-Up 
 
Scheme 5.8 Preparative-scale DKR of N-Ac-aromatic AAs (0.5-1.0 g) with: NAAAR QM CFE (1.0 
mg/mL), Acylase (10 mg/mL) and CoCl2 (5 mM) in NaPi 0.1 M pH 8. A) Scheme for L-AA resolution 
with the T. litoralis L-Acylase, reaction T=60°C. B) Scheme for D-AA resolution with the A. 
xylosoxidans D-Acylase, reaction T=37°C. All DKRs were incubate at 250 rpm for 24h. 
To prove that the NAAAR QM/Acylase couple can be used for the industrial-scale production 
of enantiopure amino acids, the DKR of a few N-Ac-aromatic AAs was scaled up (0.5-1.0 g 
substrate) and each reaction was repeated using both the A. xylosoxidans D-Acylase and T. 
litoralis L-Acylase as shown in Scheme 5.8. The DKR at scale were set up with higher substrate 
loading, 150-200 mM compared to 60 mM at analytical scale, the enzyme loading of the 
acylases was also increased to 10 mg/mL to avoid possible substrate inhibition.191 All 
biotransformations were set up and incubated at 37 or 60°C, depending on the acylase used, 
for 24 h. After one day incubation a conversion of substrate to product > 90% was calculated 
by crude 1H-NMR spectroscopy. The products were isolated by filtration and full chemical 
characterisation was carried out. 
As shown in Figure 5.16, all yields obtained are quite high (> 60%), only exception is L-Phg 
resolution with a yield of 50.2%. Once more, the T. litoralis L-Acylase/NAAAR QM couple gave 
products with higher enantiopurity (>99% by chiral HPLC), while the A. xylosoxidans D-
Acylase showed low to average stereoselectivity (Figure 5.17). The increase of the acylase 
loading in the scale-up process was counterproductive for the D-AAs resolutions, with lower 
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enantiomeric excess values, especially for the production of D-4-NO2-Phe (D-2u) and D-4-F-
Phe (D-2v), than those obtained in the small-scale screening (Chapter 5.7.2). 
 
Figure 5.16 Isolated products obtained from the NAAAR QM DKR scale up, on the top row the L-AAs 
and on the bottom row the D-AAs, each reported with its percentage Yield, m/z and ee. 
The performance of NAAAR QM for the resolution of N-Ac-AAs at gram-scale is comparable 
with the NAAAR DM DKR of N-Ac-allylglycine reported by Baxter et al,121 who were able to 
isolate D-allylglycine with 89% yield and >99% ee after 18 h incubation. To note that to 
achieve those results with the DM an E. coli fermentation was necessary to produce enough 
enzyme, while a normal 2 L cell culture grow-up/expression, was sufficient to produce 
enough QM CFE for 8 scale up reactions. Given NAAAR QM wide substrate scope and the low 
enzyme loading required to obtain an efficient process, this racemase mutant has high 




Figure 5.17 Chiral HPLC analysis of the preparative N-Ac-4-F-Phe (1v) DKRs. A) HPLC profile for the 
resolution of both enantiomers of the starting material N-Ac-4-F-Phe (blue) and product 4-F-Phe 
(red). Standards samples at a concentration of 25 mM. B) Superimposition of racemic 4-F-Phe 
standard (red) and L-4-F-Phe (L-2v) DKR sample (black) chiral HPLC curves. C) Superimposition of 
racemic 4-F-Phe standard (red) and D-4-F-Phe (D-2v) DKR sample (black) chiral HPLC curves. All 
samples analysed by HPLC on a Chirobiotic T (Teicoplanin) column, isocratic gradient: elution phase 




5.9 Conclusions and Future Work 
The initial aims of the projects have been met. The three Amycolaptopsis sp TS-160 NAAAR 
variants: WT, DM (G291D F323Y) and QM (Q26A M50I G291D F323Y), have been fully 
characterised and the active mutants applied for the production of non-canonical amino 
acids. 
The main target of the thesis was the biocatalytic synthesis of L-phosphinothricin (PT) via 
DKR; considering the aliphatic and charged nature of this amino acid side chain, NAAAR WT 
and DM were deemed to be the best choice to couple with ArgE, since the QM was 
engineered to accept aromatic N-Ac-AAs and ArgE is almost completely inactive towards 
these substrates (see Chapter 3.3 and 3.8). 
The kinetic parameters of NAAAR WT and DM for two substrates (N-Ac-D-Met and N-Ac-D-
Phe) were calculated, using the continuous coupled colorimetric L-AAO assay, and by 
comparing the WT and DM results, a 6-fold increase in activity (kcat) was calculated for the 
reactions catalysed by the double mutant, in accordance with the results reported in 
literature.121 Indeed, this NAAAR mutant was able to completely racemase a sample of 
enantiopure N-Ac-D-Met in just one hour. 
Unfortunately, neither E. coli ArgE, SvDea or any other commercial acylases tested, were 
active towards the target N-Ac-PT, thus NAAAR DM activity towards this particular substrate 
could not be tested. This is in contrast with the results presented in a patent (US6177616, 
2001). However, the NAAAR DM/ArgE couple was used in the DKR of N-Ac-NCAAs and the 
results show great potential for scaled up production of unnatural L-amino acids, such as 
propargylglycine (2g) and 1-triazolylalanine (2i). However, to ensure an efficient process 
(higher yields and lower reaction times), it is necessary to optimise the reaction conditions; 
so far, an incubation temperature of 50°C has given the highest conversions at the expense 
of ArgE stability in the reaction mixture, although overnight precipitation was observed. A 
possible solution to overcome the different thermostability of NAAAR and ArgE would consist 
in the immobilization of the two enzymes, either on the same or on separate matrixes.196,197 
The substrate scope of NAAAR QM was also investigated, by setting up a series of small scale 
DKRs, but given the preference of this racemase for aromatic N-Ac-AAs, the acylases from Dr. 
Reddy’s Laboratories were used in the screening. The NAAAR QM can be efficiently coupled 
with either a T. litoralis L-Acylase or A. xylosoxidans D-Acylase for the production of 
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enantiopure amino acids and is able to accept a range of N-Ac-aromatic or aliphatic amino 
acids, but shows low tolerance with polar and sterically hindered substrates, such as: N-Ac-
Cit (2t) and N-Ac-BpyA. Furthermore, BpyA is known to be a good ligand for binding to 
transition metals, used for the preparation of artificial metallo-enzymes.17 It is possible that 
N-Ac-BpyA, in a ten-fold excess compared to CoCl2, coordinates with the cobalt present in 
the reaction mixture, essential for NAAAR activity, deactivating the racemase. Future work 
could involve repeating the reactions using a greater excess of CoCl2 and lower N-Ac-BpyA 
concentration. To be certain that NAAAR is not able to accept this substrate, it would be 
necessary to monitor directly the racemization step starting from either N-Ac-L-BpyA, or N-
Ac-D-BpyA. However, since no enantiopure samples were available, it can only be concluded 
with certainty that neither the T. litoralis L-Acylase nor the A. xylosoxidans D-Acylase from 
Dr. Reddy’s Laboratories show activity for this substrate. In terms of enantioselectivity the 
NAAAR QM/ T. litoralis L-Acylase couple gave better results than the NAAAR QM/ A. 
xylosoxidans D-Acylase couple. It should be noted that this is independent of NAAAR, which 
simply catalyse the racemization equilibrium, but is related to the choice of the D-Acylase.  
Given the positive results obtained from the initial screening, the NAAAR QM/Acylase couple 
was exploited to perform scale up DKR of four substrates. The average to high isolated yields 
of enantiopure amino acids produced, combined with the low NAAAR loading and the easy 
reaction set-up and product isolation protocol, make this process ideal for industrial 
application. However, the only limitation would be the poor enantioselectivity of the A. 
xylosoxidans D-Acylase used. This problem can be easily overcome either through testing 




6 Materials and Methods 
6.1 Materials and Reagents 
6.1.1 Overview 
Reagents, chemicals and media were purchased from Sigma-Aldrich, Thermo Fisher Scientific 
or Bio-Rad and used without further purification. Competent cells, pET plasmids and 
restriction enzymes were purchased from New England Biolabs (NEB), Novagen and Life 
Technologies. Primers were purchased from Sigma-Aldrich, while chromatography columns 
were obtained from GE Healthcare.  
6.1.2 Competent cells 
Various E. coli cell lines were used to store and amplify plasmids, during cloning and for the 
production of recombinant proteins (Table 6.1). 
Cell Line Supplier Application 
DH5 α New England Biolabs 
(NEB) 
Amplification and storage of plasmid DNA 
C2987 Life Technologies Plasmid storage and amplification during 
cloning and mutagenesis (high 
transformation efficiency) 
BL21 (DE3) New England Biolabs 
(NEB) 
Protein expression host 
Rosetta (DE3) Novagen Protein expression host 
Table 6.1: E. coli strains used in this work. 
6.1.3 Plasmids  
Various plasmids (Table 6.2) were used during cloning to obtain recombinant proteins with 
various affinity tags. The pETHisTEV was gifted to us from Prof Jim Naismith, Oxford 
University. 
Plasmid Resistance Application 
pET28a Kanamycin Expression of proteins with a N-terminal 6xHis tag 
or no affinity tag 
pETHisTEV Kanamycin Expression of proteins with a N-terminal Tobacco 
Etch Virus (TEV) 6xHis tag 
pEBSRCTEVC10HIS Ampicillin Expression of proteins with a C-terminal 10xHis 
tag  
pET20b Ampicillin Expression of proteins with no affinity tag 
pET22b Ampicillin Expression of proteins with no affinity tag 
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pET26b Kanamycin Expression of proteins with no affinity tag 
Table 6.2: List of expression plasmid used in this work. 
6.1.4 Growth media, antibiotics and induction 
Media was prepared by dissolving the components (Table 6.3) in distilled water and was then 
sterilized in the autoclave (20 min at 120°C). For the terrific broth the buffer solution was 
prepared and sterilized separately and combined with the media just before use.  
Antibiotic stocks were prepared at a concentration of: 30 mg/mL for kanamycin, 100 mg/mL 
for ampicillin and 35 mg/mL for chloramphenicol. The ampicillin and kanamycin stocks were 
dissolved in distilled water (dH2O), while chloramphenicol was dissolved in ethanol; all stocks 
were stored at -20°C. 
During protein expression the desired antibiotic was added to the cooled sterilized media 
with a 1:1000 dilution from the stock solution for a final concentration of: 30 µg/mL for 
kanamycin, 100 µg/mL for ampicillin and 35 µg/mL for chloramphenicol.  
Induction was carried out by diluting (1:1000 ratio) an isopropyl β-D-1-thiogalactopyranoside 
(IPTG) stock of the appropriate concentration (0.1-1.0 M) in the growth solution. All stocks 
were stored at -20°C. 
Media Ingredients 
Luria Bertani (LB) 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl 
LB Agar 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar 
Super Optimal Broth 
(SOC) 
10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 2.5 mM KCl, 
10 mM MgCl2, 2% w/v glucose 
Sorbitol media LB components were dissolved in 100 mM Na phosphate pH 
7.5 along with 0.5 M sorbitol 
Terrific Broth (TB) 12 g/L tryptone, 24 g/L yeast extract, 5 g/L glycerol (dissolve 
in 900 mL dH2O), 23.1 mg/L KH2PO4 and 125.4 mg/L K2HPO4 
(dissolve in 100 mL dH2O).  
Table 6.3: List of media used in this study and their recipes. 
6.1.5 Buffers 
Buffers were prepared by dissolving all components in distilled water and adjusting the pH 
to the desired value, using either hydrochloric acid (HCl) or sodium hydroxide (NaOH). Prior 
to chromatography all buffers were filtered through a 0.22 filter and degassed by sonication. 
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Phosphate buffer saline (PBS, pH = 7.4) is obtained by dissolving 5 tablets (Sigma) in 1 L of 
dH2O, for a final concentration of KH2PO4 0.24 g/L, Na2HPO4 1.44 g/L, KCl 0.2 g/L and NaCl 8.0 
g/L. 
Buffer Components 
ArgE lysis 50 mM Tris pH 8.0, 150 mM NaCl, 20 mM Imidazole 
ArgE elution 50 mM Tris pH 8.0, 150 mM NaCl, 500 mM Imidazole 
ArgE storage 50 mM Tris pH 8.0, 150 mM NaCl 
NAAAR lysis and storage 50 mM sodium phosphate pH 8.0, 100 mM NaCl 
NAAAR elution 50 mM sodium phosphate pH 8.0, 1.0 M NaCl 
TEV lysis PBS, 300 mM NaCl, 10 mM imidazole 
TEV elution PBS, 300 mM NaCl, 500 mM imidazole 
TEV storage 50 mM Tris pH 8.0, 300 mM NaCl, 50% glycerol 
SvDea lysis 0.1 M CAPS pH 9.5, 150 mM NaCl, 20 mM Imidazole 
SvDea elution 0.1 M CAPS pH 9.5, 150 mM NaCl, 500 mM Imidazole 
SvDea storage 0.1 M CAPS pH 9.5, 150 mM NaCl, 10% glycerol 
Table 6.4: List of buffers and their components used for protein purification in this project. 
 
6.2 Molecular Biology 
The Escherichia coli ArgE gene (cloned into a pET28a plasmid) and Streptomyces 
viridochromogenes Tü494 Dea (cloned into a pUC57 plasmid) were purchased from 
GenScript. 
6.2.1 Site Directed Mutagenesis 
All primers (see Appendices) for site directed mutagenesis (SDM) were designed following 
the overlapping method.170 All SDM PCR reactions (Vf = 50 µL) were set up as reported in 
Table 6.5 and the following thermal cycle was used to carry out the reaction: 98°C x 30 s, 
(98°C x 30 s, 65°/55°C x 30 s, 72°C x 3 min) x 30, 72°C x 10 min. 
Reagents Volumes (µL) 
Phusion buffer 5x 10 
dNTPs 10 mM 1.0 
Fwd primer 10 μM 2.5 
Rev primer 10 μM 2.5 
DNA template (~100 ng) 1.0 
DMSO 1.5 
Phusion DNA polymerase (NEB) 1.0 
dH2O up to 50 
Table 6.5: Quantities of reagents used in an SDM reaction. 
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25 µL of reaction product were digested overnight at 37°C to remove the methylated parental 
DNA. The digestion reaction contained 1 µL DpnI (NEB), 3 µL 10xCustsmart buffer (NEB), 25 
µL reaction mixture and 1 µL dH2O; 5 µL of the digested mixture were transformed in E.coli 
C2987 cells and incubated overnight at 37°C (see Section 6.2.8).  
Few colonies were selected for DNA isolation (see Section 6.2.9) and the presence of the 
desired mutation was confirmed from the sequencing results (see Section 6.2.10). 
6.2.2 ArgE Directed Evolution 
6.2.2.1 MEGAWHOP-PCR protocol 
The following primers were used to set up an error prone PCR reaction,192 using the 
conditions reported in Table 6.6 and the following thermal cycle: 98°C x 2 min, (98°C x 30 s, 
50°/55°/60°/65°C x 30 s, 72°C x 1.5 min) x 25, 72°C x 10 min. 
ArgE Fwd: ATGTCGTACCATCACCATCACCATCACGATTACGAT 
ArgE Rev: CGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTTA 
Reagents Volumes (µL) 
Mutagenic buffer 10x 5.0 
EP dNTPs 10x 5.0 
Fwd primer 25 μM 1.0 
Rev primer 25 μM 1.0 
DNA template (~100 ng) 1.0 
MnCl2 12.5 mM 2.0 
Taq DNA polymerase (NEB) 0.5 
dH2O up to 50 
Table 6.6: Quantities of reagents used in an error-prone reaction. 
This PCR product was used as template to run a High-Fidelity PCR reaction (Table 6.7) to 
amplify the mutagenic product, using the following thermal cycle: 98°C x 2 min, (98°C x 30 s, 
50°/55°/60°/65°C x 30 s, 72°C x 1.5 min) x 25, 72°C x 10 min. 
Reagents Volumes (µL) 
Phusion buffer 5x 10 
dNTPs 10 mM 1.0 
Fwd primer 10 μM 2.5 
Rev primer 10 μM 2.5 
error-prone PCR product 1.0 
Phusion DNA polymerase (NEB) 1.0 
dH2O up to 50 
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Table 6.7: Quantities of reagents used in a High-Fidelity PCR reaction. 
The PCR product was purified via agarose gel (see Section 6.2.5) and cloned into a pETHisTev 
plasmid via a MEGAWHOP-PCR,180,192 Table 6.8. The following optimized thermal cycle was 
employed: 68°C x 5 min, 98°C x 2min, (98°C x 10 s, 68°C x 3 min) x 35, 72°C x 5 min. 40 µL 
reaction mixture was digested with 1 µL DpnI (NEB), 3 µL 10xCustsmart buffer (NEB), and 1 
µL dH2O to remove the methylated parental DNA. The digestion reaction was incubated at 
37°C overnight and 5 µL of digested mixture was transformed in E.coli BL21 (DE3) cells and 
incubated overnight at 37°C (see Section 6.2.8). The resulting colonies were screened for 
activity as described in Section 6.3.2. 
Reagents Volumes (µL) 
Phusion buffer 5x 10 
dNTPs 10 mM 1.0 
pETHISTEV-ArgE template (~100 ng) 0.5 
Amplified error-prone PCR product (~20 ng) 20 
DMSO 1.5 
Phusion DNA polymerase (NEB) 1.0 
dH2O up to 50 
Table 6.8: Quantities of reagents used in a MEGAWHOP PCR reaction. 
6.2.2.2 Gibson Assemby protocol 
The following primers were designed to amplify the ArgE gene. 
ArgE Fwd: ATGTCGTACTACCATCACCATCACCATC 
ArgE Rev: GTGGTGGTGGTGGTGCTCGAGTT 
These primers were employed to set up an error prone PCR reaction, using the condition 
reported in Table 6.9 and the following thermal cycle: 95°C x 2 min, (95°C x 30 s, 
55°/60°/65°/68°C x 30 s, 72°C x 1.5 min) x 30, 72°C x 10 min. 
Reagents Volumes (µL) 
Mutagenic buffer 10x 5.0 
EP dNTPs 10x 5.0 
Fwd primer 25 μM 1.0 
Rev primer 25 μM 1.0 
DNA template (~100 ng) 1.0 
MnCl2 12.5 mM 2.0 
Taq DNA polymerase (NEB) 0.5 
dH2O up to 50 
Table 6.9: Quantities of reagents used in an error-prone reaction. 
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While in parallel a High-Fidelity PCR (see Table 6.10) was set up to amplify the pETHisTEV 
plasmid backbone, using the following primers. Thermocycle conditions: 98°C x 2 min, (98°C 
x 30 s, 50°/55°/60°/65°C x 30 s, 72°C x 1.5 min) x 30, 72°C x 10 min. 
pETHisTEV Fwd: TAACTCGAGCACCACCACCACCA 
pETHisTEV Rev: GTGATGGTGATGGTAGTACGACA 
Reagents Volumes (µL) 
Phusion buffer 5x 10 
dNTPs 10 mM 1.0 
Fwd primer 25 μM 1.0 
Rev primer 25 μM 1.0 
DNA template (~100 ng) 1.0 
DMSO 1.5 
Phusion DNA polymerase (NEB) 1.0 
dH2O up to 50 
Table 6.10: Quantities of reagents used in a high-fidelity reaction. 
Both PCR products were purified by agarose gel extraction (see Section 6.2.5) and ligated 
together using the Gibson Assembly protocol (see Section 6.2.7.2), with a 1:2 molar ratio of 
vector to insert. 5 µL ligation reaction were used to transform an aliquot of E. coli C2987. 
All colonies obtained were picked with a sterile loop and re-suspended in 600 µL of sterile 
water. DNA was extracted and used to transform E.coli BL21 (DE3) cells. The resulting 
colonies were used for selection. 
6.2.3 SvDea Subcloning 
The following primers were employed to introduce the NcoI restriction site at the N-terminus 
of the Svdea gene. 
SvDea Fwd: CCATCCATGGCGAGCAGCGAA 
SvDea Rev: TGGTGCTCGAGTTAGCGTTCGCC 
A High-Fidelity PCR (Table 6.11) was run using this thermal cycle conditions: 98°C x 2 min, 
(98°C x 30 s, 55°/65°C x 30 s, 72°C x 1.0 min) x 30, 72°C x 10 min. 
The presence of the PCR product was confirmed by running an analytical agarose gel using 5 
µL of reaction mixture. The remaining 45 µL was cleaned using the ZYMO Research DNA clean 
& concentrator kit, following the manufacture protocol and digested overnight at 37°C at the 
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NcoI and XhoI restriction sites, along with 45 µL of empty pETHisTEV plasmid. Each reaction 
(50 µL) contained 45 µL of DNA, 2 µL of each restriction enzyme, and 1 µL of CutSmart buffer 
The digested fragments were purified via agarose gel and ligated (see Section 6.2.7.1). 5 µL 
of ligation reaction was transformed in C2987 cells. 
Reagents Volumes (µL) 
Phusion buffer 5x 10 
dNTPs 10 mM 1.0 
Fwd primer 25 μM 1.0 
Rev primer 25 μM 1.0 
DNA template (~100 ng) 1.0 
DMSO 1.5 
Phusion DNA polymerase (NEB) 1.0 
dH2O up to 50 
Table 6.11: Quantities of reagents used in a high-fidelity reaction. 
6.2.4 ArgE Subcloning 
The pET28a-ArgE construct was digested, along the empty pETHisTEV plasmid at the NcoI 
and XhoI restriction sites overnight at 37°C. Each reaction (50 µL) contained 45 µL of DNA 
(~100 ng/µL), 2 µL of each restriction enzyme, and 1 µL of CutSmart buffer. The DNA 
fragments were purified via agarose gel and ligated; 5 µL of reaction mixture was 
transformed into C2987 cells. 
6.2.5 Agarose gel electrophoresis and extraction 
The gels were prepared mixing 1.5 g of agarose in 150 mL of TAE buffer (40 mM Tris, 20 mM 
acetic acid and 1 mM EDTA). The suspension was heated until the agarose completely 
dissolved and then cooled-down to 40-50°C, before adding GelRed (10 µL). The solution was 
poured in a casting mold and allowed to polymerize. The gel was loaded with the marker 
(Hyperladder I, Bioline) and the PCR products or other DNA samples, mixed with the 6x Purple 
DNA loading dye (NEB). The gel was run for 1 h at a constant voltage of 100 V. The DNA 
samples were visualized under UV-light and the bands of interest were cut from the gel using 







DNA samples (40 µL) were mixed with CutSmart buffer (5 µL), two appropriate restriction 
enzymes (2 µL) and water (1 µL). The mixture was incubated at 37°C overnight and the 
product purified via Agarose gel electrophoresis. 
6.2.7 Ligation 
6.2.7.1 T4 DNA ligase protocol 
A ratio of 1:3 of backbone (50 ng) to insert was selected to perform the ligation reaction (100 
ng total DNA). The backbone and insert were mixed with 10x T4 DNA ligation buffer (1 µL) 
and T4 DNA ligase (1 µL), and the volume was brought up to 10 µL using water. The reaction 
was incubated at room temperature for 15 min and 5 µL of the reaction mixture was used to 
transform an aliquot of C2987 cells. 
The following equation was used to calculate the amount of insert DNA needed in the ligation 
reaction with a 1:3 ratio: 
insert (ng) =  
vector (ng) × size of insert (kbp)





6.2.7.2 Gibson Assembly protocol 
A 2-fold molar excess of insert to backbone (100 ng) was used to perform a ligation by mixing 
together the insert and vector with the Gibson Assembly master mix (10 µL, NEB). Water was 
used to bring the reaction volume up to 20 µL. The reaction was incubated at 50°C for 15 min 
and 2 µL of reaction mixture was used to transform into C2987 cells. 
The following equation was used to calculate the pmol of DNA needed for the ligation: 
𝐷𝑁𝐴 (𝑝𝑚𝑜𝑙) =
DNA (ng)  ×  1000
 size of fragment (bp)  ×  650 Da
 
6.2.8 Heat shock transformation 
Plasmid DNA (2-5 μL) was mixed with an aliquot of E. coli competent cells and incubated on 
ice for 30 minutes. The cells were heat shocked at 42°C for 45 min and immediately put back 
in ice for an additional 2 min. SOC (100 µL) was added to the cell and the mixture incubated 
at 37°C for 1 h on a shaker (200 rpm). After incubation the solution was spread on the surface 




6.2.9 DNA miniprep 
10 mL of LB containing the appropriate antibiotic (10 µL) was inoculated with a single colony, 
picked from a fresh agar plate. The samples were incubated at 37°C for 18-20 h. The cells 
were harvested by centrifugation at 4000 rpm with a Heraeus Multifuge X3R equipped with 
a TX-1000 rotor for 15 min (4°C). The supernatant was discarded and the plasmid DNA 
extracted from cell pellets with a Qiagen QIAprep Miniprep kit, following the manufacture 
protocol. DNA concentration estimated using the nanodrop. 
6.2.10 Analytical digest and sequencing 
Incorporation of the gene of interest into the vector was checked after cloning by digesting 
the plasmid DNA (7 µL) with the appropriate restriction enzymes (1 µL each) and CutSmart 
buffer (1 µL). These samples were incubated at 37°C for 2 h and subsequently mixed with 6x 
Purple DNA loading dye (2 µL) and loaded onto an agarose gel. After the run the gel was 
checked using the UV-light; positive samples have two band: one at the size of the insert and 
one at the size of the vector. To confirm the gene sequence the positive samples were 
sequenced by GATC using the T7 and pET-RP primers. 
 
6.3 Protein production 
6.3.1 Expression test protocol 
10 mL of LB with appropriate antibiotic was inoculated with a single colony of E. coli BL21 
(DE3) cells. The culture was incubated for 18-20 h at 37°C on an orbital shaker (200 rpm). 250 
μL of this overnight culture was inoculated into 10 mL of fresh media with appropriate 
antibiotic. These samples were incubated on an orbital shaker, until the optical density of the 
cells at 600 nm (OD600) reached a value of 0.6-0.8 for LB media or 1.0-1.5 for TB media. The 
expression was induced by addition of IPTG at various concentrations and the cultures were 
incubated at 30°C for 4 h or 20°C for 18-20 h. Cultures were harvested by centrifugation at 
4000 rpm, 4°C with a Heraeus Multifuge X3R equipped with a TX-1000 rotor for 15 min; the 
supernatant was discarded and the cell pellets re-suspended in 1mL of PBS buffer and lysed 
via sonication for 30 s (10 s ON/OFF). The soluble and insoluble fractions were separated by 
centrifugation with a benchtop centrifuge and the pellets re-suspended in 1 mL of PBS buffer. 
Level of expression of soluble and insoluble fractions was determined by analysis with a 
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denaturing 12% or 15% SDS-PAGE gel run at 200 V for 1 h. The optimal conditions determined 
were used for scale-up expression. 
6.3.2 ArgE mutant library screening 
In a sterile 24-well plate, colonies were picked into 2 mL LB media + kanamycin and incubated 
at 150 rpm at 37°C for 20 h. 100 μL of this overnight culture was inoculated into 2 mL of fresh 
media with kanamycin on a new 24-well plate, which was incubated at 37°C until OD600 
reached a value of 0.6-0.8. Protein expression was induced by adding 0.2 mM IPTG and 0.1 
mM ZnSO4, the plate was incubated at 20°C overnight. Cultures were harvested by 
centrifugation at 4000 rpm, 4°C with a Heraeus Multifuge X3R equipped with a TX-1000 rotor 
for 40 min; the supernatant was discarded and the cell pellets re-suspended in 200 μL of NaPi 
0.1 M pH 8 + 150 mM NaCl buffer and lysed by addition of 50 μL BugBuster primary amine 
free reagent. The plate was incubated at 25°C for 20 min and centrifuged at 4000 rpm, 4°C 
for 30 min. The cell free extract supernatant was employed to test the mutant library activity. 
6.3.3 NAAAR variants expression122 
250 mL of LB with antibiotic was inoculated with a single colony of E. coli BL21 (DE3) cells 
from a fresh plate, containing an expression plasmid with a variant of the naaar gene. The 
culture was incubated for 18-20 h at 37°C on an orbital shaker (200 rpm). The OD600 was 
measured and this culture was diluted into 1 L of TB with appropriate antibiotic to a final 
OD600 of 0.1. The new cultures were grown at 37°C until their OD reached a value of 1.0-1.5. 
At that point the protein expression was induced by addition 0.4 mM IPTG. The cultures were 
incubated at 20°C for 20 h before harvesting. Cultures were harvested by centrifugation at 
4000 rpm, 4°C with a Heraeus Multifuge X3R equipped with a TX-1000 rotor for 15 min. The 
supernatant was discarded and the pellets stored at -20°C. 
6.3.4 ArgE Expression 
250 mL of LB with antibiotic was inoculated with a single colony of E. coli BL21 (DE3) cells 
from a fresh plate, containing an expression plasmid with a variant of the arge gene. The 
culture was incubated for 18-20 h at 37°C on an orbital shaker (200 rpm). The optical density 
of the cells at 600 nm (OD600) was measured and this culture was diluted into 1 L of LB with 
appropriate antibiotic to a final OD600 of 0.1. The new cultures were grown at 37°C until their 
OD reached a value of 0.6-0.8. At that point the protein expression was induced by addition 
0.2 mM IPTG and 0.1 mM ZnSO4. The cultures were incubated at 20°C for 20 h before 
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harvesting. Cultures were harvested by centrifugation at 4000 rpm, 4°C with a Heraeus 
Multifuge X3R equipped with a TX-1000 rotor for 15 min. The supernatant was discarded and 
the pellets stored at -20°C. 
6.3.5 SvDea Expression 
250 mL of LB with antibiotic was inoculated with a single colony of E. coli BL21 (DE3) cells 
from a fresh plate, containing an expression plasmid with a variant of the Svdea gene. The 
culture was incubated for 18-20 h at 37°C on an orbital shaker (200 rpm). The optical density 
of the cells at 600 nm (OD600) was measured and this culture was diluted into 1 L of TB with 
appropriate antibiotic to a final OD600 of 0.1. The new cultures were grown at 37°C until their 
OD reached a value of 1.0-1.5. At that point the protein expression was induced by addition 
0.2 mM IPTG. The cultures were incubated at 20°C for 20 h before harvesting. Cultures were 
harvested by centrifugation at 4000 rpm, 4°C with a Heraeus Multifuge X3R equipped with a 
TX-1000 rotor for 15 min. The supernatant was discarded and the pellets stored at -20°C. 
6.3.6  TEV Expression 
250 mL of LB with antibiotic was inoculated with a single colony of E. coli Rosetta cells from 
a fresh plate, containing the pET28a-TEV construct. The culture was incubated for 18-20 h at 
37°C on an orbital shaker (200 rpm). The optical density of the cells at 600 nm (OD600) was 
measured and this culture was diluted into 1 L of LB with appropriate antibiotic to a final 
OD600 of 0.1. The new cultures were grown at 37°C until their OD reached a value of 0.6-0.8. 
At that point the protein expression was induced by addition 0.4 mM IPTG. The cultures were 
incubated at 20°C for 20 h before harvesting. Cultures were harvested by centrifugation at 
4000 rpm, 4°C with a Heraeus Multifuge X3R equipped with a TX-1000 rotor for 15 min. The 
supernatant was discarded and the pellets stored at -20°C. 
The purification of TEV is carried out in three steps: cell free extract preparation via 
sonication, followed by IMAC with a HisTrap FF 1 mL column and overnight dialyses in storage 
buffer. The TEV sample is concentrated to 2 mg/mL and stored at -80°C. 
 
6.4 Protein purification 
All purification steps were carried out at 4°C or on ice on an AKTA Purifier machine, unless 
otherwise stated. Samples (20 µL) from all steps were retained for SDS-PAGE analysis. 
164 
 
6.4.1 Cell free extract preparation 
6.4.1.1 Sonication 
Cells were resuspended in buffer and lysed by sonication for 15 cycles (30 sec on, 30 sec off). 
The lysed cell suspension was clarified by centrifugation (Thermo Scientific Multifuge X3R) at 
10000 rpm for 45 min at 4 °C and the supernatant filtered on 0.45 μM syringe filters to obtain 
the cell free extract.  
6.4.1.2 Chemo-lyses 
Cells were resuspended in buffer and lysed by treatment with lysozyme (from chicken egg 
white, Sigma) 10 mg/ g of pellet. The suspension was gently stirred for ~20 h at 4°C, following 
incubation the lysate was centrifuged at 10000 rpm for 45 min at 4 °C and the supernatant 
recovered for use in further purification steps. 
6.4.2 Anion exchange 
The cell-free extract was loaded on a HiPrep Q FF 16/10 (GE Healthcare) column. The column 
was washed with 5 column volumes (CV) of lysis buffer, then the protein was eluted with the 
elution buffer using a step gradient of NaCl (0.1-1 M), 0-45% over 9 CV and 45-100% over 2 
CV, at 2.0 mL/min.121 Fractions containing the protein were mixed together and concentrated 
with a MW cut off (MWCO) concentrator (Sartorius) to a final volume of 1-5 mL. 
6.4.3 Nickel NTA purification 
6.4.3.1 HisTrap protocol 
The cell-free extract was loaded onto a 1 mL HisTrap nickel affinity column (GE Healthcare). 
The column was washed with lysis buffer for 5 CVs, then the protein eluted with the elution 
buffer using a linear gradient of imidazole (20 to 500 mM) over 30 CVs. Fractions containing 
the protein were mixed together and concentrated with a MWCO concentrator (Sartorius) to 
a final volume of 1-5 mL. 
6.4.3.2 Manual HisTrap column 
Ni2+ resin was washed 3-5 times with the lyses buffer and added to the cell free extract. The 
suspension was stirred at 4°C on an orbital shaker (150 rpm) for 2 h to allow the His-tagged 
protein to bind to the resin. The suspension was packed on a column, washed with lysis buffer 
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and the protein eluted using the elution buffer (500 mM imidazole). Fractions collected 
during elution were tested with Bradford assay to identify which sample contained the 
enzyme. These fractions were mixed together, concentrated with a MWCO concentrator 
(Sartorius) to a final volume of 1-5 mL and filtered on 0.45 μM syringe filters. 
6.4.4 TEV cleavage  
The His-tagged protein solution was incubated with 2 mg/mL of pure TEV protease and 
dialysed against storage buffer 2L for 16 h at 4°C. Following dialysis, the protein was injected 
into a 1 mL HisTrap nickel affinity column, the untagged enzyme was eluted with 20 CV of 
storage buffer, then the TEV protease was washed off the column using elution buffer (500 
mM imidazole). The collected non-tagged protein is concentrated with a MWCO 
concentrator (Sartorius) to a final volume of 1-5 mL 
6.4.5 Size exclusion chromatography 
The concentrated enzyme (1-5 mL) was loaded onto a pre-equilibrated (storage buffer) 
HiPrep™ 16/600 size exclusion column (120 mL). Recombinant protein was eluted at a flow 
rate of 0.5 or 1 mL min-1 (based on the column backpressure). The fractions containing clean 
protein of interest were combined and frozen at -80 °C (NAAAR requires a 20% glycerol buffer 
for storage). 
Enzyme SEC column 
E. coli ArgE 16/60 Superdex™ S-200 
S. viridochromogenes Dea 16/60 Superdex™ S-75 
Amycolaptopsys NAAAR 16/60 Sephacryl™ S-300 
Table 6.12 Pre-calibrated SEC columns employed for enzyme purification in this work. 
 
6.5  Protein characterization 
6.5.1 Mass spectrometry 
Protein Liquid Chromatography-Mass Spectrometry (LC-MS/ESI) analyses were carried out 
on a SYNAPT G2 mass spectrometer. The source was an electrospray ionization (ESI). 10 µL 
protein (10-20 µM) was injected and eluted following a gradient 5-95% MeCN + 0.1% formic 
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acid in water + 0.1% formic acid over a 12 mins period. Mass spectra were analysed with 
MassLynx software. 
6.5.2 SDS-PAGE electrophoresis 
An average gel (16 mL) consisted of a 12% (6.9 mL H2O, 4.8 mL of 40% acrylamide, 4 mL of 
1.5 M Tris pH 8.8, 150 μL of 10% w/v SDS, 300 μL of 50 mg mL-1 ammonium peroxodisulfate 
and 20 μL TEMED) or 15% (5.6 mL H2O, 6 mL of 40% acrylamide, 4 mL of 1.5 M Tris pH 8.8, 
150 μL of 10% w/v SDS, 300 μL of 50 mg mL-1 ammonium peroxodisulfate and 20 μL TEMED) 
running gel and a 4% stacking gel (2.9 mL H2O, 0.75 mL of 40% acrylamide, 1.25 mL of 0.5 M 
Tris pH 6.8, 50 μL of 10% w/v SDS, 100 μL of 50 mg mL-1 ammonium peroxodisulfate and 5 μL 
TEMED). Polyacrylamide gel electrophoresis (PAGE) samples were prepared by 1:1 dilution 
in 2x SDS loading buffer (2.5 mL Tris, 0.5 M pH 6.8, 2 mL glycerol, 4Ml of 10% w/v SDS, 1 mL 
β-mercaptoethanol and 0.5 mL of 0.1% w/v bromophenol blue). These samples were boiled 
at 100°C for 5-10 minutes and 10 µL loaded onto the gel and run for ~ 60 min at 200V/180mA. 
Protein was visualised by InstantBlue Coomassie Stain (Expedeon Ltd) and the mass 
estimated using LMW marker (GE Healthcare). 
6.5.3 Protein concentration 
Protein concentration of pure samples and cell free extracts were estimated with the 
nanodrop, measuring the absorbance at 280/260 nm. The extinction coefficient of the 
enzymes was calculated from the amino acid sequence using the ProtParam tool 
(https://web.expasy.org/protparam/) software. 
Enzyme ε (M-1cm-1) 
E. coli N-His tag ArgE 43360 
E. coli non-tagged ArgE 37400 
S. viridochromogenes Dea 45170 
Amycolaptopsys NAAAR 34170 
Table 6.13 Extinction coefficients of the various constructs used to estimate protein concentration 
6.5.4 ICP-MS 
Pure protein at a concentration of 1 mg/mL was employed to estimate the zinc and cobalt 
content of the enzyme, while a sample of storage buffer was used as blank; the analysis was 
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carried out by Dr Lorna Eades (University of Edinburgh, School of Chemistry). Samples (1 mL) 
were analysed by ICP-MS using an Agilent 7500ce (with octopole reaction system), employing 
a RF forward power of 1540 W and reflected power of 1 W, with argon gas flows of 0.81 L 
min-1 and 0.20 L min-1 for carrier and makeup flows, respectively. Sample solutions were 
taken up into the Micro mist nebuliser by peristaltic pump at a rate of approximately 1.2 mL 
min-1. Skimmer and sample cones were made of nickel. 
The instrument was operated in spectrum multi-tune acquisition mode and three replicate 
runs per sample were employed. Isotopes 59Co, 66Zn and 68 Zn were analysed in ‘no gas’ mode 
(Argon only) and each mass was analysed in fully quantitative mode with three points per 
unit mass. 
A range of calibration standards for each element were prepared using single element 1000 
mg l-1 standards (Fisher Scientific UK LTD Bishop Meadow Road, Loughborough, 
Leicestershire LE11 5RG), diluted with 18.2 Ω deionised water. A 100-fold dilution of Merk 
ICP Multi element standard solution VI CertiPUR® was employed as a reference standard for 
each of the elements. An internal standard (100 ppb Rh) was spiked into each standard and 
sample to correct for any instrument drift or matrix changes. Samples were diluted prior to 
analysis using18.2 Ω deionised water.   
Parameters for no gas mode:  
Ion Lenses: Quadrupole Parameters: 
Extract1:  0 V OctP Bias: -6 V 
Extract 2: -133 V QP Bias: -3 V 
Omega Bias-ce: -20 V 
 
Omega Lens-ce: 0 V 
 
Cell Entrance: -30 V 
 
QP focus: 3 V 
 









6.6 Assays protocols 
6.6.1 The L-AAO assay 
The high-throughput L-AAO assay122 was employed to determine the activity and kinetic 
parameters of the deacetylase and NAAAR enzymes. The data was elaborated with OriginLab 
(all experiments were repeated in triplicates). 
For E. coli ArgE the kinetic analysis was carried out with a reaction mixture containing various 
concentration of substrate, ArgE 2.0-0.2 μM, CoCl2 100 μM, HRP (Sigma Aldrich) 10 U/mL, 
LAAO from Crotalus atrox (Sigma Aldrich) 70-250 mU/mL and o-dianisidine 0.1 mg/mL in 100 
mM NaPi buffer pH 8. The reactions were incubated at 40°C and the absorbance at 436 nm 
was measured at intervals of 30 s for 1 hour. The concentration of ArgE and L-AAO was 
adjusted considering the enzymes activity towards the substrate used. 
For Amycolaptopsis NAAAR the kinetic analysis was carried out with a reaction mixture 
containing various concentration of substrate, NAAAR 0.50 μM, Dr Reddy’s L-Acylase 1.25 
mg/mL, MgCl2 5 mM, HRP (Sigma Aldrich) 10 U/mL, LAAO from Crotalus atrox (Sigma Aldrich) 
70 mU/mL and o-dianisidine 0.1 mg/mL in 100 mM NaPi buffer pH 8. The reactions were 
incubated at 50°C and the absorbance at 436 nm was measured at intervals of 30 s for 1 hour.  
6.6.2 The p-NO2 phenol assay185 
The colorimetric p-NP assay was employed to test S. viridochromogenes Dea activity and 
determine its kinetic parameters for various p-NP esters. The substrate stocks are prepared 
in AcCN and the final reaction mixture contains various concentration of substrate and SvDea 
100-50 μg/mL in 100 mM NaPi buffer pH 8. The reactions were incubated at 50°C and the 
absorbance at 405 nm was measured at intervals of 30 s for 1 hour. The data was elaborated 
with OriginLab (all experiments were repeated in triplicates). 
6.6.3 The OPA assay 
The OPA assay protocol reported by Kang et al.178 was employed.  
The reactive mixture was formed by mixing 10 mL of OPA (Merck) 15 mM and N-Ac-L-Cys 
(Sigma) 30 mM in ethanol with 50 mL of NaBi 140 mM buffer pH 9.5. This solution can be 
conserved at 4°C in darkness for up to three days. 
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The derivatization proceeds by mixing in a 96-well plate 40 μL of an amino acid standard 
solution or reaction mixture with 40 μL of reactive mixture. The plate is slowly shacked for 
30 s, then 100 μL of water is added and the fluorescence is recorded using a microplate 
reader (λex = 340 nm and λem = 460 nm). Measures are repeated in triplicates. 
6.6.4 Marfey’s derivatization protocol157 
50 µL of amino acid standard or reaction mixture were mixed with 100 µL of Marfey’s reagent 
(1% w/v dissolved in Acetone) and 20 µL of 1 M NaHCO3. The sample was heated at 60 °C for 
30 min at 250 rpm in a Thermo Shaker (PCMT). After the sample cooled down to room 
temperature, 40 µL of 1 M HCl were added. 
The samples were centrifuged for 10 minutes at 10000 rpm at r.t. and the supernatant (10 
µL) was injected onto Luna 5u C18 RP-HPLC column (100 Å, 250 x 4.60 mm, Phenomenex). 
The LC gradient ran with a step gradient from 15% to 50 % AcCN in water with 0.1% TFA over 
30 min and 50% to 15% of AcCN over 5 min, flow rate 1.0 mL min-1, temperature: 25°C, 
detection at 340 nm. A standard sample is always run as reference. 
 
6.7 Biotransformations  
6.7.1 ArgE biotransformations protocol 
500 µL reactions were set up using various N-acetyl-L-AAs (20 mM), E. coli ArgE 0.25, 0.50 or 
1.00 mg/mL and CoCl2 100 µM in 100 mM NaPi pH 8. The reactions were incubated at 40°C, 
250 rpm for 24 h. 20 µL HClconc. were added to the reaction mixture to precipitate the enzyme, 
the samples were centrifuged for 10 min at 13000 rpm at r.t. and the supernatant analyzed 
by 1H-NMR, LC-MS and HPLC.  
6.7.2 SvDea hydrolysis of N-Ac-L-amino acids 
500 µL reactions were set up using various N-acetyl-L-AAs (20 mM) and S. viridochromogenes 
SvDea 0.25, 0.50 or 1.00 mg/mL in 100 mM NaPi pH 8. The reactions were incubated at 50°C, 
250 rpm for 24 h. 20 µL HClconc. were added to the reaction mixture to precipitate the enzyme, 
the samples were centrifuged for 10 min at 13000 rpm at r.t. and the supernatant analyzed 




6.7.3 NAAAR/deacetylase DKR 
NAAAR DM and QM were overexpressed as reported in Chapter 6.3.3. Cell pellets were re-
suspended in 50 mM TRIS-HCL pH 8.0 (around 5 gr in 25 mL of buffer, 20% w/v) and sonicated 
on ice during 10 minutes (10s ON, 10s OFF), following ultracentrifugation for 30 min at 10000 
rpm. The clear supernatant was filtered through a 0.22 µM filter. The protein concentration 
of this cell-free extract (CFE) was quantified with the nanodrop. DKRs were set up in a Vf 500 
μL with 50 mM racemic N-acetyl amino acids, 1 mg/mL NAAAR DM or QM CFE, L/D-acylase 
(2.5 mg/mL) and CoCl2 (1 mM) in NaPi 0.1 M pH 8 and incubated at either 60° or 37°C, 
depending on the acylase used, for 24 h at 250 rpm. The reactions were quenched by addition 
of 10 μL of NaOH 5M, the enzyme was removed by centrifugation at 13000 rpm for 10 min 
at r.t. and the crude reaction mixtures analyzed by 1H-NMR and HPLC. 
6.7.4 Gram scale enzymatic reaction 
NAAAR QM CFEs was prepared as described above. Reactions were carried out in conical 
flasks containing: 1 g N-acetyl-D,L-amino acids, 250 mg L/D-acylase, 5 mM CoCl2 and 1 mg/mL 
NAAAR QM CFE in 25 mL 100 mM NaPi pH 8.0, Vf: 25 mL. After 24 h incubation at either 60° 
or 37°C, 250 rpm, depending on the acylase used, the reactions were quenched by addition 
of HClconc and the pH of the solution adjusted to 2. After removing the solvent under vacuum, 
the crude mixture was dissolved in the minimum amount of MeOH and the precipitated salts 
and enzymes were removed by filtration. The methanol phase was collected, concentrated 
under vacuum and the product precipitated by addition of an excess of acetone. Pure amino 
acid hydrochloride was isolated by filtration under vacuum, dried and analyzed via NMR, MS 
and HPLC.  
 
6.8 Organic Synthesis 
6.8.1 Deprotection of FMOC amino acids 
FMOC-amino acid (3 g) was placed in a round bottom flask and dissolved in DMF (0.1 M). 
Following the addition of piperidine (10 eqv) the solution was left stirring at r.t. for 2 h. The 
reaction was quenched by removing the solvent in vacuo and the residue was dissolved in 
hexane with the formation of a white precipitate. This precipitate was collected and washed 
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first with hexane (20 mL x 3) and then with EtOH (20 mL x 3). The combined ethanolic phases 
were concentrated under vacuum to obtain pure amino acid as a white powder. 
6.8.2 Ester hydrolysis 
The amino acid ester derivative (500 mg) was placed in a round bottom flask and dissolved 
in HCl 6 M (0.1 M); this solution was stirred under reflux for 16 h. The reaction was quenched 
by removing the solvent under vacuum and the free amino acid was obtained as a white 
powder. 
6.8.3 Amino acid acetylation 
6.8.3.1 1st protocol (hydrophobic amino acids)83 
In a round bottom flask the amino acid (2 g-200 mg) was dissolved in a 1:1 mixture of DMF 
and water (1.0 M). NEt3 (1.2 eqv) and Ac2O (2.2 eqv) were added dropwise to the solution 
under stirring. After 20 h at r.t. the solvent was removed under vacuum and the residues re-
dissolved in water; the pH of the solution was adjusted to 10 with NaCO3 sat and the mixture 
washed with Et2O (20 mLx3). The organic phase discarded and the pH of the water phase was 
adjusted to 2 with HCl 2 M and the solution extracted with EtOAc (20 mLx3). The organic 
phase was dried under MgSO4, filtered and the solvent removed under vacuum to give pure 
N-acetyl-amino acid. 
6.8.3.2 2nd protocol (polar amino acids)83 
In a round bottom flask the amino acid (2 g-200 mg) was dissolved in a 1:1 mixture of DMF 
and water (1.0 M). NEt3 (1.2 eqv) and Ac2O (2.2 eqv) were added dropwise to the solution 
under stirring. After 20 h at r.t. the solvent was removed under vacuum and the residues re-
dissolved in water; the pH of the solution was adjusted to 10 with NaCO3 sat and the mixture 
washed with Et2O (20 mLx3). The organic phase discarded and the pH of the water phase was 
adjusted to 2 with HCl 2 M and the solvent removed under vacuum. The white solid was 
dissolved in the minimum amount of MeOH, the solution filtered and methanol removed in 
vacuo to give pure N-acetyl-amino acid. 
6.8.3.3  3rd protocol (aromatic amino acid)191 
In a round bottom flask the amino acid (1.5 g) and NaOH (2.0 eqv) were dissolved in a 1:3 
mixture of acetone and water (0.1 M). Slowly Ac2O (1.5 eqv) was added to the solution and 
after addition, the mixture was left stirring for 20 h at r.t. The reaction was quenched by 
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removal of the acetone under vacuum, NaCO3 sat was added to the remaining solution until 
the pH reached a value of 10. The solution was then washed with Et2O (20 mLx3) and the pH 
of the water phase was adjusted to 2 with HCl 2 M. This solution was extracted with EtOAc 
(20 mLx3) and the collected organic phases were dried under MgSO4, filtered and the solvent 
removed under vacuum to give pure N-acetyl-amino acid. 
6.8.4 Marfey’s reagent synthesis157 
L-alanine amide (0.131 g, 1.5 mmol) was dissolved into acetone (0.1 M); 1 mL of NaOH (1 M) 
was added to the mixture, which was left stirring for 5 min or until the starting material is 
completely dissolved. MgSO4 (2.8 g) was added to the solution, which was stirred at r.t. for 3 
h, before being filtered. The filtered solution was added dropwise into a second solution of 
di-nitro-di-fluoro benzene (173 mg, 0.85 mmol) in acetone (0.2 M). The reaction mixture was 
stirred at r.t. for 30 minutes and quenched by addition of cold water (20 mL) dropwise. The 
bright yellow needle shaped crystals formed are filtered under vacuum, washed with cold 
water, dried and stored in darkness. 
 
6.9 Compound Characterization 
6.9.1 NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded at 298 K on Bruker PRO500 or 
AVA500 spectrometers running at 500 MHz, solvent peak taken as reference. Coupling 
constants J, were calculated using MestreNova. The following abbreviations (and their 
combinations) are used to label the multiplicities: s (singlet), d (doublet), t (triplet), q 
(quadruplet) and m (multiplet). 
For reaction monitoring the NMR samples were prepared by adding 100 μL of D2O to 400 μL 
of reaction mixtures and the NMR spectra recorded on a 500 MHz, single EspriSat experiment 
for water (16 scans, solvent peak suppression). Relative conversions measured by 
comparison of the integrals of the acetate peak of the substrate and the product. 
𝐶𝑜𝑛𝑣 (%) =  
(𝐼𝑃)
(𝐼𝑃 + 𝐼𝑅)




6.9.2 LC-ESI MS spectrometry 
The analysis was run on a Bruker micrOTOF LC-MS system with an ESI source. The samples 
for characterization were prepared by dissolving 5-10 mg materials in 1 mL MS grade water 
or methanol, while for reaction monitoring 50 μL of reaction mixture were diluted in 50 μL 
of H2O and AcCN 1:1 mixture (MS grade solvents) and filtered before injection. 
6.9.3 Chiral HPLC 
6.9.3.1 Reaction monitoring 
Time point samples were taken from an enzymatic reaction by diluting 20 μL of reaction 
mixture in 0.025% triethyl ammonium acetate (TEAA):MeOH (75:25) at different times. 
Samples were then analyzed by chiral HPLC using a Chirobiotic T column (Astec, chiral phase 
Teicoplanin, 5 μm, 250 mm x 4.6 mm) and the following isocratic conditions: mobile phase: 
0.025% TEAA:MeOH (75:25, v/v), flow rate: 0.5 mL min-1, detection λ: 210 nm, temperature: 
40 °C, run time: 30 minutes.121 The column was calibrated with single enantiomers of the free 
amino acids and their N-acetyl derivatives, reactions were run in triplicates. The Chromoleon 
software (Dionex) was used to measure the area under substrate and product peaks.  
6.9.3.2 Enantiomeric excess calculation 
Following reaction work-up, HPLC samples were prepared by 1:40 dilution of reaction 
mixture into the HPLC mobile phase, all samples were filtered before injection into the HPLC 
column (Chirobiotic T, Flow: 0.5 mL/min, 40°C, Mobile phase: 60:40 MeOH: 0.025% TEAA, 
protocol adapted from Turner et.al.194). Free amino acids standards and their N-acetyl 
derivatives were run for reference. The Chromoleon software (Dionex) was used to measure 
the area under substrate and product peaks. The enantiomeric excess (ee) was calculated 
using the area of the peaks for each enantiomer with the following formula: 
𝑒𝑒% =
|(𝐴𝑟𝑒𝑎 𝑆 − 𝐴𝑟𝑒𝑎 𝑅)|
(𝐴𝑟𝑒𝑎 𝑆 + 𝐴𝑟𝑒𝑎 𝑅)
· 100 
 
6.10 Crystal trials 
This work was carried out in collaboration with Prof Gideon Grogan (University of York). 
Recombinant purified E. coli non-tagged ArgE WT and E144A mutant at 14 mg mL-1 was 
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crystallised by sitting-drop vapour diffusion at 18 °C. Crystallisation experiments were set up 
in 96 well MRC plates with commercially available screens from Molecular Dimensions 
Limited with 2/3 nL drops of protein and 2/3 nL well solution and equilibrated against 100 μL 
of well solution. Crystals grew in two conditions, CSS1+2 C12 (0.8 M Na formate, 0.1 M Tris 
pH 8, 8% PEG 20k and 8% PEG 550 MME) and D12 (0.8 M Na formate, 0.1 M Tris pH 8, 10% 
PEG 8k and 10% PEG 1k), which yielded prism shaped protein crystals with a 6 Å resolution. 
Various attempts were made to try to optimise these conditions, using both the sitting and 
hanging drop methods (4-5 μL drop size), however no diffracting quality crystals were 
obtained. More screening and optimisation are required. Datasets were collected on 





The aim of this thesis was to characterize two N-acetyl amino acids deacetylases with 
biocatalytic potential and couple them with an engineered Amycolaptopsis NAAAR. This 
would enable the development of an efficient biocatalytic dynamic kinetic resolution for the 
synthesis of L-phosphinothricin and other non-canonical amino acids. 
E. coli ArgE is a co-catalytic zinc dependant metallo-deacetylase, involved in the biosynthesis 
of arginine in bacteria. This hydrolase was reported to be active towards N-Ac-PT, which 
makes the enzyme an ideal candidate for the DKR of this particular substrate. Following 
expression and purification of the acylase, ICP-MS and EDXRF analysis suggest the presence 
of only one Zn2+ ion bound for ArgE monomer and chiral HPLC confirmed the high 
stereoselectivity of the enzyme for the substrate L-isomer. The high-throughput colorimetric 
L-AAO assay was employed to optimize the reaction conditions, screen for activity and 
perform the kinetic analysis towards N-acetyl canonical and non-canonical amino acids.  
A novel 1H NMR assay was developed to monitor the deacetylation reaction and to calculate 
the conversions. ArgE did not show any activity toward N-Ac-PT, contrary to what was 
previously reported in literature. However, the wide substrate scope and high TONs and 
enantioselectivity suggest that the enzyme has a good biocatalytic potential for the synthesis 
of a wide range of NCAAs. Indeed, ArgE was efficiently coupled with NAAAR DM in a DKR of 
various aliphatic and heterocyclic amino acids. While the NAAAR QM, with enhanced activity 
for aromatic substrates, was coupled with two acylases with opposite stereoselectivity 
(obtained from Dr. Reddy’s laboratories): T. litoralis L-Acylase and A. xylosoxidans D-Acylase, 
reported to be active towards these compounds.  
A small-scale screening was run to study the QM substrate scope and eight DKRs were scaled 
up to produce enantiopure phenylalanine derivatives. The amino acids were isolated with an 
average yield ≥ 70%. Given the higher L-Acylase stereoselectivity, the four L-AAs produced 
were optically pure with an ee of 99.9%, while the D-AAs products suffered from low to 
average ees (25-85%). 
The crystal structure of ArgE has not been resolved. Following various rounds of optimization, 
the crystal trials performed had yielded protein crystals with a 4 Å resolution and the quality 
of the electron density map was not sufficient to resolve the enzyme structure. SDM studies 
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based on a homology model allowed to identify the residues directly involved in catalysis 
(E144) and intermediate stabilization (H195). With this, a random mutagenesis approach was 
employed to engineer ArgE and increase its activity although no positive hits have been 
isolated thus far.  
S. viridochromogenes Dea is a novel deacetylase which catalyses the last step in the 
production of the herbicidal tripeptide bialaphos. In this work, the expression, purification 
and characterization of SvDea was reported for the first time. The 1H NMR and two 
colorimetric assays, pNP and L-AAO, were employed to probe the enzyme substrate scope. 
The results obtained suggest that SvDea is selective towards its natural substrate yet the N-
Ac-L-PTT hydrolysis requires to be scaled-up and repeated to obtain more conclusive data. 
The homology model reveals the use of a hydrolytic mechanism based on a catalytic triad, 
formed by S143, E237 and H267, while sequence analogy confirms that SvDea belongs to the 
HSL family suggesting that the enzyme may be involved in the catabolism of triglycerides. 
This work mainly focused on the optimization of a biocatalytic process for the production of 
enantiopure amino acids. While a strereoseletive approach from prochiral precursors is the 
preffered strategy currently employed; the DKR here reported proved to be a good 
alternative given the high yields and ees achieved. Furthermore, Amycolatopis NAAAR is a 
robust enzyme (high thermostability) with a broad substrate range, able to work cooperatly 
with various L- and D-selective aminoacylases, opening the road for the production of 
numerous usefull and potentially bioactive target compounds. With the increased interest in 
“safe” nature-derived agrochemicals, being able to prepare L-PT with a novel and 
environmentally friendly strategy would be advantageus. However, N-Ac-L-PT is not 
commonly accepted by many hydrolases as substrate, a broad screen of a large Acylase 
panel, followed by potentially engineering of both the NAAAR and the stereoselective 
hydrolase, may be required to obtain an efficient biocatalytic DKR applicable at industrial 
scale. Moreover, studying and understanding the mechanism of the enzymes involved in the 
biosynthesis of phosphinothricin could led to the development of novel and unexpected 
strategies for the production of this natural product. 
Future work will mainly focus on using the error-prone PCR protocol optimised to evolve E. 
coli ArgE and widening the S. viridochromogenes Dea substrate scope by testing the enzyme 
activity for various acetylated esters or derivatives and scaling up the N-acetyl bialaphos 
hydrolysis. Further crystal trials will be set up using new mutants and/or constructs to obtain 
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good quality SvDea and ArgE crystals and to resolve the two deacetylase crystal structures. 
More studies will be conducted to study SvDea activity on fatty acids esters, and its 
involvement in the microorganism fatty acids metabolism. If an engineered version of ArgE 
active towards N-Ac-L-PT is isolated, this mutant will be coupled with the NAAAR variants to 
test the racemase activity towards this natural product and, if required, further mutagenesis 
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Appendix 6 Table containing all the primes used for the SDM of the ArgE gene and their sequences, 
the mutated sites are in bold. 
Primers Sequence 
ArgE E144A Fwd GCT GAT GCA GAA ACC AGT ATG GCC  
ArgE E144A Rev ACT GGT TTC TGC ATC TGC AGT CGC  
ArgE E145A Fwd GAT GAA GCA ACC AGT ATG GCC GGA 
ArgE E145A Rev TCC GGC CAT ACT GGT TGC TTC ATC  
ArgE E169A Fwd ATT GGC GCA CCG ACG TCA CTA CAA  
ArgE E169A Rev TTG TAG TGA CGT CGG TGC GCC AAT  
ArgE D112A Fwd ATC CTT GCT GCG CTA CGC GAT GTC GAC 
ArgE D112A Rev TAG CGC AGC AAG GAT AAA CGC AAA AAA 
ArgE H195I Fwd TCG GGG AAT TCC AGC GAT CCA 
ArgE H195I Rev GGA TTA CCC CGA CTG GCC CTG AAT  
ArgE R264A Fwd GAT ATT GCT CCG CTG CCT GGC ATG  
ArgE R264A Rev CAT GCC AGG CAG CGG AGC AAT ATC 
C-HisTag ArgE  Fwd TG GCA TGG ACT CGA GCA CCA C 





Appendix 7 Sequence alignment between E. coli ArgE (Uniprot accession code P23908), DapE from H. 
influenzae (31.5 % sequence identity, PDB entry code 3IC1), N-acetyl-ornithine deacetylase from 
Rhodopseudomonas palustris (27.5 % sequence identity, PDB entry code 3PFO) and N-acetyl-ornithine 
hydrolase from Spaerobacter thermophilus (29.0 % sequence identity, PDB entry code 4Q7A) obtained 
from CLUSTAL omega. White over red residues are conserved across all species, red on white are 
conserved across most while black on white are variable across species. The residues of interest are 































































Appendix 13 untagged Amycolaptopsis sp. TS1-60A NAAAR DM amino acid sequence from pET26b 







Appendix 14 untagged Amycolaptopsis sp. TS1-60A NAAAR QM amino acid sequence from pET26b 









Appendix 15 X-ray data collection for E. coli ArgE E144A mutant crystals. Numbers in brackets refer 
to data for highest resolution shells. 
 ArgE 
Beamline Diamond I04-1 
Wavelength (Å) 0.91587 
Resolution (Å) 215.55-2.75 (2.83-2.75) 
Space Group P6322 
Unit cell (Å) a = b = 248.90 ; c = 116.74  
α = β = 90.0 γ = 120.0 ° 
No. of molecules in the asymmetric unit 4 
Unique reflections 55565 (4487) 
Completeness (%) 100.0 (100.0) 
Rmerge (%) 0.38 (4.95) 
Rp.i.m. 0.11 (1.50) 
Multiplicity 23.1 (23.2) 
<I/(I)> 8.5 (0.9) 
Overall B factor from Wilson plot (Å2) 61 





Appendix 16 X-ray data collection for N-acetyl phosphinothricin. Single colourless plate-shaped 
crystals were recrystallised from a mixture of acetone and water by slow evaporation. A suitable 
crystal 0.44×0.11×0.04 mm3 was selected and mounted on a MITIGEN holder in Paratone oil on an 
Rigaku Oxford Diffraction SuperNova diffractometer. The crystal was kept at a steady T = 120.0 K 
during data collection. The structure was solved with the ShelXT (Sheldrick, 2015) structure solution 
program using the Intrinsic Phasing solution method and by using Olex2 (Dolomanov et al., 2009) as 
the graphical interface. The model was refined with version 2018/3 of ShelXL (Sheldrick, 2015) using 
Least Squares minimisation. 
N-Acetyl phosphinothricin  DC19001  
Dcalc./ g cm-3  1.411 
m/mm-1  2.366 
Formula Weight  223.16 
Colour  colourless 
Shape  plate 
Size/mm3  0.44×0.11×0.04 
T/K  120 
Crystal System  monoclinic 
Space Group  P21/n 
a/Å  10.9212(5) 
b/Å  6.5192(3) 
c/Å  15.1831(6) 
a/°  90 
b/°  103.721(4) 
g/°  90 
V/Å3  1050.15(8) 
Z  4 
Z'  1 
Wavelength/Å  1.54184 
Radiation type  CuKa 
Qmin/°  4.52 
Qmax/°  76.303 
Measured Refl.  16514 
Independent Refl.  2184 
Reflections with I > 2(I)  1972 
Rint  0.0717 
Parameters  138 
Restraints  3 
Largest Peak  0.552 
Deepest Hole  -0.477 
GooF  1.062 
wR2 (all data)  0.1472 
wR2  0.1431 
R1 (all data)  0.0556 
R1  0.052 
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Appendix 17 ArgE D112A mutant characterization via SDS-PAGE gel electrophoresis and denaturing 
LC-ESI MS spectrometry. 12% SDS-PAGE gel, lane 1 LMWM (M), lane 2 soluble CFE (L), lane 3 cell 
pellets (P) and lane 4-6 HisTrap fractions (~3 mL each). 
 
Appendix 18 ArgE H195I mutant characterization via SDS-PAGE gel electrophoresis and denaturing 
LC-ESI MS spectrometry. 12% SDS-PAGE gel, lane 1 LMWM (M), lane 2 soluble CFE (L), lane 3 cell 
pellets (P) and lane 4-6 HisTrap fractions (~3 mL each). 
 
Appendix 19 ArgE R264A mutant characterization via SDS-PAGE gel electrophoresis and denaturing 
LC-ESI MS spectrometry. 12% SDS-PAGE gel, lane 1 LMWM (M), lane 2 soluble CFE (L), lane 3 cell 





Appendix 20 Calibration curves for N-Ac-L-Met, N-Ac-D-Met, L-Met and D-Met obtained by chiral 
HPLC analysis. For each compound a stock solution at 100 mM concentration was prepared and 
diluted to obtain ten standards for the calibration curve. 20 μL of standard were diluted in 0.025% 
triethyl ammonium acetate (TEAA):MeOH (75:25) to prepare the samples for analysis. Samples were 
then run by HPLC using a Chirobiotic T column (Astec, chiral phase Teicoplanin, 5 μm, 250 mm x 4.6 
mm) and the following isocratic conditions: mobile phase: 0.025% TEAA:MeOH (75:25, v/v), flow 
rate: 0.5 mL min-1, detection λ: 210 nm, temperature: 40 °C, run time: 30 minutes. Each sample 







Appendix 21 Characterization of reaction products isolated. NMR run on a Bruker AVA500 or Pro500 
(500 MHz) instrument, with the solvent peak used as reference. LCMS samples prepared in MS grade 
water or methanol were run on a Bruker MicrOTOF system with an ESI source. Chiral HPLC analysis 
were run on a Chirobiotic T column (Astec, chiral phase Teicoplanin, 5 μm, 250 mm x 4.6 mm) and the 
following isocratic conditions: mobile phase: 0.025% TEAA:MeOH (40:60, v/v), flow rate: 0.5 mL min-
1, detection λ: 210 nm, temperature: 40 °C, run time: 30 minutes. 
Marfey’s Reagent (FDAA) synthesis 
 
L-alanine amide (0.131 g, 1.5 mmol) were dissolved into acetone (0.1 M); 1 mL of NaOH (1 M) was 
added to the mixture, which was left stirring for 5 min or until the starting material is completely 
dissolved. MgSO4 (2.8 g) was added to the solution, which was stirred at r.t. for 3 h, before being 
filtered. The filtered solution was added dropwise into a second solution of di-nitro-di-fluoro benzene 
(173 mg, 0.85 mmol) in acetone (0.2 M). The reaction mixture was stirred at r.t. for 30 minutes and 
quenched by addition of cold water (20 mL) dropwise. The bright yellow needle shaped crystals formed 
are filtered under vacuum, washed with cold water, dried and stored in darkness. 
Yield: 88 % 
1H NMR: (500 MHz, MeOD) δ 9.11 (d, J = 6.8 Hz, 1H), 6.96 (d, J = 14.3 Hz, 1H), 4.40 (p, J = 6.7 Hz, 1H) 
and 1.46 (d, J = 6.7 Hz, 3H). 
13C NMR: (126 MHz, MeOD) δ 174.40, 160.79, 158.66, 147.90, 127.11, 101.47, 52.14 and 17.80. 
19F NMR: (500 MHz, MeOD) δ -104.22 (d, 1F) 
TOF-ESI MS: calculated. 273.2 [M + H] +, found 273 
Commercially available. 
FMOC-2-amino acids de-protection 
 
FMOC-allylglycine (3g, 7.6 mmol) was placed in a round bottom flask and dissolved in DMF (0.1 M, 76 
mL). Following the addition of piperidine (10 eqv, 7.5 mL) the solution was left stirring at r.t. for 2 h. 
The reaction was quenched by removing the solvent in vacuo and the residue was dissolved in hexane 
with the formation of a white precipitate. This precipitate was collected and washed first with hexane 
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(20 mL x 3) and then with EtOH (20 mL x 3). The combined ethanolic phases were concentrated under 
vacuum to obtain pure allylglycine (2b) as a white powder. 
 
Yield: 88 % 
1H NMR: (500 MHz, D2O) δ 3.50 (q, J = 7.2 Hz, 3H), 2.59 (s, 1H), 1.36 (d, J = 7.2 Hz, 3H). 
13C NMR: (126 MHz, D2O) δ 174.93, 58.90, 30.98 and 14.56. 
TOF-ESI MS: calculated. 114.1 [M + H] +, found 114 
 
Yield: 95 % 
1H NMR: (500 MHz, D2O) δ 5.67 (ddt, J = 17.4, 10.2, 7.3 Hz, 1H), 5.23 – 5.09 (m, 2H), 3.70 (dd, J = 7.1, 
4.9 Hz, 1H), 2.62 – 2.44 (m, 2H). 
13C NMR: (126 MHz, D2O) δ 182.74, 134.43, 117.92, 55.41 and 39.10. 
TOF-ESI MS: calculated. 116.2 [M + H] +, found 116 
Commercially available. 
 
Yield: 87 % 
1H NMR: (500 MHz, D2O) δ 3.81 (t, J = 5.5 Hz, 1H), 2.75 (ddd, J = 5.2, 2.7, 1.4 Hz, 2H), 2.41 (t, J = 2.7 Hz, 
1H). 
13C NMR: (126 MHz, D2O) δ 181.10, 81.32, 71.42, 54.41 and 24.42. 





Yield: 81 % 
1H NMR: (500 MHz, D2O) δ 7.21 (dd, J = 5.1, 1.2 Hz, 1H), 6.92 (dd, J = 5.2, 3.4 Hz, 1H), 6.84 (dt, J = 3.4, 
1.0 Hz, 1H), 3.48 (dd, J = 6.3, 5.6 Hz, 1H), 3.11 (dt, J = 6.2, 0.8 Hz, 2H). 
13C NMR: (126 MHz, D2O) δ 181.85, 140.06, 127.23, 126.48, 124.69, 57.26 and 34.75. 
TOF-ESI MS: calculated 172.1 [M + H] +, found 172 
Chiral HPLC: R.T. = 9.33 min (L) and 10.20 min (D), racemate 
Esters hydrolysis 
 
5j (316 mg, 1.58 mmol) was placed in a round bottom flask and dissolved in HCl 6M (0.1 M, 16 mL); 
this solution was stirred under reflux for 16 h. The reaction was quenched by removing the solvent 
under vacuum, isolating 2-amino-3-(2-methylthiazol-4-yl) propanoic acid hydrochloride (2j) as a white 
powder. 
 
Yield: 95 % 
1H NMR: (500 MHz, D2O) δ δ 7.49 (s, 1H), 4.24 – 4.19 (m, 1H), 3.63 – 3.32 (m, 2H), 2.81 (s, 3H). 
TOF-ESI MS: calculated 187.1 [M + H] +, found 187 




Yield: 98 %. 
1H NMR: (500 MHz, D2O) δ 4.05 (t, J = 6.3 Hz, 1H), 3.31 (t, J = 6.7 Hz, 2H), 2.16 – 1.86 (m, 2H), 1.74 
(dddt, J = 18.9, 12.5, 9.5, 6.0 Hz, 2H). 
13C NMR: (126 MHz, D2O) δ 171.76, 158.92, 53.62, 52.47, 26.91 and 23.26. 
TOF-ESI MS: calculated 220.2 [M + H] +, found 220 
 
Yield: 70 % 
1H NMR: (500 MHz, D2O) δ 6.02 (ddd, J = 15.5, 6.5, 1.0 Hz, 1H), 5.51 (ddd, J = 15.6, 8.2, 1.5 Hz, 1H), 
4.43 (d, J = 8.2 Hz, 1H), 2.45 – 2.24 (m, 1H), 0.97 (d, J = 6.8 Hz, 6H). 
13C NMR: (126 MHz, D2O) δ 181.89, 139.55, 126.33, 58.40, 30.18, 28.48 and 21.43 
TOF-ESI MS: calculated 144.1 [M + H] +, found 144 
Acetylation of polar amino acids 
 
In a round bottom flask 2u (297mg, 1.71 mmol) was dissolved in a 1:1 mixture of DMF and water (1.0 
M, 1.86 mL). NEt3 (290 μL, 1.2 eqv) and Ac2O (317 μL, 2.2 eqv) were added dropwise to the solution 
under stirring. After 20 h at r.t. the solvent was removed under vacuum and the residues re-dissolved 
in water; the pH of the solution was adjusted to 10 with NaCO3 sat and the mixture washed with Et2O 
(20 mLx3). The pH of the water phase was adjusted to 2 with HCl 2 M and the solvent removed under 
vacuum. The white solid was dissolved in the minimum amount of MeOH, the solution filtered and 




Yield: 73 % 
1H NMR: (500 MHz, D2O) δ 4.40 – 4.29 (m, 1H), 2.16 – 2.02 (m, 1H), 1.96 (s, 3H), 1.94 – 1.71 (m, 3H), 
1.45 (d, J = 14.0 Hz, 3H). 
13C NMR: (126 MHz, D2O) δ 174.80, 174.36, 53.03, 52.90, 26.18, 25.44, 23.44, 23.42, 21.60, 13.16 and 
13.89. 
31P NMR: (500 MHz, D2O) δ 39.38 (ddq, J = 21.1, 14.0, 7.4 Hz). 
TOF-ESI MS: calculated 222.1 [M - H]-, found 222 
 
Yield: 41.4 % 
1H NMR: (500 MHz, D2O) δ 4.35 (dd, J = 8.6, 5.0 Hz, 1H), 3.29 (t, J = 6.7 Hz, 2H), 2.02 (s, 3H), 1.97 – 1.63 
(m, 4H). 
13C NMR: (126 MHz, D2O) δ 178.83, 173.59, 158.85, 54.76, 40.75, 28.85, 23.91 and 21.88. 
TOF-ESI MS: calculated 262.1151 [M + H]+, found 262.1148 
 
Yield: 17.8 % 
1H NMR: (500 MHz, D2O) δ 4.77 (d, J = 7.2 Hz, 1H), 4.01 (dd, J = 11.7, 5.1 Hz, 1H), 3.90 (dd, J = 11.7, 3.6 
Hz, 1H), 2.06 (s, 3H). 
13C NMR: (126 MHz, D2O) δ  
203 
 
TOF-ESI MS: calculated 164.5 [M - H]-, found 164 
 
Yield: 49.6 % 
1H NMR: (500 MHz, D2O) δ 4.66 – 4.60 (m, 1H), 3.10 – 3.03 (m, 1H), 2.94 (dd, J = 14.2, 8.3, 1H),2.96 (s, 
3H), 2.08 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 174.30, 174.13, 52.13, 34.59, 21.64. 
TOF-ESI MS: calculated C7H11NO3S 178.0551 [M + H]+, found 178.0535 
 
Yield: 66 % 
1H NMR: (500 MHz, D2O) δ 4.38 (dd, J = 9.1, 5.1 Hz, 1H), 3.67 (s, 3H), 2.50 (t, J = 7.3 Hz, 2H), 2.28 – 2.13 
(m, 1H), 2.01 (s, 3H), 2.09 – 1.89 (m, 1H). 
13C NMR: (126 MHz, D2O) δ 178.31, 176.25, 173.63, 54.41, 52.23, 30.48, 26.95 and 21.90. 
TOF-ESI MS: calculated 202.2 [M - H]-, found 202 
 
Yield: 1 % 
1H NMR: (500 MHz, D2O) δ 4.42 (dd, J = 9.1, 5.3 Hz, 1H), 3.74 (s, 3H), 3.68 (s, 3H), 2.49 (t, J = 7.2 Hz, 
2H), 2.20 (m, 1H), 2.01 (s, 3H), 2.06 – 1.91 (m, 1H). 




Yield: 11.5 % 
1H NMR: (500 MHz, D2O) δ 4.44 (dd, J = 7.9, 5.0 Hz, 1H), 4.27 – 4.17 (m, 2H), 4.12 – 4.00 (m, 2H), 2.21 
– 2.08 (m, 1H), 2.03 (s, 3H), 1.99 – 1.83 (m, 3H), 1.58 (d, J = 13.8 Hz, 3H), 1.28 (dt, J = 16.9, 7.1 Hz, 6H). 
13C NMR: (126 MHz, D2O) δ 174.37, 173.67, 172.94, 62.82, 62.02, 61.96, 53.07, 52.94, 24.70, 23.95, 
23.18, 23.11, 21.59, 15.74, 15.70, 13.27, 12.19, 11.46. 
61P NMR: (500 MHz, D2O) δ 42.92 (m). 
TOF-ESI MS: calculated 280.3 [M - H]-, found 280 
 
Yield: 76.3 % 
1H NMR: (500 MHz, D2O) δ 4.23 – 4.15 (m, 1H), 3.09 (t, J = 6.8 Hz, 2H), 2.01 (s, 3H), 1.81 (m, 1H), 1.69 
(m, 1H), 1.58 – 1.47 (m, 2H). 
13C NMR: (126 MHz, D2O) δ 179.10, 173.57, 161.58, 55.02, 46.69, 28.90, 25.62 and 21.88. 
TOF-ESI MS: calculated 216.1 [M - H]-, found 216 
Chiral HPLC: R.T. = 4.61 min (L) and 5.46 min (D), racemate 
The L-stereoisomer is commercially available. 
Acetylation of hydrophobic amino acids 
The reaction was carried out using the same protocol as 2u. After 20 h at r.t. the solvent was removed 
under vacuum and the residues re-dissolved in water; the pH of the solution was adjusted to 10 with 
NaCO3 sat and the mixture washed with Et2O (20 mLx3). The organic phase discarded and the pH of the 
water phase was adjusted to 2 with HCl 2 M and the solution extracted with EtOAc (20 mLx3). The 





Yield: 19 % 
1H NMR: (500 MHz, D2O) δ 5.28 (s, 1H), 3.01 (s, 3H), 2.12 (s, 3H), 1.38 (s, 3H). 
TOF-ESI MS: calculated 144.2 [M - H]-, found 144 
 
Yield: 41 % 
1H NMR: (500 MHz, D2O) δ 5.78 (ddt, J = 17.1, 10.2, 7.0 Hz, 1H), 5.22 – 5.10 (m, 2H), 4.40 (dd, J = 8.2, 
5.2 Hz, 1H), 2.68 – 2.42 (m, 2H), 2.01 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 178.48, 173.50, 133.92, 117.90, 54.83, 36.07 and 21.86. 
TOF-ESI MS: calculated 156.1 [M - H]-, found 156 
Chiral HPLC: R.T. = 4.71 min (L) and 5.43 min (D), racemate 
 
Yield: 52 % 
1H NMR: (500 MHz, D2O) δ 4.53 (t, J = 5.9 Hz, 1H), 2.75 (ddd, J = 5.6, 2.7, 1.4 Hz, 2H), 2.41 (t, J = 2.7 Hz, 
1H), 2.04 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 176.82, 173.64, 80.66, 71.31, 53.51, 21.90 and 21.81. 
TOF-ESI MS: calculated 154.1 [M - H]-, found 154 




Yield: 43.0 % 
1H NMR: (500 MHz, D2O) δ 7.22 (dd, J = 5.2, 1.2 Hz, 1H), 6.91 (dd, J = 5.1, 3.5 Hz, 1H), 6.85 (dd, J = 3.5, 
1.1 Hz, 1H), 4.54 (dd, J = 8.3, 5.0 Hz, 1H), 3.34 (dd, J = 15.1, 5.0, 1H), 3.18 (dd, J = 15.0, 8.3, 1H), 1.88 
(s, 3H).13C NMR: (126 MHz, D2O) δ 177.37, 173.49, 139.67, 127.11, 126.47, 124.85, 56.20, 31.80 and 
21.94. 
TOF-ESI MS: calculated 214.0540 [M + H]+, found 214.0535 
Chiral HPLC: R.T. = 4.97 min (L+D), racemate 
 
Yield: 46.7 % 
1H NMR: (500 MHz, D2O) δ 7.44 (s, 1H), 4.46 (t, J = 6.5 Hz, 1H), 3.39 (dd, J = 15.1, 5.1, 1H), 3.18 (dd, J = 
15.1, 9.0 Hz, 1H), 2.84 (s, 3H), 1.96 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 177.83, 173.22, 168.12, 151.23, 115.53, 55.01, 32.22, 21.84 and 17.65. 
TOF-ESI MS: calculated for C9H11ClFNO2 227.1 [M - H]-, found 227 
Chiral HPLC: R.T. = 4.73 min (L) and 5.62 min (D), racemate 
 
Yield: 56 % 
1H NMR: (500 MHz, D2O) δ 5.99 (dd, J = 15.6, 6.5 Hz, 1H), 5.86 (dd, J = 15.5, 6.5 Hz, 1H), 5.63 (ddd, J = 
15.6, 7.0, 4.1 Hz, 2H), 4.72 (d, J = 6.6 Hz, 2H), 2.15 (s, 3H), 2.15 (s, 3H), 1.08 (m, 12H). 
207 
 
13C NMR: (126 MHz, D2O) δ 177.69, 173.81, 173.45, 173.03, 144.22, 141.26, 122.03, 119.00, 57.48, 
55.16, 53.08, 48.88, 21.92, 21.54, 21.28 and 21.03. 
TOF-ESI MS: calculated 170.2 [M - H]-, found 170.2 
 
Yield: 58.8 % 
1H NMR: (500 MHz, D2O) δ 3.52 (d, J = 9.4 Hz, 1H), 2.00 (s, 3H), 1.11 (m, 1H), 0.71 – 0.54 (m, 2H), 0.54 
– 0.42 (m, 1H), 0.32 (m, 1H). 
13C NMR: (126 MHz, D2O) δ 178.92, 173.37, 59.44, 21.72, 12.78, 2.92 and 2.35. 
TOF-ESI MS: calculated 158.0828 [M + H]+, found 158.0814 
 
Yield: 53 % 
1H NMR: (500 MHz, D2O) δ 4.11 (s, 1H), 2.04 (s, 3H) and 1.00 (s, 9H). 
13C NMR: (126 MHz, D2O) δ 175.04, 174.26, 61.97, 32.99, 25.83 and 21.56. 
TOF-ESI MS: calculated C8H16O3 174.1150 [M + H]+, found 174.1127 
 
Yield: 79.3 % 
1H NMR: (500 MHz, D2O) δ 4.49 (dd, J = 7.6, 6 Hz, 1H), 1.99 (s, 3H), 1.82 (dd, J = 11.6, 2.4 Hz, 1H), 1.61 
(dd, J = 11.6, 7.6 Hz, 1H) and 1.00 (s, 9H). 
13C NMR: (126 MHz, D2O) δ 180.78, 173.08, 53.16, 45.23, 29.91, 28.85 and 21.99. 
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TOF-ESI MS: calculated 188.1288 [M + H]+, found 188.1284 
Acetylation of aromatic amino acids 
 
In a round bottom flask 2y (1.5 g, 6.1 mmol) and NaOH (0.55 g, 2.0 eqv) were dissolved in a 1:3 mixture 
of acetone and water (0.1 M, 60 mL). Slowly Ac2O (1.0 mL, 1.5 eqv) was added to the solution and after 
addition the mixture was left stirring for 20 h. The reaction was quenched by removal of the acetone 
under vacuum and by addition of NaCO3 sat to the remaining solution until the pH reached a value of 
10. The solution was then washed with Et2O (20 mLx3) and the pH of the water phase was adjusted to 
2 with HCl 2 M. This solution was extracted with EtOAc (20 mLx3) and the collected organic phase was 
dried under MgSO4, filtered and the solvent removed under vacuum to give pure N-acetyl-4-NO2-
phenylalanine (2u). 
 
Yield: 84.0 % 
1H NMR: (500 MHz, D2O) δ 8.24 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 4.76 – 4.68 (m, 1H), 3.40 
(dd, J = 13.9, 5.3 Hz, 1H), 3.16 (dd, J = 14.0, 9.3 Hz, 1H), 1.96 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 175.00, 173.77, 146.68, 145.22,130.21, 123.68, 53.95, 36.69 and 21.50. 
TOF-ESI MS: calcd. for C11H12NO5 252.1006 [M - H]-, found 252.0998 
Chiral HPLC: R.T. = 4.64 min (L) and 5.71 min (D), racemate 
  
Yield: 33.6 % 
1H NMR: (500 MHz, D2O) δ 7.21 (t, J = 9.0 Hz, 2H), 7.04 (t, J = 9.0 Hz, 2H), 4.37 (dd, J = 8.5, 5.0 Hz 1H) 
3.12 (dd, J = 14.0, 5.0 Hz, 1H), 2.86 (dd, J = 14.0, 8.5 Hz, 1H) and 1.89 (s, 3H). 
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13C NMR: (126 MHz, D2O) δ 178.09, 173.24, 162.47, 160.55, 133.59, 133.56, 130.77, 130.70, 115.10, 
114.93, 50.44, 36.91, 21.80. 
19F NMR: (500 MHz, D2O) δ -117.49 (m, 1F). 
TOF-ESI MS: calcd. for C9H11ClFNO2 224.1 [M - H]-, found 224 
Chiral HPLC: r R.T. = 9.01 min, ee > 99.9% 
Commercially avaiable 
 
Yield: 62.9 % 
1H NMR: (500 MHz, D2O) δ 7.34 (d, J = 8.0 Hz, 2H), 7.22 (d, , J = 8.0 Hz, 2H), 4.40 (dd, J = 9.0, 5.0f Hz 
1H) 3.15 (dd, J = 14.0, 5.0 Hz, 1H), 2.88 (dd, J = 13.5, 8.5 Hz, 1H) and 1.90 (s, 3H). 
13C NMR: (126 MHz, D2O) δ 177.99, 173.24, 136.48, 131.81, 130.68, 128.34, 56.25, 37.11 and 21.81. 
TOF-ESI MS: calcd. for C11H12O3N1Cl 242.0591 [M + H]+, found 242.0581 
Chiral HPLC: R.T. = 4.69 min (L) and 5.18 min (D), racemate 
 
Yield: 85.3 % 
1H NMR: (500 MHz, D2O) δ 7.40 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 4.40 (dd, J = 9.0, 4.9 Hz, 1H), 
3.13 (dd, J = 13.9, 4.8 Hz, 1H), 2.85 (dd, J = 14.0, 9.0 Hz, 1H), 1.90 (d, J = 5.2 Hz, 4H). 
13C NMR: (126 MHz, D2O) δ 177.97, 173.23, 136.99, 131.32, 131.12, 119.93, 56.20, 37.17, 21.84. 
TOF-ESI MS: calcd. for C11H12O3N1Br 284.0074 [M + H]+, found 284.0073 









1H NMR: (500 MHz, D2O) δ 7.48 (m, 5H), 4.34 (t, J = 9.0 Hz, 1H), 3.38 (dd, J = 14.5, 7.5 Hz, 1H) and 3.25 
(dd, J = 14.5, 7.5 Hz, 1H). 
13C NMR: (126 MHz, D2O) δ 171.19, 134.16, 129.43, 129.24, 128.01, 54.47 and 35.72 
TOF-ESI MS: calcd. for C9H12ClNO2 202.06 [M + H] +, found 202.1 




Yield: 61.9 % 
1H NMR: (500 MHz, D2O) δ 8.10 (d, 2H), 7.38 (d, 2H), 3.48 (t, J = 9.0 Hz, 1H) 3.00 (dd, J = 13.5, 8.0 Hz, 
1H) and 2.89 (dd, J = 13.5, 8.0 Hz, 1H). 
13C NMR: (126 MHz, D2O) δ 181.76, 146.96, 146.35, 130.29, 123.66 57.36 and 40.86.  
TOF-ESI MS: calcd. for C9H11ClN2O4 247.04 [M + H] +, found 247.1 






Yield: 84.5 % 
1H NMR: (500 MHz, D2O) δ 7 7.14 (m, 2H), 6.99 (t, J = 8.0 Hz, 2H), 3.37 (t, J = 9.0 Hz, 1H) 2.84 (dd, J = 
13.5, 5.5 Hz, 1H) and 2.73 (dd, J = 13.5, 5.5 Hz, 1H).  
13C NMR: (126 MHz, D2O) δ 171.79, 163.19, 161.25, 134.12, 134.07, 130.98, 130.92, 115.20, 115.03, 
57.72and 40.03. 
19F NMR: (500 MHz, D2O) δ -117.49 (m, 1F). 
TOF-ESI MS: calcd. for C9H11ClFNO2 220.05 [M + H] +, found 220.1 





1H NMR: (500 MHz, D2O) δ 7.30 (m, 5H) and 4.27 (s, 1H).  
13C NMR: (126 MHz, D2O) δ 181.14, 142.21, 128.85, 127.54, 126.84 and 60.50  
TOF-ESI MS: calcd. for C8H10ClNO2 188.04 [M + H] +, found 188.0 







1H NMR: (500 MHz, D2O) δ 7.39 (t, 2H), 7.30 (m, 3H), 3.51 (t, J = 9.0 Hz, 1H), 3.00 (dd, J = 13.5, 5.5, 1H) 
and 2.84 (dd, J = 13.5, 7.5, 1H). 
13C NMR: (126 MHz, D2O) δ 182.47, 138.33, 129.46, 128.65, 126.71, 57.49 and 40.87 
TOF-ESI MS: calcd. for C9H12ClNO2 202.06 [M + H] +, found 202.1 





1H NMR: (500 MHz, D2O) δ 8.27 (d, J = 9.1 Hz, 2H), 7.58 (d, J = 9.1 Hz, 2H), 4.36 (t, J = 9.0 Hz, 1H) 3.48 
(dd, J = 14.5, 6, 1H) and 3.38 (dd, J = 14.5, 7.5, 1H). 
13C NMR: (126 MHz, D2O) δ 171.16, 147.23, 142.50, 136.22, 130.52, 124.17, 122.99, 59.35 and 35.62. 
TOF-ESI MS: calcd. for C9H11ClN2O4 247.04 [M + H] +, found 247.1 





1H NMR: (500 MHz, D2O) δ 7.36 (m, 2H), 7.19 (m, 2H), 4.32 (t, J = 9.0 Hz, 1H), 3.36 (dd, J = 14.5, 5.5, 
1H), 3.25z (dd, J = 14.5, 7.5, 1H) 
13C NMR: (126 MHz, D2O) δ 171.79, 163.19, 161.25, 131.23, 131.17, 130.00, 129.98, 115.97, 115.79, 
59.37 and 34.95 
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19F NMR: (500 MHz, D2O) δ -115.46 (m, 1F) 
TOF-ESI MS: calcd. for C9H11ClFNO2 220.05 [M + H] +, found 220.1 





1H NMR: (500 MHz, D2O) δ 7.39 (m, 5H) and 4.36 (s, 1H) 
13C NMR: (126 MHz, D2O) δ 181.14, 142.17, 128.85, 127.54, 126.84 and 60.59 
TOF-ESI MS: calcd. for C8H10ClNO2 188.04 [M + H] +, found 188.0 





Appendix 22 Full NMR charachterization of compound 1l. A) COSY NMR. B) HSQC NMR. C) NOESY 
NMR. D) Overlay of 1l 1H-NMR taken at various temperatures (25, 30, 40 and 60°C). 
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